(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2015 (14.05.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/069287 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61K 31/4436* (2006.01)
C07D 401/14 (2006.01) *A61K 31/4439* (2006.01)
C07D 405/14 (2006.01) *A61P 35/00* (2006.01)
C07D 409/04 (2006.01) *A61P 27/02* (2006.01)
C07D 409/14 (2006.01) *A61P 29/00* (2006.01)
A61K 31/443 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/US2013/069337

(22) International Filing Date:
8 November 2013 (08.11.2013)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant *(for all designated States except US)*: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(72) Inventors; and
(71) Applicants *(for US only)*: **GUO, Xialing** [US/US]; 2912 Canto De Los Ciervo, San Clemente, California 92673 (US). **ZHU, Zhen** [CN/US]; 12 Banyan, Foothill Ranch, California 92610 (US).

(74) Agents: **WURST, John** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: COMPOUNDS AS TYROSINE KINASE MODULATORS

(57) Abstract: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.



Formula I

WO 2015/069287 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with information concerning one or more priority claims considered void (Rule 26bis.2(d))*

18572 CIP PCT (AP)

COMPOUNDS AS TYROSINE KINASE MODULATORS

Inventors: Xialing Guo and Zhen Zhu

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation in part of U.S. Application Serial No. 13/673,437 filed November 9, 2012 which is a continuation in part of U.S. Application Serial No. 12/875,218, filed August 31, 2010, which claims priority under 35 U.S.C. 119(e) to United States Provisional Application Nos. 61/239,603, filed on Sep 03, 2009, 61/306,616, filed on Feb 22, 2010, 61/356,699 filed on June 21, 2010 and 61/360,531 filed on July 01, 2010, all of which are expressly incorporated herein by reference in their entireties.

FIELD OF THE INVENTION

The present invention is directed to novel compounds with multiple aromatic components capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction. The present invention is also directed to methods of prevention and/or treatment of disorders related to unregulated tyrosine kinase signal transduction, including but not limited to, cell growth disorders, metabolic disorders, blood vessel proliferative disorders, inflammatory disorders, neurodegenerative diseases and immune disorders.

BACKGROUND OF THE INVENTION

Protein tyrosine kinases ("PTKs") play an important role in the control of cell growth and differentiation. PTKs comprise a large and diverse class of proteins having enzymatic activity. PTKs can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular). For example, signal transduction mediated by receptor tyrosine kinases ("RTKs") is initiated by extracellular interaction with a specific growth factor (i.e., a ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic homeostasis, and responses to the extracellular microenvironment).

18572 CIP PCT (AP)

With respect to RTKs, it has been shown also that tyrosine phosphorylation sites function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Several intracellular substrate proteins that associate with RTKs have been identified and are divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack a catalytic domain but serve as adapters and associate with catalytically active molecules. The specificity of the interactions between receptors or proteins and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. These observations suggest that the function of each RTK is determined not only by its pattern of expression and ligand availability, but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

The RTKs comprise a large family of transmembrane receptors with diverse biological activities. The intrinsic function of RTKs is activated upon ligand binding, which results in phophorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses. At present, at least nineteen distinct RTK subfamilies have been identified. One RTK subfamily, designated the HER subfamily, is believed to be comprised of EGFR, HER2, HER3 and HER4. Ligands to the HER subfamily of receptors include epithelial growth factor (EGF), TGF-α, amphiregulin, HB-EGF, betacellulin and heregulin. The second subfamily of RTKs, designated the insulin subfamily, is comprised of the INS-R, the IGF-1R and the IR-R. The third RTK subfamily, the "PDGF" family, includes the PDGF α and β receptors, CSFIR, c-kit and FLK-II. Another subfamily of RTKs, identified as the FLK family, is believed to be comprised of the kinase insert domain-receptor fetal liver kinase-1 (KDR/FLK-1), the fetal liver kinase 4 (FLK-4) and the fms-like tyrosine kinase 1 (flt-1). Each of these receptors was initially believed to be a receptor for hematopoietic growth factors. Two other subfamilies of RTKs have been designated as the FGF receptor family (FGFR1, FGFR2, FGFR3 and FGFR4) and the Met subfamily (c-met and Ron). Because of the similarities between the PDGF and FLK subfamilies, the two subfamilies are often considered together. The known RTK subfamilies are identified in Plowman et al, 1994, DN&P 7(6): 334-339, which is incorporated herein by reference.

18572 CIP PCT (AP)

The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty-four individual non-receptor tyrosine kinases, comprising eleven subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs, and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, 1993, Oncogen 8: 2025-2031, which is incorporated herein by reference.

Many of the protein tyrosine kinases (PTKs), whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways leading to cellular signal cascades and pathogenic conditions such as cancer, psoriasis and hyper immune responses. In view of the importance of PTKs to the control, regulation and modulation of cell proliferation and the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase "inhibitors" using a variety of approaches, including the use of mutant ligands (U.S. Patent No. 4,966,849), soluble receptors and antibodies (Kendall & Thomas, 1994, Proc. Nat'l Acad. Sci 90: 10705-09; Kim, et al, 1993, Nature 362: 841-844), RNA ligands (Jellinek, et al, Biochemistry 33: 10450-56); Takano, et al, 1993, Mol. Bio. Cell 4:358A; Kinsella, et al, 1992, Exp. Cell Res. 199: 56-62; Wright, et al, 1992, J. Cellular Phys. 152: 448-57) and tyrosine kinase inhibitors (U.S. Patent No. 5,330,992; Mariani, et al, 1994, Proc. Am. Assoc. Cancer Res. 35: 2268).

More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT Application No. WO 92/20642), vinylene-azaindole derivatives (PCT Application No. WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT Application No. WO 94/03427), tricyclic polyhydroxylic compounds (PCT Application No. WO 92/21660) and benzylphosphonic acid compounds (PCT Application No. WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer.

18572 CIP PCT (AP)


In addition, other small molecules were studied as tyrosine kinase inhibitors, such as the compounds disclosed in U.S. Pat. Nos. 6,765,012; 6,541,504; 6,747,025; 5,792,783; 5,834,504; 5,883,113; 5,883,116 and 5,886,020, all of which are incorporated by reference in their entireties.

The identification and use of compounds which specifically inhibit signal transduction by modulating the activity of receptor and non-receptor tyrosine is one aspect of the present invention.

SUMMARY OF THE INVENTION

The present invention is directed to compounds represented by Formula I capable of modulating, regulating and/or inhibiting tyrosine kinase signal transduction, and uses of the compounds and compositions incorporating the compounds for disease treatment and prevention.

The compounds of the present invention can be found in general Formula I:



Formula I

wherein

X is selected from the group consisting of NR^1, O, $S(O)_n$;

n is 0 or an integer of from 1 to 2;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^I is selected from the group consisting of hydrogen, halogen, C_1 to C_8 alkyl, $S(O)_fR^4$, $(CR^5R^6)_dC(O)OR^4$, $S(O)_f(CR^5R^6)_dC(O)OR^4$, $(CR^5R^6)_dAr$, $NR^4(CR^5R^6)_dAr$, $O(CR^5R^6)_dAr$, $S(O)_f(CR^5R^6)_dAr$, $(CR^5R^6)_dS(O)_fR^4$, $NR^4(CR^5R^6)_dS(O)_fR^4$, $O(CR^5R^6)_d\ S(O)_fR^4$, $S(O)_f(CR^5R^6)_eS(O)_fR^4$, $(CR^5R^6)_dC(O)N(R^4)_2$, $NR^4(CR^5R^6)_dC(O)N(R^4)_2$, $O(CR^5R^6)_dC(O)N(R^4)_2$, $S(O)_f(CR^5R^6)_eC(O)N(R^4)_2$, $(CR^5\ R^6)_dOR^4$, $S(O)_f(CR^5R^6)_dOR^4$, $(CR^5\ R^6)_dOSO_2R^4$, $S(O)_f(CR^5\ R^6)_eOSO_2R^4$, $(CR^5\ R^6)_dP(O)(OR^4)_2$, $S(O)_f(CR^5\ R^6)_eP(O)(OR^4)_2$, $OC(O)(CR^5R^6)_dN(R^4)_2$, $C(O)(CR^5R^6)_dN(R^4)_2$, $C(O)N{=}S(O)R^5\ R^6$, $NR^2C(O)(CR^5R^6)_dN(R^4)_2$, $(CR^5R^6)_dR^5$, $S(O)_f(CR^5R^6)_dR^5$, $HNC(O)R^4$, $HN\text{-}C(O)OR^4$, $(CR^5R^6)_dN(R^4)_2$, $S(O)_f(CR^5R^6)_dN(R^4)_2$, $OC(O)OR^4$, $(CR^5R^6)_dC(O)(CR^5R^6)_dR^4$, $(CR^5R^6)_dC(O)(CR^5R^6)_dOR^4$, and $(CR^5R^6)_dC(O)(CR^5R^6)_dN(R^4)_2$, wherein each R^4 is independently selected from the group consisting of hydrogen, hydroxyl, C_1-C_8 alkyl, aryl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, $(CR^5R^6)_d$ and $N(R^4)_2$ may form a 3-7 membered heterocyclic ring, comprising of aziridine, azetidine, pyrrolidine, 5-fluoropyrrolidine, piperidine, 6-fluoropiperidine, N-methylpiperazine, morpholine, 2,6-dimethylmorpholine, thiomorpholine, and wherein said heterocyclic ring may be optionally substituted with up to three of R^5; wherein R^5 and R^6 are independently selected from the group consisting of hydrogen, halo, hydroxyl, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl, sulfonate and CR^5R^6 may represent a carbocyclic or heterocyclic ring of from 5 to 6 carbons or alternatively, $(CR^5R^6)_d$ and $(CR^5R^6)_e$ may form a 3-7 membered carbocyclic or heterocyclic ring, wherein the ring may be optionally substituted with up to three of hydroxyl, halo, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl and sulfonate;

a is 0 or an integer of from 1 to 3;

d is 0 or an integer of from 1 to 5;

18572 CIP PCT (AP)

e is an integer of from 1 to 4;

f is 0 or an integer of from 1 to 2;

R^{II} is independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, aryloxy, aryloxyalkyl, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, (NR^2R^3)alkoxy, (NR^2R^3)alkenyl, (NR^2R^3)alkyl, (NR^2R^3)carbonylalkenyl, and (NR^2R^3)carbonylalkyl, wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

b is 0 or an integer of from 1 to 2;

Y is selected from the group consisting of:

(1') —(CH_2)g—O—(CH_2)h—;
(2') —(CH_2)g—NR^1—(CH_2)h—;
(3') —(CH_2)g—$S(O)_n$—(CH_2)h—;
(4') —(CH_2)g—SO_2N R^2—(CH_2)h—;
(5') —(CH_2)g—NR^2SO_2—(CH_2)h—;
(6') —(CH_2)g— CO—(CH_2)h—;
(7') —(CH_2)g— $C(O)NR^2$—(CH_2)h—;
(8') —(CH_2)g— $NR^2C(O)$—(CH_2)h—;
(9') —(CH_2)g—C≡C—(CH_2)h—;
(10') —(CH_2)g— $NR^2C(O)NR^3$—(CH_2)h—;
(11') —(CH_2)g—(CH_2)h—;
(12') —(CH_2)g—CF_2—(CH_2)h—;
(13') —(CH_2)g—CCl_2—(CH_2)h—;
(14') —(CH_2)g—CHF—(CH_2)h—;
(15') —(CH_2)g—CH(OH)—(CH_2)h—;
(16') —(CH_2)g—CR^2R^3—(CH_2)h—;
(17') —(CH_2)g—C═C—(CH_2)h—;
and (18') a single bond;

wherein

18572 CIP PCT (AP)


g is 0 or an integer of from 1 to 3;

h is 0 or an integer of from 1 to 3;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered cyclic ring;

Ring A is selected from the group consisting of:



(i) Phenyl;


(ii) Naphthyl;

(iii) A 5 or 6 membered monocyclic heteroaryl group which have 1-5 heteroatoms independently selected from the group consisting of O, N and S;

and (iv) An 8 to 10 membered bicyclic heteroaryl group which have 1-6 heteroatoms independently selected from the group consisting of O, N and S;

Ring A can be illustrated but not limited to the following:

18572 CIP PCT (AP)



wherein

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^{III} represents optionally 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl, C_1-C_5 alkoxy, hydroxy, amino, C_1-C_5 alkylamino, C1-C6 dialkylamino, halogen, cyano, and nitro;

Z is selected from the group consisting of

(1') $(CH_2)_iN(R^7)C(O)N(R^8)(CH_2)_j$;

(2') $(CH_2)_iN(R^7)C(S)N(R^8)(CH_2)_j$;

(3') $(CH_2)_iN(R^7)C(O)$;

(4') $C(O)N(R^8)(CH_2)_j$;

18572 CIP PCT (AP)

(5') $(CH_2)_iN(R^7)S(O)_2$;

and (6') $S(O)_2N(R^8)(CH_2)_j$;


wherein

i is 0 or 1;

j is 0 or 1;

R^7 and R^8 are independently selected from the group consisting of hydrogen and alkyl.

Ring B is selected from the group consisting of:



(i') Phenyl;


(ii') Naphthyl;

(iii') A 5 or 6 membered monocyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;

and (iv') An 8 to 10 membered bicyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;

18572 CIP PCT (AP)

Ring B can be illustrated but not limited to the following:



wherein

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^{IV} represents optionally 1-3 substituents, independently selected from the group consisting of alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and —NR^9R^{10}; wherein R^9 and R^{10} are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl.

Some embodiments of the present invention are included in the following paragraphs:

(1) A compound according to Formula I, including any tautomer, stereoisomer, diastereoisomeric form, polymorphic form, crystal form, a solvate, a hydrate, a metabolite, a pharmaceutically acceptable salt or prodrug, mixture of different stereoisomers, and any mixture of different crystal forms.


(2) A compound of Formula I in the form of a prodrug.

(3) The compound according to paragraph 1, wherein Z is selected from the group consisting of $(CH_2)_iN(R^7)C(O)$, $C(O)N(R^8)(CH_2)_j$, $(CH_2)_iN(R^7)S(O)_2$ and $S(O)_2N(R^8)(CH_2)_j$.

(4) The compound according to paragraphs 1 – 3, wherein Y is selected from the group consisting of —$(CH_2)g$—O—$(CH_2)h$—; —$(CH_2)g$—NR^1—$(CH_2)h$—;

—$(CH_2)g$—$S(O)_n$—$(CH_2)h$—; —$(CH_2)g$—$SO_2N\ R^2$—$(CH_2)h$—;
—$(CH_2)g$—NR^2SO_2—$(CH_2)h$—; —$(CH_2)g$— CO—$(CH_2)h$—;
—$(CH_2)g$— $C(O)NR^2$—$(CH_2)h$—; —$(CH_2)g$— $NR^2C(O\ )$—$(CH_2)h$—;
—$(CH_2)g$—C≡C—$(CH_2)h$—; —$(CH_2)g$— $NR^2C(O)NR^3$—$(CH_2)h$ and a single bond.

(5) The compound according to paragraphs 1 – 4, wherein Ring A and Ring B are independently selected from the group consisting of



(6) The compound according to paragraphs 1 – 5, wherein Y is selected from the group consisting of —$(CH_2)g$—$(CH_2)h$—; —$(CH_2)g$—CF_2—$(CH_2)h$—; —$(CH_2)g$—CCl_2—$(CH_2)h$—; —$(CH_2)g$—CHF—$(CH_2)h$—; —$(CH_2)g$—CH(OH)—$(CH_2)h$—;

—$(CH_2)g$—CR^2R^3—$(CH_2)h$—; and —$(CH_2)g$—C═C—$(CH_2)h$—.

(7) The compound according to paragraphs 1 – 6, wherein X is NH.

(8) A compound selected from the group consisting of

(1') [({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetic acid;

(2') methyl [({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetate;

(3') ({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)acetic acid;

(4') methyl ({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)acetate;

(5') 5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid;

(6') methyl 5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylate;

(7') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-hydroxy-1H-pyrrole-3-carboxamide;

(8') 4-fluoro-N-(2-fluoro-5-methylphenyl)-3-[(2-{4-[(3-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]benzamide;

(9) N-(2,3-dihydroxypropyl)-5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy) pyridin-2-yl]-1H-pyrrole-3-carboxamide;

(10) N-(2-fluoro-5-methylphenyl)-3-[(2-{4-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]benzamide;

(11') 5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-hydroxy-1H-pyrrole-3-carboxamide;

(12') methyl 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate;

(13') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid;

(14') N-ethyl-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide;

(15') N-(2,3-dihydroxypropyl)-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide;

(16') 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide;

(17') N-hydroxy-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide;

(18') N-(3-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-methyl-2-furamide;

(19') 5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid;

(20') methyl 5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate;

(21') 2,3-dihydroxypropyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate;

(22') 5-[4-(3-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid;

(23') methyl 5-[4-(3-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate;

(24') 2-hydroxyethyl 5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate;

(25') 2-hydroxyethyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate;

(26') 5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid;

(27') methyl 5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate;

(28') 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid;

(29') methyl 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate;

(30') N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide;

(31') N-(3-{[2-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-methyl-2-furamide;

(32') 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid;

(33') methyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate;

(34') 3-methyl-N-(3-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide;

(35') methyl 4-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-2-carboxylate;

(36') 2-fluoro-5-methyl-N-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)benzamide; and (37') 3-methyl-N-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide.

(9) The compound according to paragraph 1, wherein Z is $(CH_2)_iN(R^7)C(O)N(R^8)(CH_2)_j$ or $(CH_2)_iN(R^7)C(S)N(R^8)(CH_2)_j$, provided that when Ring B is pyrazole, R^{IV} is not a phenyl or substituted phenyl.

(10) The compound according to paragraph 9, wherein Y is selected from the group consisting of —(CH_2)g—O—(CH_2)h—; —(CH_2)g—NR^1—(CH_2)h—;

—(CH_2)g—$S(O)_n$—(CH_2)h—; —(CH_2)g—$SO_2N\ R^2$—(CH_2)h—;


—(CH_2)g—NR^2SO_2—(CH_2)h—; —(CH_2)g— CO—(CH_2)h—;

—(CH_2)g— $C(O)NR^2$—(CH_2)h—; —(CH_2)g— $NR^2C(O)$—(CH_2)h—;

—(CH_2)g—C≡C—(CH_2)h—; —(CH_2)g— $NR^2C(O)NR^3$—(CH_2)h, and a single bond.

(11) The compound according to paragraph 9, wherein Y is selected from the group consisting of —(CH_2)g—(CH_2)h—; —(CH_2)g—CF_2—(CH_2)h—; —(CH_2)g—CCl_2—(CH_2)h—; —(CH_2)g—CHF—(CH_2)h—; —(CH_2)g—CH(OH)—(CH_2)h—; —(CH_2)g—CR^2R^3—(CH_2)h—; and —(CH_2)g—C=C—(CH_2)h—.

(12) The compound according to paragraphs 9 – 11, wherein Ring A and Ring B are independently selected from the group consisting of




(13) The compound according to paragraphs 9 – 12, wherein X is NH.

(14) The compound according to paragraphs 9 – 12, wherein X is S.

(15) The compound according to paragraphs 9-14, wherein R^I is selected from the group consisting of hydrogen, halogen, C_1 to C_8 alkyl, $(CR^5R^6)_dC(O)OR^4$, $(CR^5R^6)_dAr$, $NR^4(CR^5R^6)_dAr$, $(CR^5R^6)_dC(O)N(R^4)_2$, $NR^4(CR^5R^6)_dC(O)N(R^4)_2$, $O(CR^5R^6)_dC(O)N(R^4)_2$, $(CR^5R^6)_dOR^4$, $OC(O)(CR^5R^6)_dN(R^4)_2$, $C(O)(CR^5R^6)_dN(R^4)_2$, $C(O)N=S(O)R^5R^6$, $NR^2C(O)(CR^5R^6)_dN(R^4)_2$, $(CR^5R^6)_dR^5$, $HNC(O)R^4$, $HN\text{-}C(O)OR^4$, $(CR^5R^6)_dN(R^4)_2$, $S(O)_f(CR^5R^6)_dN(R^4)_2$, $OC(O)OR^4$, $(CR^5R^6)_dC(O)(CR^5R^6)_dR^4$, $(CR^5R^6)_dC(O)(CR^5R^6)_dOR^4$, and $(CR^5R^6)_dC(O)(CR^5R^6)_dN(R^4)_2$, wherein each R^4 is independently selected from the group consisting of hydrogen, hydroxyl, C_1-C_8 alkyl, aryl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, $(CR^5R^6)_d$ and $N(R^4)_2$ may form a 3-7 membered heterocyclic ring, comprising of aziridine, azetidine, pyrrolidine, 5-fluoropyrrolidine, piperidine, 6-fluoropiperidine, N-methylpiperazine, morpholine, 2,6-dimethylmorpholine, thiomorpholine, and wherein said heterocyclic ring may be optionally substituted with up to three of R^5; wherein R^5 and R^6 are independently selected from the group consisting of hydrogen, halo, hydroxyl, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl, sulfonate and CR^5R^6 may represent a carbocyclic or heterocyclic ring of from 5 to 6 carbons or alternatively, $(CR^5R^6)_d$ and $(CR^5R^6)_e$ may form a 3-7 membered carbocyclic or heterocyclic ring, wherein the ring may be optionally substituted with up to three of hydroxyl, halo, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl and sulfonate.

(16) A compound of Formula II:

18572 CIP PCT (AP)



Formula II

wherein

W is C or N;

X is selected from the group consisting of NR^1, O, and $S(O)_n$;

n is 0 or an integer of from 1 to 2;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^5 and R^6 are independently selected from the group consisting of hydrogen, halo, hydroxyl, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl, sulfonate;

R^{II} is independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, aryloxy, aryloxyalkyl, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, (NR^2R^3)alkoxy, (NR^2R^3)alkenyl, (NR^2R^3)alkyl, (NR^2R^3)carbonylalkenyl, and (NR^2R^3)carbonylalkyl, wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

b is 0 or an integer of from 1 to 2;

Y is selected from the group consisting of:

(1') —(CH_2)g—O—(CH_2)h—;

18572 CIP PCT (AP)

(2') —$(CH_2)g—NR^1—(CH_2)h$—;
(3') —$(CH_2)g—S(O)_n—(CH_2)h$—;
(4') —$(CH_2)g—SO_2N\ R^2—(CH_2)h$—;
(5') —$(CH_2)g—NR^2SO_2—(CH_2)h$—;
(6') —$(CH_2)g—\ CO—(CH_2)h$—;
(7') —$(CH_2)g—\ C(O)NR^2—(CH_2)h$—;
(8') —$(CH_2)g—\ NR^2C(O\ )—(CH_2)h$—;
(9') —$(CH_2)g—C\equiv C—(CH_2)h$—;
(10') —$(CH_2)g—\ NR^2C(O)NR^3—(CH_2)h$—;
(11') —$(CH_2)g—(CH_2)h$—;
(12') —$(CH_2)g—CF_2—(CH_2)h$—;
(13') —$(CH_2)g—CCl_2—(CH_2)h$—;
(14') —$(CH_2)g—CHF—(CH_2)h$—;
(15') —$(CH_2)g—CH(OH)—(CH_2)h$—;
(16') —$(CH_2)g—CR^2R^3—(CH_2)h$—;
(17') —$(CH_2)g—C{=}C—(CH_2)h$—;
and (18') a single bond;

wherein


g is 0 or an integer of from 1 to 3;

h is 0 or an integer of from 1 to 3;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered cyclic ring;


Ring A is selected from the group consisting of:



(i) Phenyl;
(ii) Naphthyl;
(iii) A 5 or 6 membered monocyclic heteroaryl group which have 1-5 heteroatoms independently selected from the group consisting of O, N and S;

and (iv) An 8 to 10 membered bicyclic heteroaryl group which have 1-6 heteroatoms independently selected from the group consisting of O, N and S;

Ring A can be illustrated but not limited to the following:



wherein

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^{III} represents optionally 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl, C_1-C_5 alkoxy, hydroxy, amino, C_1-C_5 alkylamino, C1-C6 dialkylamino, halogen, cyano, and nitro;

Z is selected from the group consisting of

(1') $(CH_2)_iN(R^7)C(O)N(R^8)(CH_2)_j$;
(2') $(CH_2)_iN(R^7)C(S)N(R^8)(CH_2)_j$;
(3') $(CH_2)_iN(R^7)C(O)$;
(4') $C(O)N(R^8)(CH_2)_j$;
(5') $(CH_2)_iN(R^7)S(O)_2$;
and (6') $S(O)_2N(R^8)(CH_2)_j$;


wherein

i is 0 or 1;
j is 0 or 1;

18572 CIP PCT (AP)


R^7 and R^8 are independently selected from the group consisting of hydrogen and alkyl;

Ring B is selected from the group consisting of:



(i') Phenyl;
(ii') Naphthyl;
(iii') A 5 or 6 membered monocyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;
and (iv') An 8 to 10 membered bicyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;

Ring B can be illustrated but not limited to the following:



wherein

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^{IV} represents optionally 1-3 substituents, independently selected from the group consisting of alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy,


haloalkyl, hydroxy, hydroxyalkyl, nitro, and —NR^9R^{10}; wherein R^9 and R^{10} are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl;

and any pharmaceutical acceptable salt or prodrug.

(17) The compound according to paragraph 16, wherein Z is selected from the group consisting of $(CH_2)_iN(R^7)C(O)$, $C(O)N(R^8)(CH_2)_j$, $(CH_2)_iN(R^7)C(O)N(R^8)(CH_2)_j$ and $(CH_2)_iN(R^7)C(S)N(R^8)(CH_2)_j$.

(18) The compound according to paragraphs 16 – 17, wherein Y is selected from the group consisting of —$(CH_2)g$—O—$(CH_2)h$—; —$(CH_2)g$—NR^1—$(CH_2)h$—; —$(CH_2)g$—$S(O)_n$—$(CH_2)h$—; —$(CH_2)g$—$SO_2N\ R^2$—$(CH_2)h$—; —$(CH_2)g$—NR^2SO_2—$(CH_2)h$—; —$(CH_2)g$— CO—$(CH_2)h$—; —$(CH_2)g$— $C(O)NR^2$—$(CH_2)h$—; —$(CH_2)g$— $NR^2C(O\ )$—$(CH_2)h$—; —$(CH_2)g$—C≡C—$(CH_2)h$—; —$(CH_2)g$— $NR^2C(O)NR^3$—$(CH_2)h$ and a single bond.

(19) The compound according to paragraphs 16 – 18, wherein Ring A and Ring B are independently selected from the group consisting of



(20) The compound according to paragraphs 16-19, wherein W is C.

(21) A method of use of the compounds of paragraphs 1 – 20, wherein the compounds are used as tyrosine kinase modulators;

(22) Use of the compounds of paragraphs 1 – 20 in the preparation of a medicament for the treatment or prevention of diseases or conditions related with unregulated tyrosine kinase activities, comprising administering a therapeutically effective amount of the compound of paragraphs 1 – 20 together with a pharmaceutically acceptable carrier;

(23) The use of paragraph 22, wherein the diseases or conditions are selected from the group consisting of cell growth and metabolic disorders, blood vessel proliferative disorders, inflammatory disorders, neurodegenerative diseases, and immune disorders.

(24) The use of paragraphs 22 – 23 wherein the diseases or conditions are selected from the group consisting of colorectal cancer, lung cancer, hematological cancer, renal cancer, liver cancer, breast cancer, diabetic retinopathy, macular degeneration, age-related macular degeneration, retinopathy of prematurity, ocular angiogenesis, retinal edema, retinal ischemia, diabetic macular edema, cystoid macular edema, retinal vein occlusion, branch vein occlusion, preretinal neovascularization, laser-induced choroidal neovascularization, neovascularization associated with keratoplasty, glaucoma and ocular tumors, arthritis, restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, diabetes mellitus, wound healing, inflammation, neurodegenerative diseases and immune disorders.

(25) The use of paragraphs 22 – 23 wherein the conditions and diseases are wound healing or to alleviate transplant rejection.

(26) A pharmaceutical composition comprising a therapeutic effective amount of a compound according to paragraphs 1 – 20 together with a pharmaceutically acceptable carrier which is suitable for systematic, parenteral, local or topical delivery.

(27) The pharmaceutical composition of paragraph 26, which are in the form selected from the group comprising of tablets, capsules, intravenous injections, intramuscular injections, local injections, topical creams, gels and ointments, eye drops, ophthalmic solutions, ophthalmic suspensions, ophthalmic emulsions, intravitreal injections, subtenon injections, ophthalmic biodrodible implant, and non-bioeordible ophthalmic inserts or depots.

(28) Use of the compounds of paragraphs 1-20 in the preparation of a medicament for the treatment of diseases and conditions, wherein the medicament contains pharmaceutical acceptable composition according to paragraphs 26 and 27.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a powder X-Ray Diffraction (XRPD) of Example 78;

Fig 2 shows a powder X-Ray Diffraction (XRPD) of Example 69;

18572 CIP PCT (AP)

Fig 3 shows a fluorescein angiography (blood-retinal barrier breakdown) of Example 121, Example 84 Sodium, Example 83, Example 78, Example 75 Sodium, Example 69, and Example 66; and

Fig 4 shows a fundus photography (retinal vasodilation and vessel tortuosity) of Example 121, Example 84 Sodium, Example 83, Example 78, Example 75 Sodium, Example 69, and Example 66.


DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a series of compounds with multiple aromatic components useful as protein tyrosine kinase inhibitors. The compounds of the present invention are useful for treating diseases related to unregulated tyrosine kinase signal transduction, for example, cancer, blood vessel proliferative disorders, fibrotic disorders, and neurodegenerative diseases. In particular, compounds of the present invention are useful for the treatment of colorectal cancer, lung cancer, hematological cancer, renal cancer, liver cancer, breast cancer, diabetic retinopathy, macular degeneration, age-related macular degeneration, retinopathy of prematurity, ocular angiogenesis, retinal edema, retinal ischemia, diabetic macular edema, cystoid macular edema, retinal vein occlusion, branch vein occlusion, preretinal neovascularization, laser-induced choroidal neovascularization, neovascularization associated with keratoplasty, glaucoma and ocular tumors, arthritis, restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, diabetes mellitus, wound healing, transplant rejection, inflammation, neurodegenerative diseases and immune disorders.

18572 CIP PCT (AP)

1. Compounds of the Invention

In one aspect of the invention, the compounds of the present invention can be represented by the general formula I:



Formula I

wherein

X is selected from the group consisting of NR^1, O, and $S(O)_n$;

n is 0 or an integer of from 1 to 2;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^I is selected from the group consisting of hydrogen, halogen, C_1 to C_8 alkyl, $S(O)_fR^4$, $(CR^5R^6)_dC(O)OR^4$, $S(O)_f(CR^5R^6)_dC(O)OR^4$, $(CR^5R^6)_dAr$, $NR^4(CR^5R^6)_dAr$, $O(CR^5R^6)_dAr$, $S(O)_f(CR^5R^6)_dAr$, $(CR^5R^6)_dS(O)_fR^4$, $NR^4(CR^5R^6)_dS(O)_fR^4$, $O(CR^5R^6)_d S(O)_fR^4$, $S(O)_f(CR^5R^6)_eS(O)_fR^4$, $(CR^5R^6)_dC(O)N(R^4)_2$, $NR^4(CR^5R^6)_dC(O)N(R^4)_2$, $O(CR^5R^6)_dC(O)N(R^4)_2$, $S(O)_f(CR^5R^6)_eC(O)N(R^4)_2$, $(CR^5 R^6)_dOR^4$, $S(O)_f(CR^5R^6)_dOR^4$, $(CR^5 R^6)_dOSO_2R^4$, $S(O)_f(CR^5 R^6)_eOSO_2R^4$, $(CR^5 R^6)_dP(O)(OR^4)_2$, $S(O)_f(CR^5 R^6)_eP(O)(OR^4)_2$, $OC(O)(CR^5R^6)_dN(R^4)_2$, $C(O)(CR^5R^6)_dN(R^4)_2$, $C(O)N=S(O)R^5 R^6$, $NR^2C(O)(CR^5R^6)_dN(R^4)_2$, $(CR^5R^6)_dR^5$, $S(O)_f(CR^5R^6)_dR^5$, $HNC(O)R^4$, $HN\text{-}C(O)OR^4$, $(CR^5R^6)_dN(R^4)_2$, $S(O)_f (CR^5R^6)_dN(R^4)_2$, $OC(O)OR^4$, $(CR^5R^6)_dC(O)(CR^5R^6)_dR^4$, $(CR^5R^6)_dC(O)(CR^5R^6)_dOR^4$, and $(CR^5R^6)_dC(O)(CR^5R^6)_dN(R^4)_2$, wherein each R^4 is independently selected from the group consisting of hydrogen, hydroxyl, C_1-C_8 alkyl, aryl,

C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, $(CR^5R^6)_d$ and $N(R^4)_2$ may form a 3-7 membered heterocyclic ring, comprising of aziridine, azetidine, pyrrolidine, 5-fluoropyrrolidine, piperidine, 6-fluoropiperidine, N-methylpiperazine, morpholine, 2,6-dimethylmorpholine, thiomorpholine, and wherein said heterocyclic ring may be optionally substituted with up to three of R^5; wherein R^5 and R^6 are independently selected from the group consisting of hydrogen, halo, hydroxyl, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl, sulfonate and CR^5R^6 may represent a carbocyclic or heterocyclic ring of from 5 to 6 carbons or alternatively, $(CR^5R^6)_d$ and $(CR^5R^6)_e$ may form a 3-7 membered carbocyclic or heterocyclic ring, wherein the ring may be optionally substituted with up to three of hydroxyl, halo, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl and sulfonate;

a is 0 or an integer of from 1 to 3;

d is 0 or an integer of from 1 to 5;

e is an integer of from 1 to 4;

f is 0 or an integer of from 1 to 2;

R^{II} is independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, aryloxy, aryloxyalkyl, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, (NR^2R^3)alkoxy, (NR^2R^3)alkenyl, (NR^2R^3)alkyl, (NR^2R^3)carbonylalkenyl, and (NR^2R^3)carbonylalkyl, wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

b is 0 or an integer of from 1 to 2;

Y is selected from the group consisting of:

(1') —(CH_2)g—O—(CH_2)h—;

(2') —(CH_2)g—NR^1—(CH_2)h—;

(3') —(CH_2)g—$S(O)_n$—(CH_2)h—;

(4') —(CH_2)g—SO_2N R^2—(CH_2)h—;

(5') —$(CH_2)g—NR^2SO_2—(CH_2)h$—;

(6') —$(CH_2)g$— CO—$(CH_2)h$—;

(7') —$(CH_2)g$— $C(O)NR^2$—$(CH_2)h$—;

(8') —$(CH_2)g$— $NR^2C(O)$—$(CH_2)h$—;

(9') —$(CH_2)g—C\equiv C—(CH_2)h$—;

(10') —$(CH_2)g$— $NR^2C(O)NR^3$—$(CH_2)h$—;

(11') —$(CH_2)g—(CH_2)h$—;

(12') —$(CH_2)g—CF_2—(CH_2)h$—;

(13') —$(CH_2)g—CCl_2—(CH_2)h$—;

(14') —$(CH_2)g$—CHF—$(CH_2)h$—;

(15') —$(CH_2)g$—CH(OH)—$(CH_2)h$—;

(16') —$(CH_2)g—CR^2R^3—(CH_2)h$—;

(17') —$(CH_2)g—C{=}C—(CH_2)h$—;

and (18') a single bond.

wherein

g is 0 or an integer of from 1 to 3;


h is 0 or an integer of from 1 to 3;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

18572 CIP PCT (AP)

R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered cyclic ring;

Ring A is selected from the group consisting of:




(i) Phenyl;

(ii) Naphthyl;

(iii) A 5 or 6 membered monocyclic heteroaryl group which have 1-5 heteroatoms independently selected from the group consisting of O, N and S;

and (iv) An 8 to 10 membered bicyclic heteroaryl group which have 1-6 heteroatoms independently selected from the group consisting of O, N and S;

Ring A can be illustrated but not limited to the following:



wherein

18572 CIP PCT (AP)

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N.

R^{III} represents optionally 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl, C_1-C_5 alkoxy, hydroxy, amino, C_1-C_5 alkylamino, C1-C6 dialkylamino, halogen, cyano, and nitro;

Z is selected from the group consisting of

(1') $(CH_2)_iN(R^7)C(O)N(R^8)(CH_2)_j$;

(2') $(CH_2)_iN(R^7)C(S)N(R^8)(CH_2)_j$;

(3') $(CH_2)_iN(R^7)C(O)$;

(4') $C(O)N(R^8)(CH_2)_j$;

(5') $(CH_2)_iN(R^7)S(O)_2$;

and (6') $S(O)_2N(R^8)(CH_2)_j$;


wherein

i is 0 or 1;

j is 0 or 1;

R^7 and R^8 are independently selected from the group consisting of hydrogen and alkyl;

Ring B is selected from the group consisting of:



(i') Phenyl;


18572 CIP PCT (AP)

(ii') Naphthyl;

(iii') A 5 or 6 membered monocyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;

and (iv') An 8 to 10 membered bicyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;

Ring B can be illustrated but not limited to the following:




wherein

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^{IV} represents optionally 1-3 substituents, independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and —NR^9R^{10}; wherein R^9 and R^{10} are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl;

18572 CIP PCT (AP)

In another aspect of the invention, the compounds of the present invention can be represented by the general formula II:



Formula II

wherein

W is C or N;

X is selected from the group consisting of NR^1, O, and $S(O)_n$;

n is 0 or an integer of from 1 to 2;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^5 and R^6 are independently selected from the group consisting of hydrogen, halo, hydroxyl, C_1-C_8 alkyl, C_1-C_8 hydroxyalkyl, C_1-C_8 alkoxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, hydroxycarbonyl, hydroxycarbonylalkyl, amide, alkylamide, amidoalkyl, and sulfonate;

R^{II} is independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, aryloxy, aryloxyalkyl, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, (NR^2R^3)alkoxy, (NR^2R^3)alkenyl, (NR^2R^3)alkyl, (NR^2R^3)carbonylalkenyl, and (NR^2R^3)carbonylalkyl, wherein R^2 and R^3 are independently selected from the group consisting

of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

b is 0 or an integer of from 1 to 2;

Y is selected from the group consisting of:

(1') —(CH_2)g—O—(CH_2)h—;

(2') —(CH_2)g—NR^1—(CH_2)h—;

(3') —(CH_2)g—$S(O)_n$—(CH_2)h—;

(4') —(CH_2)g—SO_2N R^2—(CH_2)h—;

(5') —(CH_2)g—NR^2SO_2—(CH_2)h—;

(6') —(CH_2)g— CO—(CH_2)h—;

(7') —(CH_2)g— C(O)NR^2—(CH_2)h—;

(8') —(CH_2)g— NR^2C(O)—(CH_2)h—;

(9') —(CH_2)g—C≡C—(CH_2)h—;

(10') —(CH_2)g— NR^2C(O)NR^3—(CH_2)h—;

(11') —(CH_2)g—(CH_2)h—;

(12') —(CH_2)g—CF_2—(CH_2)h—;

(13') —(CH_2)g—CCl_2—(CH_2)h—;

(14') —(CH_2)g—CHF—(CH_2)h—;

(15') —(CH_2)g—CH(OH)—(CH_2)h—;

(16') —(CH_2)g—CR^2R^3—(CH_2)h—;

(17') —(CH_2)g—C═C—(CH_2)h—;

and (18') a single bond;

wherein

g is 0 or an integer of from 1 to 3;


h is 0 or an integer of from 1 to 3;

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and

heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered cyclic ring;

Ring A is selected from the group consisting of:




(i) Phenyl;

(ii) Naphthyl;

(iii) A 5 or 6 membered monocyclic heteroaryl group which have 1-5 heteroatoms independently selected from the group consisting of O, N and S;

and (iv) An 8 to 10 membered bicyclic heteroaryl group which have 1-6 heteroatoms independently selected from the group consisting of O, N and S;

Ring A can be illustrated but not limited to the following:



wherein

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl,


haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively R^2 and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^{III} represents optionally 1-3 substituents independently selected from the group consisting of C_1-C_5 linear or branched alkyl, C_1-C_5 linear or branched haloalkyl, C_1-C_5 alkoxy, hydroxy, amino, C_1-C_5 alkylamino, C1-C6 dialkylamino, halogen, cyano, and nitro;

Z is selected from the group consisting of


(1') $(CH_2)_iN(R^7)C(O)N(R^8)(CH_2)_j$;
(2') $(CH_2)_iN(R^7)C(S)N(R^8)(CH_2)_j$;
(3') $(CH_2)_iN(R^7)C(O)$;
(4') $C(O)N(R^8)(CH_2)_j$;
(5') $(CH_2)_iN(R^7)S(O)_2$;
and (6') $S(O)_2N(R^8)(CH_2)_j$;
wherein
i is 0 or 1;
j is 0 or 1;
R^7 and R^8 are independently selected from the group consisting of hydrogen and alkyl.

Ring B is selected from the group consisting of:



(i') Phenyl;
(ii') Naphthyl;
(iii') A 5 or 6 membered monocyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;
and (iv') An 8 to 10 membered bicyclic heteroaryl group which have 1-3 heteroatoms independently selected from the group consisting of O, N and S;

Ring B can be illustrated but not limited to the following:



wherein

R^1 is independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, CF_3, alkyl, alkylcarbonyl, alkoxycarbonyl, aryl, heterocycloalkyl, hydroxyalkyl, and alkyl(N R^2R^3), wherein R^2 and R^3 are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl, and heterocyclylsulfonyl; alternatively $R^2$and R^3 and may be taken together to form a 5-7 membered heterocyclic ring with N;

R^{IV} represents optionally 1-3 substituents, independently selected from the group consisting of alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, nitro, and —NR^9R^{10}; wherein R^9 and R^{10} are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl;
and including any pharmaceutically acceptable salt or prodrug.

Unless otherwise indicated, reference to a compound should be construed broadly to include compounds, pharmaceutically acceptable salts, prodrugs, tautomers, stereoisomers, diastereoisomers, alternate solid forms, crystal forms, polymorphic forms, hydrates, solvates, metabolites, mixtures of stereoisomers, mixtures of crystal forms, non-covalent complexes, and combinations thereof, of a chemical entity of a depicted structure or a chemical name. Whenever

there is a conflict between chemical name and its structure drawing, the structure drawing should be used to interpret the compound of the present invention.

A pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human. A pharmaceutically acceptable salt also refers to any salt which may form *in vivo* as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt. A salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).

A "prodrug" is a compound, which when administered to the body of a subject (such as a mammal), breaks down in the subject's metabolic pathway to provide an active compound of Formula I. More specifically, a prodrug is an active or inactive "masked" compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a subject or patient. One common form of a prodrug is a masked carboxylic acid group. Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bundgaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, Apr. 11, 1981) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group. Prodrug preparation is well known in the art. For example, “Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, *Organic Chemistry of Drug Design and Drug Action*, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496-557, provides further detail on the subject.

Tautomers are isomers that are in rapid equilibrium with one another. For example, tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion. Unless stereochemistry is explicitly and unambiguously depicted, a structure is intended to include every possible stereoisomer, both pure or in any possible mixture.

Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein. For example, alternate solid forms may be amorphous forms, crystal forms, polymorphs, and the mixtures thereof.

Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.

2. Uses, Formulation and Administration

The present invention is also directed to the use of the compounds as protein tyrosine kinase modulators and inhibitors. These compounds can be used to treat diseases related to unregulated tyrosine kinase signal transduction, for example, various cancers, blood vessel proliferative disorders, fibrotic disorders, and neurodegenerative diseases. In particular, compounds of the present invention are useful for the treatment and/or prevention of colorectal cancer, lung cancer, hematological cancer, renal cancer, liver cancer, breast cancer, diabetic retinopathy, macular degeneration, age-related macular degeneration, retinopathy of prematurity, ocular angiogenesis, retinal edema, retinal ischemia, diabetic macular edema, cystoid macular edema, retinal vein occlusion, branch vein occlusion, preretinal neovascularization, laser-induced choroidal neovascularization, neovascularization associated with keratoplasty, glaucoma and ocular tumors, arthritis, restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, diabetes mellitus, wound healing, transplant rejection, inflammation, neurodegenerative diseases and immune disorders in the human being.

For the purposes of this disclosure, “treat,” “treating,” or “treatment” refer to the diagnosis, cure, mitigation, treatment, or prevention of disease or other undesirable condition.

18572 CIP PCT (AP)

The present invention is also directed to the preparation of a medicament for the treatment and prevention of diseases and conditions related with abnormal activities of tyrosine kinase receptors. The medicament contains a pharmaceutical acceptable composition, which comprises the therapeutic effective amount of the compounds of present invention, together with a pharmaceutical acceptable carrier.







The pharmaceutical acceptable compositions contain therapeutic effective amount of the compounds of the present invention. These compositions can be used as a medicament and administered to a mammal, such as a person, in need thereof. Different types of suitable dosage forms and medicaments are well known in the art, and can be readily adapted for delivery of the compounds of the present invention, such as, but not limited to, systematic, parenteral, local and topical delivery. The dosage forms can be tablets, capsules, intravenous injections, intramuscular injections, local injections, topical creams, gels and ointments, eye drops, ophthalmic solutions, ophthalmic suspensions, ophthalmic emulsions, intravitreal injections, subtenon injections, ophthalmic biodrodible implant, and non-bioeordible ophthalmic inserts or depots, nasal sprays and ointment, various rectal or vaginal preparations.








3. Examples








Some of the compounds of the present invention are listed in Table I.








Table 1: Exemplified Compounds of the Present Invention







18572 CIP PCT (AP)







Example#	Chemical Structure	MW	Chemical Name
1		506	[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetic acid
2		520	methyl [({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetate
3		460	({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)acetic acid
4		474	methyl ({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)acetate
5		402	5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid
6		416	methyl 5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylate







7		464	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-hydroxy-1H-pyrrole-3-carboxamide
8		533	4-fluoro-N-(2-fluoro-5-methylphenyl)-3-[(2-{4-[(3-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]benzamide
9		505	N-(2,3-dihydroxypropyl)-5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide
10		501	N-(2-fluoro-5-methylphenyl)-3-[(2-{4-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]benzamide
11		446	5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-hydroxy-1H-pyrrole-3-carboxamide
12		463	methyl 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate
13		449	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid








14		430	N-ethyl-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide
15		476	N-(2,3-dihydroxypropyl)-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide
16		402	5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide
17		418	N-hydroxy-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide
18		472	N-(3-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-methyl-2-furamide
19		431	5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid
20		445	methyl 5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate








21		477	2,3-dihydroxypropyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate
22		413	5-[4-(3-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid
23		427	methyl 5-[4-(3-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate
24		464	2-hydroxyethyl 5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate
25		447	2-hydroxyethyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate
26		419	5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid
27		433	methyl 5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate






28		421	5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid
29		435	methyl 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate
30		479	N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide
31		472	N-(3-{[2-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-methyl-2-furamide
32		403	5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid
33		417	methyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate








34		359	3-methyl-N-(3-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide
35		417	methyl 4-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-2-carboxylate
36		387	2-fluoro-5-methyl-N-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)benzamide
37		359	3-methyl-N-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide
38		573	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide
39		479	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-hydroxy-1H-pyrrole-3-carboxamide







40		521	{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}acetic acid
41		535	methyl {[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}acetate
42		478	methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylate
43		603	(4S)-5-(ethylamino)-4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid
44		659	tert-butyl (4S)-5-(ethylamino)-4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoate
45		632	(2S)-5-tert-butoxy-2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid








46		646	5-tert-butyl 1-methyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate
47		664	bis(2-hydroxyethyl) 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate
48		518	3-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoic acid
49		576	2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid
50		615	methyl 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylate
51		573	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{2-[(3S)-3-hydroxypyrrolidin-1-yl]-2-oxoethyl}-1H-pyrrole-3-carboxamide
52		619	N-{4-[(2,3-dihydroxypropyl)(methyl)amino]-4-oxobutyl}-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide







53		615	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[4-(3-hydroxypiperidin-1-yl)-4-oxobutyl]-1H-pyrrole-3-carboxamide
54		605	N-{4-[(2,3-dihydroxypropyl)amino]-4-oxobutyl}-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
55		531	N-(4-amino-4-oxobutyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
56		577	N-{2-[(2,3-dihydroxypropyl)amino]-2-oxoethyl}-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
57		664	5-(2,3-dihydroxypropyl) 1-methyl 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate
58		724	bis(2,3-dihydroxypropyl) 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate
59		590	4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-methoxy-5-oxopentanoic acid








60		559	N-[4-(ethylamino)-4-oxobutyl]-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
61		601	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[4-(3-hydroxypyrrolidin-1-yl)-4-oxobutyl]-1H-pyrrole-3-carboxamide
62		547	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[4-(hydroxyamino)-4-oxobutyl]-1H-pyrrole-3-carboxamide
63		576	2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid
64		604	dimethyl 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate








65		562	1-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]pyrrolidine-3-carboxylic acid
66		550	4-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid
67		578	ethyl 4-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate
68		532	4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid
69		536	3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoic acid
70		474	N-ethyl-5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
71		503	{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid







72		518	methyl {[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate
73		516	1-(2-fluoro-4-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-(3-methylphenyl)urea
74		530	1-{2-fluoro-4-[(2-{4-[(3-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}-3-(3-methylphenyl)urea
75		446	5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid
76		460	methyl 5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
77		622	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)-1H-pyrrole-3-carboxamide








78		532	4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid
79		560	ethyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate
80		463	5-(4-{[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]thio}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid
81		518	3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoic acid
82		576	4-{S-methyl-N-[(5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]sulfonimidoyl}butanoic acid
83		544	1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]pyrrolidine-3-carboxylic acid
84		503	{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid








85		518	methyl {[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate
86		594	1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidine-4-sulfonic acid
87		590	methyl 4-{S-methyl-N-[(5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]sulfonimidoyl}butanoate
88		477	methyl 5-(4-{[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]thio}pyridin-2-yl)-1H-pyrrole-3-carboxylate
89		441	N-methyl-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
90		512	1-{4-[(2-{4-[(3-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}-3-(3-methylphenyl)urea







91		498	1-{4-[(2-{4-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}-3-(3-methylphenyl)urea
92		502	N-(2,3-dihydroxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
93		456	N-ethyl-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
94		427	5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
95		443	N-hydroxy-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
96		464	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid
97		504	N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide







98		561	2-hydroxyethyl 5-(4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate
99		592	5-(4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-1H-pyrrole-3-carboxamide
100		608	methyl 4-{N-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]-S-methylsulfonimidoyl}butanoate
101		522	N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
102		601	methyl (2S)-1-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)pyrrolidine-2-carboxylate
103		502	N,N-diethyl-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
104		529	1-(2-fluoro-5-methylphenyl)-3-{4-[(2-{4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}urea








105		543	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
106		471	1-[4-({2-[4-(aziridin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(2-fluoro-5-methylphenyl)urea
107		445	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
108		461	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-hydroxy-1H-pyrrole-3-carboxamide
109		486	1-[4-({2-[4-(azetidin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(2-fluoro-5-methylphenyl)urea
110		504	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-hydroxypropyl)-1H-pyrrole-3-carboxamide






111		549	2-(2-methoxyethoxy)ethyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
112		474	N-ethyl-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
113		505	2-methoxyethyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
114		504	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
115		428	5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid
116		442	methyl 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
117		464	5-{4-[2-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid

118		478	methyl 5-{4-[2-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
119		500	5-(4-{4-[({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid
120		514	methyl 5-(4-{4-[({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate
121		517	5-(4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid
122		531	methyl 5-(4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate
123		463	4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylic acid
124		490	2-hydroxyethyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate

125		572	{1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidin-4-yl}acetic acid
126		586	methyl {1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidin-4-yl}acetate
127		520	N-(2,3-dihydroxypropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
128		490	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide
129		530	1-(2-fluoro-5-methylphenyl)-3-{4-[(2-{4-[(4-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}urea
130		521	2,3-dihydroxypropyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate







131		490	2-hydroxyethyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
132		516	1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea
133		516	1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea
134		446	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid
135		460	methyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
136		460	methyl 4-{4-[3-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate







137		522	N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxamide
138		474	4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N,N-dimethyl-1H-pyrrole-2-carboxamide
139		459	4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-methyl-1H-pyrrole-2-carboxamide
140		576	1-tert-butyl 2-methyl 4-{6-amino-4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-1,2-dicarboxylate
141		417	1-(4-{[2-amino-6-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-(2-fluoro-5-methylphenyl)urea
142		446	4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylic acid
143		460	methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate







144		402	1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea
145		354	1-phenyl-3-{4-[6-(1H-pyrrol-2-yl)pyridin-3-yl]phenyl}urea
146		386	1-(2-fluoro-5-methylphenyl)-3-{3-[2-(1H-pyrrol-2-yl)pyridin-4-yl]phenyl}urea
147		386	1-(2-fluoro-5-methylphenyl)-3-{4-[2-(1H-pyrrol-3-yl)pyridin-4-yl]phenyl}urea
148		386	1-(2-fluoro-5-methylphenyl)-3-{4-[2-(1H-pyrrol-2-yl)pyridin-4-yl]phenyl}urea







Additional compounds of the present invention are listed below.







Example #	Chemical Structure	MW	Chemical Name







149		556	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(2H-tetrazol-5-yl)propyl]-1H-pyrrole-3-carboxamide
150		542	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[2-(2H-tetrazol-5-yl)ethyl]-1H-pyrrole-3-carboxamide
151		558	N-(3,3-diethoxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
152		489	N-(2-aminoethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
153		589	tert-butyl (2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate
154		575	methyl [(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)amino]acetate







155		561	methyl [(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)amino]acetate
156		633	dimethyl 2,2'-[(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)imino]diacetate
157		644	ethyl [4-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazin-1-yl]acetate
158		658	ethyl [4-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)piperazin-1-yl]acetate
159		603	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[2-(hydroxymethyl)morpholin-4-yl]propyl}-1H-pyrrole-3-carboxamide
160		601	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[3-(hydroxymethyl)piperidin-1-yl]propyl}-1H-pyrrole-3-carboxamide







161		617	methyl rel-(2R,4S)-1-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)-4-hydroxypyrrolidine-2-carboxylate
162		487	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide
163		562	N-(2,2-diethoxyethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
164		631	methyl rel-(2R,4S)-1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)-4-hydroxypyrrolidine-2-carboxylate
165		547	4-methoxy-4-oxobutyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
166		546	5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoic acid







167		574	ethyl 5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoate
168		648	ethyl 4-(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazine-1-carboxylate
169		505	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide
170		580	N-(2,2-diethoxyethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
171		647	ethyl 4-{3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}piperazine-1-carboxylate
172		662	ethyl 4-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)piperazine-1-carboxylate







173		581	ethyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate
174		532	methyl 3-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate
175		550	methyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate
176		546	methyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate
177		546	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(4-hydrazino-4-oxobutyl)-1H-pyrrole-3-carboxamide
178		650	dimethyl 2,2'-({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}imino)diacetate







179		636	dimethyl 2,2'-({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}imino)diacetate
180		578	methyl ({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}amino)acetate
181		564	methyl ({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}amino)acetate
182		491	N-(2-aminoethyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide
183		592	tert-butyl {2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}carbamate
184		590	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide







185		486	1-[4-({2-[4-(azetidin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(2-fluoro-5-methylphenyl)urea
186		589	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide
187		560	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide
188		590	methyl 1-[3-({[5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)propyl]pyrrolidine-2-carboxylate
189		562	5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide
190		476	5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide(Last 0ne for early filing in 2010)







191		546	5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-piperidin-1-ylpropyl)-1H-pyrrole-3-carboxamide
192		532	5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide
193		561	5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide
194		548	5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide
195		609	N-{3-[(2,3-dihydroxypropyl)(methyl)amino]propyl}-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
196		593	methyl [(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)amino]acetate







197		553	3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoic acid
198		567	methyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate
199		536	3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-2-yl)carbonyl]amino}propanoic acid
200		550	methyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-2-yl)carbonyl]amino}propanoate
201		611	N-(3,3-diethoxypropyl)-4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxamide
202		594	N-(3,3-diethoxypropyl)-4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxamide







203		551	N-(3,3-diethoxypropyl)-5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide
204		579	N-(3,3-diethoxypropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide
205		619	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[3-(hydroxymethyl)piperidin-1-yl]propyl}-1H-pyrrole-3-carboxamide
206		621	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[2-(hydroxymethyl)morpholin-4-yl]propyl}-1H-pyrrole-3-carboxamide
207		605	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide
208		576	N-(3,3-diethoxypropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide







209		594	N-(3,3-diethoxypropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
210		521	{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid
211		536	methyl {[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate
212		621	tert-butyl (3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate
213		665	dimethyl 2,2'-[(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate
214		619	2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetic acid







215		651	dimethyl 2,2'-[(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)imino]diacetate
216		607	tert-butyl (2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate
217		649	methyl rel-(2R,4S)-1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)-4-hydroxypyrrolidine-2-carboxylate
218		591	{4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetic acid
219		619	ethyl {4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetate
220		619	1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid







221		533	1-(2-fluoro-5-methylphenyl)-3-[2-fluoro-4-({2-[4-(piperazin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]urea
222		507	N-(2-aminoethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
223		521	N-(3-aminopropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
224		633	tert-butyl 4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazine-1-carboxylate
225		520	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide
226		575	5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide







227		523	2-methoxyethyl 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
228		633	methyl 1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylate
229		592	3-morpholin-4-ylpropyl 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
230		604	dimethyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate
231		564	ethyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate
232		647	dimethyl 2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate







233		590	2-methoxyethyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate
234		650	3-hydroxy-2,2-bis(hydroxymethyl)propyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate
235		569	N-[3-(4-hydroxypiperidin-1-yl)propyl]-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
236		484	5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide
237		486	N-(3-hydroxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide
238		442	1-[4-({2-[4-(hydrazinocarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(3-methylphenyl)urea







239		555	5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide
240		547	3-hydroxy-2,2-bis(hydroxymethyl)propyl 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate
241		460	1-(2-fluoro-5-methylphenyl)-3-[4-({2-[4-(hydrazinocarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]urea
242		504	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide
243		618	methyl (2S)-1-{3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}pyrrolidine-2-carboxylate
244		507	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-hydroxypropyl)-1H-pyrrole-3-carboxamide






245		622	ethyl 4-{N-[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]-S-methylsulfonimidoyl}butanoate
246		633	N,N'-diethyl-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanediamide
247		601	1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid
248		579	2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioic acid
249		607	dimethyl 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioate
250		503	N-(3-aminopropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

251		603	tert-butyl (3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate
252		506	N-(3-aminopropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide
253		606	tert-butyl {3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}carbamate
254		576	5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide
255		606	5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid
256		662	tert-butyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate

257		635	5-tert-butoxy-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid
258		520	3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid
259		535	methyl 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate
260		640	ethyl 4-{N-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]-S-methylsulfonimidoyl}butanoate
261		620	methyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate
262		593	2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-methoxy-5-oxopentanoic acid


263		630	N,N'-diethyl-2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanediamide
264		560	5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid
265		616	tert-butyl 5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoate
266		589	5-tert-butoxy-2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid
267		603	5-tert-butyl 1-methyl 2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)pentanedioate
268		601	1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylic acid

269		657	tert-butyl 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylate
270		621	dimethyl 2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate
271		594	5-tert-butoxy-2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid
272		587	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide
273		502	5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide
274		574	3-morpholin-4-ylpropyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate

275		502	3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid
276		430	5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid
277		517	methyl 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate
278		535	3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoic acid
279		549	methyl 3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate

3.1 Compound Synthesis and Characterization


Preparation of methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate



To a mixture of methyl-1H-pyrrole-3-carboxylate (5.0 g, 39.9 mmol), bis(pinacolato)diboron (5.37 g, 21.1 mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (0.054 g, 0.20 mmol) and

$[Ir(OMe)(COD)]_2$ (0.067 g, 0.099 mmol) was added cyclohexane (60 mL). The mixture stirred at 90°C for 5 hours. The mixture was cooled to room temperature and filtered, washing with ample amounts of water and twice with hexanes. The light orange solid was collected and dried in a vacuum oven at 55°C to afford methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate (6.99 g, 70% yield).

Preparation of 3-(2-Bromo-pyridin-4-yloxy)-benzoic acid




A mixture of 2-bromo-4-chloro-pyridine (200mg, 1.04mmol), methyl-3-hydroxybenzoate (158mg, 1.04mmol), cesium carbonate (507mg, 1.56mmol) in 10ml of anhydrous DMSO was heated at 66°C for 5 hours. The mixture was diluted with ethyl acetate (100ml), washed with brine (3x50ml), dried over Na_2SO_4 and evaporated to give a colorless oil. The oil was dissolved in MeOH (8ml), and 2M NaOH solution (4ml, 8mmol) was added. The mixture was heated at 60°C for 20 minutes, poured into 50ml of water, and acidified to pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give 3-(2-bromo-pyridin-4-yloxy)-benzoic acid as white solid. Yield: 170mg, 56%.

^1H NMR (DMSO-d_6): 13.24 (br. s., 1H), 8.27 (d, J = 5.9 Hz, 1H), 7.87 (d, J = 7.6 Hz, 1H), 7.58 - 7.68 (m, 2H), 7.45 - 7.52 (m, 1H), 7.19 (d, J = 2.1 Hz, 1H), 7.00 (dd, J = 5.7, 2.2 Hz, 1H)

LR MS (ES-): 292 (M-H), 294

Preparation of 3-(2-Bromo-pyridin-4-yloxy)-N-m-tolyl-benzamide



A mixture of 3-(2-bromo-pyridin-4-yloxy)-benzoic acid (170mg, 0.58mmol), HATU (265mg, 0.69mmol),) m-toluidine (93mg, 0.87mmol) and *N,N*-diisopropylethylamine (164mg, 1.28mmol) in anhydrous DMF (10ml) was stirred at room temperature for 20 minutes. The mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried *in*


vacuo to give 3-(2-Bromo-pyridin-4-yloxy)-N-m-tolyl-benzamide as off-white solid. Yield: 150mg, 68%.

^{1}H NMR (DMSO-d_6): 10.18 (s, 1H), 8.29 (d, J = 5.9 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.78 (s, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.50 - 7.60 (m, 2H), 7.45 (dd, J = 7.9, 1.8 Hz, 1H), 7.16 - 7.25 (m, 2H), 7.02 (dd, J = 5.7, 2.2 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 2.29 (s, 3H)

LR MS (ES+): 405 ($M+Na^+$), 407

LR MS (ES-): 381 (M-H), 383


Preparation of 3-(2-Bromo-pyridin-4-yloxy)-N-(2-fluoro-5-methyl-phenyl)-benzamide



A mixture of 3-(2-bromo-pyridin-4-yloxy)-benzoic acid (200mg, 0.68mmol), HATU (312mg, 0.82mmol),) 2-fluoro-5-methylaniline (125mg, 1.0mmol) and *N,N*-diisopropylethylamine (193mg, 1.5mmol) in anhydrous DMF (10ml) was stirred at 60°C for 90 minutes. The mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried *in vacuo* to give 3-(2-bromo-pyridin-4-yloxy)-N-(2-fluoro-5-methyl-phenyl)-benzamide as off-white solid. Yield: 200mg, 74%.

Example 1

[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetic acid



To a stirred solution of methyl [({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetate (110mg, 0.21mmol) in a mixture of solvents THF/MeOH (5ml/5ml) was added 1M NaOH solution (1ml, 1mmol). The mixture was stirred at room temperature for 1 hour, and poured into 100ml of water. 2M HCl was added until pH = 4. The precipitates were filtered, washed with


water and dried *in vacuo* to give [({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetic acid as white solid. Yield: 100mg, 93%.

^{1}H NMR (DMSO-d_6): 12.41 (br. s., 1H), 11.87 (br. s., 1H), 10.12 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 8.19 (t, J = 6.0 Hz, 1H), 7.95 - 8.04 (m, 2H), 7.63 (dd, J = 10.1, 8.7 Hz, 1H), 7.41 (dd, J = 3.1, 1.6 Hz, 1H), 7.35 (dd, J = 7.3, 1.8 Hz, 1H), 7.27 (d, J = 2.3 Hz, 1H), 7.09 - 7.18 (m, 2H), 7.04 (td, J = 5.3, 2.3 Hz, 1H), 6.81 (dd, J = 5.9, 2.3 Hz, 1H), 3.82 (d, J = 5.9 Hz, 2H), 2.27 (s, 3H)

LR MS (ES-): 505 (M-H)

Example 2

methyl [({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]acetate




Similar procedure as Example 1.

^{1}H NMR (DMSO-d_6): 11.95 (br. s., 1H), 10.12 (s, 1H), 8.44 (d, J = 5.9 Hz, 1H), 8.33 (t, J = 5.9 Hz, 1H), 7.97 - 8.03 (m, 2H), 7.61 - 7.67 (m, 1H), 7.45 (br. s., 1H), 7.33 - 7.37 (m, 1H), 7.30 (s, 1H), 7.18 (br. s., 1H), 7.14 (dd, J = 10.3, 8.5 Hz, 1H), 7.02 - 7.08 (m, 1H), 6.86 (br. s., 1H), 3.91 (d, J = 5.9 Hz, 2H), 3.61 (s, 3H), 2.27 (s, 3H)

LR MS (ES+): 521 (MH), 543 ($M+Na^+$)

LR MS (ES-): 519 (M-H)


Preparation of 4-(3-Aminophenoxy)-2-chloropyridine



To a mixture of 3-aminophenol (3.7 g, 34.09 mmol) in DMSO (50 mL) was added Cs2CO3 (30.7 g, 94.46 mmol). The mixture stirred for 10 minutes and then 2,4-dichloropyridine (5.0 g,

33.79 mmol) was added. The mixture was stirred at 120°C for 1.5 h. The mixture was cooled and diluted with water. The aqueous solution was extracted with EtOAc (3 x 100 mL). The organic extracts were combined, dried over MgSO4 and concentrated to afford a dark oil. The oil was purified via column chromatography, eluting with 30-40% EtOAc/hexanes, to afford 4-(3-Aminophenoxy)-2-chloropyridine (6.63 g, 89%) as a brown solid.


Preparation of methyl 5-[4-(3-aminophenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate



A mixture of 4-(3-aminophenoxy)-2-chloropyridine (4.0 g, 18.13mmol), methyl-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate (6.82 g, 27.16mmol) and Pd(PPh3)4 (4.20 g, 3.63mmol) was added to a thick walled reaction vessel and purged with N2. A solution of 2M K2CO3 (13.59 mL) was added, followed by DME (70 mL). The reaction vessel was sealed and the mixture stirred at 92°C for 18 h. The reaction vessel was cooled to room temperature and the mixture was filtered over celite, washing with EtOAc. The filtrate was concentrated and the resultant dark oil was purified via column chromatography, eluting with 40-80% EtOAc/hexanes to afford methyl 5-[4-(3-aminophenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate (2.85 g, 51% yield).

Example 3

({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)acetic acid



Similar procedure as Example 1.

^{1}H NMR (DMSO-d_6): 12.42 (br. s., 1H), 11.91 (br. s., 1H), 10.20 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 8.21 (t, J = 5.4 Hz, 1H), 7.76 (s, 1H), 7.65 - 7.73 (m, 2H), 7.36 - 7.47 (m, 2H), 7.26 (br. s.,


18572 CIP PCT (AP)

1H), 7.12 (br. s., 1H), 6.86 - 6.98 (m, 1H), 6.77 (br. s., 1H), 6.56 (s, 1H), 3.81 (d, J = 5.9 Hz, 2H), 2.29 (s, 3H)

LR MS (ES-): 459 (M-H)

Example 4

methyl ({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)acetate




Similar procedure as Example 3.

^{1}H NMR (DMSO-d_6): 11.88 (br. s., 1H), 10.19 (s, 1H), 8.40 (d, J = 5.6 Hz, 1H), 8.32 (t, J = 5.6 Hz, 1H), 7.76 (s, 1H), 7.65 - 7.72 (m, 2H), 7.36 - 7.44 (m, 2H), 7.23 (d, J = 2.1 Hz, 1H), 7.08 (br. s., 1H), 6.90 (d, J = 7.3 Hz, 1H), 6.75 (dd, J = 5.6, 1.8 Hz, 1H), 6.56 (s, 1H), 3.89 (d, J = 5.6 Hz, 2H), 3.60 (s, 3H), 2.29 (s, 3H)

LR MS (ES+): 475 (MH), 497 ($M+Na^+$)

LR MS (ES-): 473 (M-H)


Preparation of 2-Chloro-*N*-(3-nitrophenyl)pyridine-4-amine



To a degassed (15 min, N_2) suspension of 2-chloro-4-iodopyridine (3.0 g, 12.53 mmol), 3-nitroaniline (1.82 g, 13.18 mmol), BINAP (0.39 g, 0.626 mmol) and Cs_2CO_3 (8.16 g, 25.04 mmol) in toluene (72 mL) was added $Pd(OAc)_2$ (0.084 g, 0.374 mmol). The reaction tube was sealed and the mixture stirred at 90°C for 18 h. The mixture was cooled to rt and filtered, washing with EtOAc. The orange/yellow solid collected was washed with CH_2Cl_2 until all the product washed through into the filtrate. The filtrate was concentrated to afford 2-Chloro-*N*-(3-nitrophenyl)pyridine-4-amine as a bright yellow solid. Additional product was collected from


the solid collected upon concentration of the previous filtrate, after washing with CH_2Cl_2. No further purification. Total amount of product collected was 2.85 g (91% yield).

Preparation of *tert*-Butyl 2-chloropyridin-4-yl(3-nitrophenyl)carbamate




To a stirring solution of 2-Chloro-*N*-(3-nitrophenyl)pyridine-4-amine (2.70 g, 10.82 mmol) in THF (45 mL) was added Et_3N (6.32 mL, 45.3 mmol). The mixture was cooled to 0°C, and DMAP (0.0135 g, 0.110 mmol) and BOC_2O (2.84 g, 12.99 mmol) were added. The mixture was warmed to rt and stirred for 18 h. The mixture was quenched with ice and diluted with water. Extracted with EtOAc (3 x 200 mL), washed with brine and water, dried ($MgSO_4$), and concentrated. A dark oil was afforded, which was passed through a pad of silica gel, eluting with 1:1 EtOAc/hexanes. Concentrated and dried under high vacuum to afford *tert*-Butyl 2-chloropyridin-4-yl(3-nitrophenyl)carbamate (3.65 g, 96.5% yield).

Preparation of methyl 5-(4-(*tert*-butoxycarbonyl(3-nitrophenyl)amino)pyridine-2-yl)-1*H*-pyrrole-3-carboxylate




A mixture of *tert*-Butyl 2-chloropyridin-4-yl(3-nitrophenyl)carbamate (3.65 g, 10.43 mmol), methyl-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate (5.48 g, 21.82 mmol), xantphos (0.72 g, 1.25 mmol) and Pd_2dba_3 (0.72 g, 0.79 mmol) was added to a thick walled reaction vessel and purged with N_2. A solution of 2M K_2CO_3 (8.76 mL) was added, followed by dioxane (67 mL). The reaction vessel was sealed and the mixture stirred at 105°C for 18 h. The reaction vessel was cooled to rt and the mixture was filtered over celite, washing with EtOAc. The filtrate was concentrated to afford a dark oil, which was purified via column chromatography eluting with 30-50% EtOAc/hexanes to afford methyl 5-(4-(*tert*-butoxycarbonyl(3-nitrophenyl)amino)pyridine-2-yl)-1*H*-pyrrole-3-carboxylate (2.98 g, 65% yield) as an orange oil.

Preparation of methyl 5-(4-((3-nitrophenyl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxylate



Methyl 5-(4-(*tert*-butoxycarbonyl(3-nitrophenyl)amino)pyridine-2-yl)-1*H*-pyrrole-3-carboxylate (0.40 g, 0.91 mmol) was taken up in toluene (38 mL) and SiO_2 (9.0 g) was added. The mixture stirred at reflux for 20 h. The mixture was cooled to rt and filtered over celite, washing with EtOAc. The filtrate was concentrated to a bright orange color. The solid was taken up in hexanes and filtered. The solid was then washed with CH_2Cl_2/hexanes to afford methyl 5-(4-((3-nitrophenyl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxylate (0.15 g, 49% yield) as a bright yellow solid.

Preparation of methyl 5-(4-((3-aminophenyl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxylate




Methyl 5-(4-((3-nitrophenyl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxylate (1.32 g, 3.9 mmol) was taken up in EtOAc/EtOH (1:1; 90 mL) and purged with N_2. Pd/C (10%, 0.145 g) was added and the mixture was stirred under an atmosphere of H_2 at rt for 18 h. The mixture was filtered over celite, washing with EtOAc/EtOH. The filtrate was concentrated, taken back up in EtOAc and filtered over celite again to remove any residual catalyst. The filtrate was concentrated again and taken back up in EtOAc. The solution was filtered and the filtrate was concentrated to afford a tan solid. The solid was washed with CH_2Cl_2/hexanes (1:2) and dried under high vacuum to afford methyl 5-(4-((3-aminophenyl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxylate (1.15 g, 96% yield) as a tan solid.

Example 5

5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid


18572 CIP PCT (AP)



To a stirred solution of methyl 5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylate (10mg, 0.024mmol) in a mixture of solvents THF/MeOH (5ml/5ml) was added 2ml of 1M NaOH (2mmol) solution. The mixture was heated in a 60°C bath for 16 hours, cooled to room temperature and poured into 100ml of water. 2M HCl was added until pH = 5. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give 5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid as light brown solid. Yield: 2mg.

Example 6

methyl 5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylate



A mixture of 3-methyl-2-furoic acid (22 mg, 0.18mmol), HATU (73mg, 0.19mmol) and *N,N*-diisopropylethylamine (45mg, 0.35mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of methyl 5-(4-((3-aminophenyl)amino)pyridin-2-yl)-1H-pyrrole-3-carboxylate (50mg, 0.16mmol). The mixture was stirred at room temperature for 3 hours and poured into 100ml of water. The precipitates were filtered, washed with water and dried *in vacuo* to give methyl 5-[4-({3-[(3-methyl-2-furoyl)amino]phenyl}amino)pyridin-2-yl]-1H-pyrrole-3-carboxylate as off-white solid. Yield: 10mg, 15%.

^{1}H NMR (DMSO-d_6): 13.60 (br. s., 1H), 12.37 (br. s., 1H), 10.14 (s, 1H), 8.15 (d, J = 6.5 Hz, 1H), 7.86 (t, J = 1.9 Hz, 1H), 7.77 (d, J = 1.8 Hz, 1H), 7.58 (br. s., 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.32 - 7.38 (m, 2H), 7.22 (br. s., 1H), 6.97 (d, J = 7.6 Hz, 1H), 6.86 (dd, J = 6.2, 2.1 Hz, 1H), 6.57 (d, J = 1.8 Hz, 1H), 3.71 (s, 3H), 2.32 (s, 3H)


LR MS (ES+): 417 (MH)

18572 CIP PCT (AP)

LR MS (ES-): 415 (M-H)

Example 7

5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-hydroxy-1H-pyrrole-3-carboxamide



Similar procedure as Example 1.


^{1}H NMR (DMSO-d_6): 11.85 (br. s., 1H), 10.56 (br. s., 1H), 10.12 (s, 1H), 8.66 (br. s., 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.99 (d, J = 7.3 Hz, 2H), 7.63 (t, J = 9.4 Hz, 1H), 7.30 - 7.40 (m, 2H), 7.27 (br. s., 1H), 7.10 - 7.18 (m, 1H), 7.01 - 7.10 (m, 2H), 6.75 - 6.85 (m, 1H), 2.26 (s, 3H)

LR MS (ES+): 487 (M+Na^+)

LR MS (ES-): 463 (M-H)

Example 8

4-fluoro-N-(2-fluoro-5-methylphenyl)-3-[(2-{4-[(3-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]benzamide



Similar procedure as Example 1.


LR MS (ES+): 533 (MH), 555 (M+Na^+)

LR MS (ES-): 531 (M-H)

Example 9

N-(2,3-dihydroxypropyl)-5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)



Similar procedure as Example 1.


^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 10.11 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.89 (d, J = 7.0 Hz, 1H), 7.83 (t, J = 5.6 Hz, 1H), 7.77 (s, 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.42 - 7.46 (m, 1H), 7.39 (d, J = 1.5 Hz, 1H), 7.35 (d, J = 7.3 Hz, 1H), 7.25 (d, J = 2.1 Hz, 1H), 7.09 - 7.16 (m, 2H), 7.02 - 7.06 (m, 1H), 6.76 (dd, J = 5.7, 2.5 Hz, 1H), 4.77 (d, J = 5.0 Hz, 1H), 4.53 (t, J = 6.0 Hz, 1H), 3.50 - 3.56 (m, 1H), 3.25 - 3.30 (m, 3H), 3.08 - 3.14 (m, 1H), 2.27 (s, 3H)

LR MS (ES+): 505 (MH), 527 ($M+Na^+$)

LR MS (ES-): 503 (M-H)

Example 10

N-(2-fluoro-5-methylphenyl)-3-[(2-{4-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]benzamide



A mixture of 5-{4-[3-(2-Fluoro-5-methyl-phenylcarbamoyl)-phenoxy]-pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (50mg, 0.12mmol), HATU (55mg, 0.14mmol) and *N,N*-diisopropylethylamine (34mg, 0.26mmol) in anhydrous DMF (8ml) was stirred at room temperature for 10 minutes, followed by addition of (S)-3-pyrrolidinol (16mg, 0.18mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(2-fluoro-5-methylphenyl)-3-[(2-{4-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]benzamide as white solid. Yield: 40mg, 69%.

^{1}H NMR (DMSO-d_6): 11.91 (br. s., 1H), 10.12 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.76 (s, 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.32 - 7.51 (m, 3H), 7.26 (d, J = 6.7 Hz, 1H), 6.99

18572 CIP PCT (AP)


- 7.20 (m, 3H), 6.73 (dd, 1H), 4.91 (br. s., 1H), 4.30 (br. s., 1H), 3.76 (br. s., 2H), 3.50 (br. s., 2H), 2.28 (s, 3H), 1.86 (br. s., 2H)

LR MS (ES+): 501 (MH), 523 ($M+Na^+$)

LR MS (ES-): 499 (M-H)

Example 11

5-[4-(3-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-hydroxy-1H-pyrrole-3-carboxamide




Similar procedure as Example 10.

^1H NMR (DMSO-d_6): 11.84 (br. s., 1H), 10.56 (br. s., 1H), 10.10 (s, 1H), 8.65 (br. s., 1H), 8.40 (d, J = 5.6 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.76 (br. s., 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.44 (dd, J = 7.9, 1.5 Hz, 1H), 7.35 (d, J = 6.7 Hz, 1H), 7.31 (br. s., 1H), 7.25 (d, J = 1.8 Hz, 1H), 7.13 (dd, J = 10.3, 8.5 Hz, 1H), 7.01 - 7.07 (m, 2H), 6.75 (dd, J = 5.7, 2.2 Hz, 1H), 2.27 (s, 3H)

LR MS (ES+): 469 ($M+Na^+$)

LR MS (ES-): 445 (M-H)


Preparation of 3-(2-Chloropyridin-4-yloxy)-4-fluorobenzoic acid methyl ester



4-Fluoro-3-hydroxybenzoic acid methyl ester (1.70 g, 10.0 mmol) was dissolved in dimethylformamide (9 mL) under nitrogen at room temperature. Sodium hydride (60% oil dispersion, 0.48 g, 12 mmol) was added in portions over 30 min. The reaction was stirred for 90 minutes and then cooled in an ice bath. 2-Chloro-4-nitropyridine (1.58 g, 10.0 mmol) was added in small portions over 50 min. The reaction was stirred at room temperature for 17.5 h. Water (200 ml) was added and the mixture stirred until a brown lump formed. The water was decanted and the residue dissolved in EtOAc (150 mL). The solution was washed with brine, dried


($MgSO_4$), filtered and evaporated to give 3-(2-Chloropyridin-4-yloxy)-4-fluorobenzoic acid methyl ester. Yield: 3.10 g.

Preparation of 3-(2-Chloropyridin-4-yloxy)-4-fluorobenzoic acid



3-(2-Chloropyridin-4-yloxy)-4-fluorobenzoic acid methyl ester (2.81 g, 10.0 mmol) was dissolved in tetrahydrofuran (15 mL) and mixed with 2M lithium hydroxide (15 mL, 30 mmol). The suspension was stirred for 5 h. To the reaction was added water, then extracted with EtOAc. The aqueous layer was treated with 6M HCl (5 mL, 30 mmol) and then extracted with EtOAc (3x25 mL). The extract was dried ($MgSO_4$), filtered and evaporated to 3-(2-Chloropyridin-4-yloxy)-4-fluorobenzoic acid. Yield: 2.22 g, 83%.

Preparation of 3-(2-Chloropyridin-4-yloxy)-4-fluoro-N-(2-fluoro-5-methylphenyl)benzamide




A solution of 3-(2-Chloropyridin-4-yloxy)-4-fluorobenzoic acid (2.22 g, 8.29 mmol), 2-fluoro-5-methylaniline (1.56 g, 12.4 mmol), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 3.78 g, 9.95 mmol) and N-methylmorpholine (2.00 mL, 18.2 mmol) in dimethylformamide (22 mL) was heated at 90°C for 2 h. The solvent was evaporated *in vacuo* at 50°C. To the residue was added water resulting in a thick oil. The water was decanted and the oil dissolved in EtOAc then extracted twice with water, 1M hydrochloric acid and brine. The organic layer was dried ($MgSO_4$), filtered and evaporated to crude 6 (3.37 g). Trituration with dichloromethane (25 mL) gave 3-(2-Chloropyridin-4-yloxy)-4-fluoro-N-(2-fluoro-5-methylphenyl)benzamide as white solid. Yield: 1.788 g, 58%.

Example 12

methyl 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate


18572 CIP PCT (AP)



A mixture of 3-(2-Chloropyridin-4-yloxy)-4-fluoro-N-(2-fluoro-5-methylphenyl)benzamide (1.217 g, 3.25 mmol), methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate (1.63 g, 6.50 mmol) and potassium carbonate (0.67 g, 4.87 mmol) in water (2.5 mL) and dioxane (15 mL) was purged with nitrogen for several minutes. To the mixture was added tetrakis-triphenylphosphine palladium(0) (0.18 g, (0.16 mmol). The reaction was sealed under nitrogen and heated at 100°C for 15 h. The cooled reaction was mixed with dichloromethane and filtered through Celite. The red solution was evaporated. The resulting oil was dissolved in dichloromethane, put on a column of silica gel (80 g) and eluted with hexane/EtOAc (1:1) to afford methyl 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate as white solid. Yield: 1.162 g, 77%.

Example 13

5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid



Similar procedure as Example 12.


^{1}H NMR (DMSO-d_6): 12.03 (br. s., 1H), 11.85 (br. s., 1H), 10.11 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.98 (d, J = 6.2 Hz, 2H), 7.62 (t, J = 9.4 Hz, 1H), 7.43 (br. s., 1H), 7.30 - 7.39 (m, 2H), 7.08 - 7.19 (m, 2H), 7.04 (br. s., 1H), 6.79 (d, J = 3.2 Hz, 1H), 2.26 (s, 3H)

LR MS (ES-): 448 (M-H)

Example 14

N-ethyl-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)




Similar procedure as Example 31.

LR MS (ES+): 453 ($M+Na^+$)

Example 15

N-(2,3-dihydroxypropyl)-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide



Similar procedure as Example 31.


^1H NMR (DMSO-d_6): 11.83 (br. s., 1H), 10.21 (s, 1H), 8.40 (d, J = 5.9 Hz, 1H), 7.85 (t, J = 6.0 Hz, 1H), 7.78 (s, 1H), 7.63 - 7.74 (m, 2H), 7.35 - 7.48 (m, 2H), 7.23 (d, J = 2.1 Hz, 1H), 7.10 (s, 1H), 6.85 - 6.96 (m, 1H), 6.75 (dd, J = 5.7, 2.2 Hz, 1H), 6.57 (s, 1H), 4.78 (d, J = 4.7 Hz, 1H), 4.53 (t, J = 5.9 Hz, 1H), 3.48 - 3.61 (m, 1H), 3.24 – 3.33 (m, 3H), 3.04 - 3.19 (m, 1H), 2.30 (s, 3H)

LR MS (ES+): 499 ($M+Na^+$)

LR MS (ES-): 475 (M-H)

Example 16

5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide



Similar procedure as Example 31.


18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 10.21 (s, 1H), 8.40 (d, J = 5.9 Hz, 1H), 7.77 (s, 1H), 7.65 - 7.74 (m, 2H), 7.31 - 7.48 (m, 3H), 7.23 (d, J = 1.2 Hz, 1H), 7.07 (br. s., 1H), 6.86 - 6.95 (m, 1H), 6.75 (d, J = 3.5 Hz, 2H), 6.57 (s, 1H), 2.30 (s, 3H)

LR MS (ES-): 401 (M-H)

Example 17

N-hydroxy-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide




Similar procedure as Example 31.

^{1}H NMR (DMSO-d_6): 11.84 (br. s., 1H), 10.49 - 10.64 (m, 1H), 10.20 (s, 1H), 8.60 - 8.74 (m, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.65 - 7.81 (m, 3H), 7.41 (t, J = 7.9 Hz, 1H), 7.32 (br. s., 1H), 7.23 (s, 1H), 7.02 (br. s., 1H), 6.85 - 6.94 (m, 1H), 6.69 - 6.78 (m, 1H), 6.57 (s, 1H), 2.30 (s, 3H)

LR MS (ES-): 417 (M-H)

Example 18

N-(3-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-methyl-2-furamide



Similar procedure as Example 31.


^{1}H NMR (DMSO-d_6): 11.90 (br. s., 1H), 10.20 (s, 1H), 8.40 (d, J = 5.6 Hz, 1H), 7.77 (d, J = 1.5 Hz, 1H), 7.64 - 7.73 (m, 2H), 7.36 - 7.46 (m, 2H), 7.21 - 7.30 (m, 1H), 7.03 - 7.13 (m, 1H), 6.85 - 6.93 (m, 1H), 6.70 (dd, J = 5.7, 2.2 Hz, 1H), 6.57 (d, J = 1.5 Hz, 1H), 4.90 (br. s., 1H), 4.30 (m, 1H), 3.76 (m, 1H), 3.49 (m, 2H), 2.30 (s, 3H), 1.86 (m, 2H)

LR MS (ES-): 471 (M-H)

18572 CIP PCT (AP)

Example 19

5-{4-[3-(2-Fluoro-5-methyl-phenylcarbamoyl)-phenoxy]-pyridin-2-yl}-1H-pyrrole-3-carboxylic acid



To a stirred solution of 5-{4-[3-(2-Fluoro-5-methyl-phenylcarbamoyl)-phenoxy]-pyridin-2-yl}-1H-pyrrole-3-carboxylic acid methyl ester (140mg, 0.31mmol) in THF (8ml) was added 5M NaOH solution (1ml, 5mmol). The mixture was heated at 70°C for 3 hours, cooled to room temp, and poured into 100ml of water. 2M HCl was added until pH = 4. The precipitates were filtered, washed with water, and dried to give 5-{4-[3-(2-Fluoro-5-methyl-phenylcarbamoyl)-phenoxy]-pyridin-2-yl}-1H-pyrrole-3-carboxylic acid as white solid. Yield: 120mg, 92%.


^{1}H NMR (d_6-DMSO): 12.03 (br. s., 1H), 11.89 (br. s., 1H), 10.11 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.89 (d, J = 7.3 Hz, 1H), 7.77 (s, 1H), 7.56 - 7.71 (m, 1H), 7.30 - 7.54 (m, 4H), 6.97 - 7.23 (m, 3H), 6.75 (dd, J = 5.6, 2.1 Hz, 1H), 2.28 (s, 3H)

LR MS (ES+): 454 ($M+Na^+$)

LR MS (ES-): 430 (M-H)

Example 20

5-{4-[3-(2-Fluoro-5-methyl-phenylcarbamoyl)-phenoxy]-pyridin-2-yl}-1H-pyrrole-3-carboxylic acid methyl ester



A mixture of 3-(2-bromo-pyridin-4-yloxy)-N-(2-fluoro-5-methyl-phenyl)-benzamide (200mg, 0.50 mmol), methyl-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate (251mg, 1.0 mmol) and $PdCl_2(dppf)\cdot CH_2Cl_2$ (10mg, 0.012 mmol) was added to a thick-walled reaction vessel and purged with N_2. A solution of 2M Na_2CO_3 (0.5 mL) was added, followed by DMSO (8 mL). The reaction vessel was sealed and the mixture stirred at 95°C for 16 h. The reaction vessel was cooled to room temperature and the mixture was poured into 100ml of water.

18572 CIP PCT (AP)


The precipitates were filtered, washed with water and dried to give the crude, which was purified via column chromatography eluting with 30-40% EtOAc/hexanes to afford 5-{4-[3-(2-Fluoro-5-methyl-phenylcarbamoyl)-phenoxy]-pyridin-2-yl}-1H-pyrrole-3-carboxylic acid methyl ester (150mg, 58% yield).

^{1}H NMR (d_6-DMSO): 12.14 (br. s., 1H), 10.11 (s, 1H), 8.43 (d, J = 5.6 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.77 (s, 1H), 7.64 (t, J = 7.9 Hz, 1H), 7.41 - 7.50 (m, 3H), 7.35 (s, 1H), 7.09 - 7.21 (m, 2H), 7.06 (dd, J = 5.1, 1.9 Hz, 1H), 6.76 (dd, J = 5.6, 2.3 Hz, 1H), 3.70 (s, 3H), 2.28 (s, 3H)

LR MS (ES+): 468 ($M+Na^+$)

LR MS (ES-): 444 (M-H)

Example 21




Similar procedure as Example 25.

2,3-dihydroxypropyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate

Example 22

5-[4-(3-m-Tolylcarbamoyl-phenoxy)-pyridin-2-yl]-1H-pyrrole-3-carboxylic acid




Similar procedure as Example 19.

^{1}H NMR (DMSO-d_6): 12.03 (br. s., 1H), 11.86 (br. s., 1H), 10.19 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.78 (s, 1H), 7.50 - 7.69 (m, 3H), 7.32 - 7.46 (m, 3H), 7.21 (t, J = 7.8 Hz, 1H), 7.06 (s, 1H), 6.91 (d, J = 7.3 Hz, 1H), 6.74 (dd, J = 5.6, 2.3 Hz, 1H), 2.28 (s, 3H)

18572 CIP PCT (AP)

Example 23

5-[4-(3-m-Tolylcarbamoyl-phenoxy)-pyridin-2-yl]-1H-pyrrole-3-carboxylic acid methyl ester



Similar procedure as Example 20.


^{1}H NMR (DMSO-d_6): 12.14 (br. s., 1H), 10.18 (s, 1H), 8.43 (d, J = 5.6 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.78 (s, 1H), 7.50 - 7.68 (m, 3H), 7.38 - 7.48 (m, 3H), 7.21 (t, J = 7.8 Hz, 1H), 7.12 (s, 1H), 6.91 (d, J = 7.6 Hz, 1H), 6.75 (dd, J = 5.7, 2.2 Hz, 1H), 3.70 (s, 3H), 2.28 (s, 3H)

LR MS (ES+): 450 ($M+Na^+$)

LR MS (ES-): 426 (M-H)

Example 24

2-hydroxyethyl 5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate



Similar procedure as Example 25.

^{1}H NMR (d_6-DMSO): 12.13 (br. s., 1H), 10.13 (s, 1H), 8.43 (d, J = 5.9 Hz, 1H), 7.68 (d, J = 5.0 Hz, 1H), 7.56 - 7.64 (m, 2H), 7.40 - 7.52 (m, 3H), 7.14 (s, 1H), 7.03 (d, J = 5.0 Hz, 1H), 6.89 - 6.98 (m, 1H), 6.76 (dd, J = 5.7, 2.2 Hz, 1H), 4.83 (t, J = 5.9 Hz, 1H), 4.15 (t, J = 5.1 Hz, 2H), 3.64 (q, J = 5.6 Hz, 2H), 2.44 (s, 3H)


LR MS (ES+): 486 ($M+Na^+$)

LR MS (ES-): 462 (M-H)

Example 25

2-hydroxyethyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate

18572 CIP PCT (AP)



A mixture of 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid (70mg, 0.17mmol), ethylene glycol (1ml), 1-ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (EDC• HCl, 40mg, 0.21mmol) and 4-dimethylaminopyridine (DMAP, 10mg, 0.08mmol) in anhydrous DMF (10ml) was stirred at 70°C for 3 hours then room temperature for 16 hours. The mixture was poured into 100ml of water. Saturated $NaHCO_3$ solution was added until pH = 9. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with a gradient of 3~4% MeOH/$CHCl_3$ to give 2-hydroxyethyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate as white solid. Yield: 40mg, 51%.


^{1}H NMR (d_6-DMSO): 12.13 (br. s., 1H), 10.22 (s, 1H), 8.43 (d, J = 5.9 Hz, 1H), 7.79 (s, 1H), 7.70 (s, 2H), 7.36 - 7.54 (m, 3H), 7.13 (br. s., 1H), 6.86 - 6.97 (m, 1H), 6.72 - 6.80 (m, 1H), 6.59 (s, 1H), 5.75 (s, 1H), 4.83 (t, J = 5.3 Hz, 1H), 4.14 (t, J = 4.7 Hz, 2H), 3.58 - 3.69 (m, 2H), 2.32 (s, 3H)

LR MS (ES+): 470 ($M+Na^+$)

LR MS (ES-): 446 (M-H)

Example 26

5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid



Similar procedure as Example 32.

^{1}H NMR (d_6-DMSO): 12.04 (br. s., 1H), 11.87 (s, 1H), 10.13 (s, 1H), 8.42 (d, J = 6.2 Hz, 1H), 7.68 (d, J = 4.7 Hz, 1H), 7.57 - 7.64 (m, 2H), 7.40 - 7.49 (m, 2H), 7.38 (dd, J = 3.2, 1.5 Hz, 1H),

18572 CIP PCT (AP)


7.05 - 7.09 (m, 1H), 7.03 (d, J = 5.0 Hz, 1H), 6.90 - 6.97 (m, 1H), 6.75 (dd, J = 5.7, 2.5 Hz, 1H), 2.44 (s, 3H)

LR MS (ES+): 442 ($M+Na^+$)

LR MS (ES-): 418 (M-H)

Example 27

methyl 5-[4-(3-{[(3-methyl-2-thienyl)carbonyl]amino}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate



Similar procedure as Example 33.


^1H NMR (DMSO-d_6): 12.12 (br. s., 1H), 10.10 (s, 1H), 8.35 - 8.45 (m, 1H), 7.65 (d, J = 5.0 Hz, 1H), 7.55 - 7.60 (m, 2H), 7.37 - 7.45 (m, 3H), 7.10 (s, 1H), 7.00 (d, J = 5.0 Hz, 1H), 6.87 - 6.93 (m, 1H), 6.73 (dd, J = 5.6, 2.3 Hz, 1H), 3.69 (s, 3H), 2.41 (s, 3H)

LR MS (ES+): 456 ($M+Na^+$)

LR MS (ES-): 432 (M-H)

Example 28

5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid




To a stirred solution of methyl 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate

(20mg, 0.046mmol) in a mixture of solvents THF/MeOH (5ml/5ml) was added 3ml of 1M NaOH (3mmol) solution. The mixture was heated in a 72°C bath for 3 hours, cooled to room temperature and poured into 50ml of water. 2M HCl was added until pH = 4. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give 5-(4-{4-fluoro-3-[(3-

methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid as light gray solid.
Yield: 19mg, 100%.
LR MS (ES-): 420 (M-H)

Example 29

methyl 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate




Similar procedure as Example 33.

^{1}H NMR (d_6-DMSO): 12.15 (br. s., 1H), 9.74 (s, 1H), 8.43 (d, J = 5.6 Hz, 1H), 7.81 (d, J = 1.8 Hz, 1H), 7.60 (dd, J = 6.4, 2.9 Hz, 1H), 7.34 - 7.50 (m, 3H), 7.02 - 7.18 (m, 2H), 6.75 (dd, J = 5.6, 2.3 Hz, 1H), 6.60 (d, J = 1.5 Hz, 1H), 3.72 (s, 3H), 2.31 (s, 3H)
LR MS (ES+): 458 ($M+Na^+$)
LR MS (ES-): 434 (M-H)

Example 30

N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide




Similar procedure as Example 101.

^{1}H NMR (d_6-DMSO): 11.83 (br. s., 1H), 10.20 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.77 (d, J = 1.5 Hz, 1H), 7.65 - 7.72 (m, 2H), 7.37 - 7.45 (m, 1H), 7.32 (d, J = 2.1 Hz, 1H), 7.27 (dd, J = 2.9, 1.5 Hz, 1H), 6.96 - 6.99 (m, 1H), 6.87 - 6.92 (m, 1H), 6.71 (dd, J = 5.6, 2.3 Hz, 1H), 6.57 (d, J = 1.8 Hz, 1H), 3.35 (s, 6H), 2.30 (s, 3H)
LR MS (ES+): 501 ($M+Na^+$)
LR MS (ES-): 477 (M-H)

18572 CIP PCT (AP)

Example 31

N-(3-{[2-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-methyl-2-furamide



A mixture of 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid (60mg, 0.15mmol), HATU (68mg, 0.18mmol) and *N,N*-diisopropylethylamine (43mg, 0.33mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of (S)-3-pyrrolidinol (16mg, 0.18mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. 2M HCl was added dropwise until pH = 4~5. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(3-{[2-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-methyl-2-furamide as white solid. Yield: 40mg, 56%.


^{1}H NMR (d_6-DMSO): 11.95 (br. s., 1H), 10.21 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.77 (d, J = 1.8 Hz, 1H), 7.64 - 7.74 (m, 2H), 7.35 - 7.51 (m, 2H), 7.29 (br. s., 1H), 7.12 (br. s., 1H), 6.90 (dd, J = 8.1, 1.3 Hz, 1H), 6.73 (dd, J = 5.7, 2.2 Hz, 1H), 6.57 (d, J = 1.8 Hz, 1H), 4.20 - 4.36 (m, 1H), 3.66 - 3.88 (m, 2H), 3.42 - 3.60 (m, 3H), 2.30 (s, 3H), 1.66 - 2.03 (m, 2H)

LR MS (ES+): 495 ($M+Na^+$)

LR MS (ES-): 471 (M-H)

Example 32

5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid



18572 CIP PCT (AP)


To a stirred solution of methyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate (1.30g, 3.12mmol) in a mixture of solvents THF/MeOH (10ml/10ml) was added 2ml of 5M NaOH (10mmol) solution. The mixture was heated in a 68°C bath for 8 hours, cooled to room temperature and poured into 200ml of water. 2M HCl was added until pH = 3. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid as white solid. Yield: 1.20g, 95%.

^{1}H NMR (d_6-DMSO): 11.98 (br. s., 1H), 10.22 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.79 (d, J = 1.2 Hz, 1H), 7.61 - 7.76 (m, 2H), 7.27 - 7.51 (m, 3H), 7.04 (br. s., 1H), 6.85 - 6.98 (m, 1H), 6.73 (dd, J = 5.7, 2.2 Hz, 1H), 6.59 (d, J = 1.5 Hz, 1H), 2.32 (s, 3H)

LR MS (ES-): 402 (M-H)

Example 33

methyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate



A mixture of 3-methyl-2-furoic acid (490 mg, 3.88mmol), HATU (1.71 g, 4.5mmol) and *N,N*-diisopropylethylamine (1.0g, 7.8mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of methyl 5-[4-(3-aminophenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate (1.0g, 3.24mmol). The mixture was stirred at 50°C for 2 hours and poured into 100ml of water. 2M HCl was added dropwise until pH = 4~5. The precipitates were filtered, washed with water and dried *in vacuo* to give methyl 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate as white solid. Yield: 1.30g, 96%.

^{1}H NMR (d_6-DMSO): 12.15 (br. s., 1H), 10.22 (s, 1H), 8.43 (d, J = 5.9 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.68 - 7.74 (m, 2H), 7.38 - 7.47 (m, 3H), 7.09 - 7.14 (m, 1H), 6.88 - 6.94 (m, 1H), 6.75 (dd, J = 5.6, 2.3 Hz, 1H), 6.59 (d, J = 1.5 Hz, 1H), 3.72 (s, 3H), 2.32 (s, 3H)


LR MS (ES+): 440 ($M+Na^+$)

18572 CIP PCT (AP)

LR MS (ES-): 416 (M-H)

Example 34

3-methyl-N-(3-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide



A mixture of 3-methyl-2-furoic acid (60 mg, 0.48mmol), HBTU (198 mg, 0.52mmol) and *N,N*-diisopropylethylamine (129mg, 1.0mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of 3-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}aniline (100mg, 0.40mmol). The mixture was stirred at 70°C for 3 hours and poured into 100ml of water. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 3-5% MeOH/$CHCl_3$ to give 3-methyl-N-(3-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide as white solid. Yield: 52mg, 36%.

^{1}H NMR (d_6-DMSO): 11.46 (br. s., 1H), 10.19 (s, 1H), 8.36 (d, J = 6.2 Hz, 1H), 7.77 (d, J = 1.8 Hz, 1H), 7.64 - 7.72 (m, 2H), 7.35 - 7.44 (m, 1H), 7.28 (d, J = 2.1 Hz, 1H), 6.86 - 6.91 (m, 1H), 6.81 - 6.86 (m, 1H), 6.68 - 6.74 (m, 1H), 6.65 (dd, J = 5.7, 2.5 Hz, 1H), 6.57 (d, J = 1.8 Hz, 1H), 6.06 - 6.13 (m, 1H), 2.30 (s, 3H)


LR MS (ES+): 360 (M+H)

LR MS (ES-): 358 (M-H)

Example 35

methyl 4-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-2-carboxylate

18572 CIP PCT (AP)



Similar procedure as Example 33.


^{1}H NMR (d_6-DMSO): 12.18 (br. s., 1H), 10.19 (s, 1H), 8.37 (d, J = 5.6 Hz, 1H), 7.77 (d, J = 1.8 Hz, 1H), 7.59 - 7.72 (m, 3H), 7.33 - 7.44 (m, 2H), 7.25 - 7.32 (m, 1H), 6.83 - 6.93 (m, 1H), 6.66 (dd, J = 5.6, 2.3 Hz, 1H), 6.57 (d, J = 1.2 Hz, 1H), 3.76 (s, 3H), 2.30 (s, 3H)

LR MS (ES+): 440 ($M+Na^+$)

LR MS (ES-): 416 (M-H)

Example 36

2-fluoro-5-methyl-N-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)benzamide



Similar procedure as Example 37.

^{1}H NMR (d_6-DMSO): 11.44 (br. s., 1H), 10.47 (s, 1H), 8.33 (d, J = 5.6 Hz, 1H), 7.76 - 7.86 (m, 2H), 7.46 (dd, J = 6.4, 2.1 Hz, 1H), 7.36 (ddd, J = 7.9, 5.3, 2.1 Hz, 1H), 7.13 - 7.27 (m, 4H), 6.80 - 6.87 (m, 1H), 6.66 - 6.73 (m, 1H), 6.60 (dd, J = 5.6, 2.3 Hz, 1H), 6.06 - 6.15 (m, 1H), 2.34 (s, 3H)


LR MS (ES+): 388 (M+H)

LR MS (ES-): 386 (M-H)

Example 37

3-methyl-N-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide

18572 CIP PCT (AP)




A mixture of 3-methyl-2-furoic acid (70mg, 0.55mmol), HATU (243mg, 0.64mmol),) tert-butyl 2-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1-carboxylate (160mg, 0.46mmol) and *N,N*-diisopropylethylamine (148mg, 1.15mmol) in anhydrous DMF (10ml) was stirred at 45°C for 2 hours. The mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was dissolved in 5ml of methylene chloride, followed by addition of trifluoroacetic acid (3ml). The mixture was stirred at room temperature for 16 hours. The solvents were evaporated under reduced pressure. The residue was purified by reversed-phase chromatography with a gradient of 10~50% acetonitrile/water to give 3-methyl-N-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-2-furamide as white solid. Yield: 56mg, 34%.

LR MS (ES+): 360 (M+H)

LR MS (ES-): 358 (M-H)

Preparation of 4-((2-chloropyridin-4-yl)oxy)aniline




A stirred solution of 4-aminophenol (740mg, 6.8mmol) in anhydrous DMSO (8ml) was flushed with nitrogen and treated with 1M KOBu^t / THF solution (10ml, 10mmol). The mixture was stirred at room temperature under nitrogen for 10 minutes. 2,4-dichloropyridine (1.0g, 6.8mmol) was added and the mixture was heated at 60°C for 30 minutes, cooled to room temperature and poured into 100ml of water. The resulting precipitates were filtered, washed with water and dried to give 4-((2-chloropyridin-4-yl)oxy)aniline as light brown solid. The material was used for the following reactions without further purification. Yield: 1.15g, 77%.

^{1}H NMR (d_6-DMSO): 8.21 (d, 1H), 6.77 - 6.91 (m, 4H), 6.54 - 6.68 (m, 2H), 5.16 (s, 2H)

Preparation of methyl 5-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate


18572 CIP PCT (AP)



A mixture of 4-((2-chloropyridin-4-yl)oxy)aniline (2.6 g, 11.78 mmol), methyl-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate (6.0 g, 23.90 mmol) and Pd(PPh3)4 (2.72 g, 2.35 mmol) was added to a thick walled reaction vessel and purged with N_2. A solution of 2M K_2CO_3 (17.68 mL) was added, followed by DME (90 mL). The reaction vessel was sealed and the mixture stirred at 92°C for 18 h. The reaction vessel was cooled to room temperature and the mixture was filtered over celite, washing with EtOAc. The filtrate was concentrated to afford a dark oil, which was purified via column chromatography eluting with 40-80% EtOAc/hexanes to afford methyl 5-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate (2.4 g, 65% yield).

Example 38

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide




Similar procedure as Example 132.

LR MS (ES+): 573 (MH)

Example 39

5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-hydroxy-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)




Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 11.82 (br. s., 1H), 10.55 (br. s., 1H), 9.05 (d, J = 1.8 Hz, 1H), 8.94 (d, J = 2.3 Hz, 1H), 8.64 (br. s., 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.23 (t, J = 9.2 Hz, 1H), 7.98 (dd, J = 7.8, 1.9 Hz, 1H), 7.31 (br. s., 1H), 7.26 (dd, J = 11.7, 2.6 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 6.98 - 7.05 (m, 2H), 6.76 - 6.83 (m, 1H), 6.73 (dd, J = 5.7, 2.5 Hz, 1H), 2.25 (s, 3H)

LR MS (ES-): 478 (M-H)

Example 40

{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}acetic acid



To a stirred solution of methyl {[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}acetate (60mg, 0.11mmol) in a mixture of solvents THF/MeOH (5ml/5ml) was added 1ml of 1M NaOH (1.0mmol) solution. The mixture was stirred at room temperature for 1 hour and poured into 100ml of water. 2M HCl was added until pH = 3. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give {[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}acetic acid as white solid. Yield: 50mg, 86%.


^{1}H NMR (DMSO-d_6): 12.61 (br s, 1H), 9.15 (s, 1H), 8.98 (t, J = 5.9 Hz, 1H), 8.43 - 8.48 (m, 2H), 8.40 (d, J = 1.5 Hz, 1H), 8.36 (d, J = 1.2 Hz, 1H), 7.95 (dd, J = 7.6, 1.8 Hz, 1H), 7.50 - 7.58

(m, 2H), 7.40 (d, J = 2.3 Hz, 1H), 7.12 - 7.19 (m, 2H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.73 - 6.81 (m, 2H), 3.88 (d, J = 5.9 Hz, 2H), 2.25 (s, 3H)

LR MS (ES-): 519 (M-H)

Example 41

methyl {[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}acetate



A mixture of 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylic acid (100mg, 0.22mmol), HATU (100mg, 0.26mmol) and *N,N*-diisopropylethylamine (85mg, 0.66mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of glycine methyl ester hydrochloride (41mg, 0.33mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. 2M HCl was added dropwise until pH = 4~5. The precipitates were filtered, washed with water and dried *in vacuo* to give methyl {[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}acetate as white solid. Yield: 90mg, 78%.


^{1}H NMR (DMSO-d_6): 9.17 (s, 1H), 9.10 (t, J = 5.9 Hz, 1H), 8.44 - 8.49 (m, 2H), 8.37 - 8.42 (m, 2H), 7.92 - 7.98 (m, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.8 Hz, 2H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.75 - 6.84 (m, 2H), 3.98 (d, J = 5.9 Hz, 2H), 3.63 (s, 3H), 2.25 (s, 3H)

LR MS (ES+): 557 ($M+Na^+$)

LR MS (ES-): 533 (M-H)

Preparation of methyl 4-(4-(4-aminophenoxy)pyridine-2-yl)thiophene-2-carboxylate


18572 CIP PCT (AP)



A mixture of 4-(4-aminophenoxy)-2-chloropyridine (5.0 g, 22.66mmol), methyl-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-thiophene-2-carboxylate (9.73 g, 36.25 mmol) and Pd(PPh3)4 (5.24 g, 4.53 mmol) was added to a thick walled reaction vessel and purged with N2. A solution of 2M K2CO3 (17.0 mL) was added, followed by dioxane (120 mL). The reaction vessel was sealed and the mixture stirred at 92°C for 18 h. The reaction vessel was cooled to room temperature and the mixture was filtered over celite, washing with EtOAc. The filtrate was concentrated and the resultant dark oil was purified via column chromatography, eluting with 40-60% EtOAc/hexanes to afford methyl 4-(4-(4-aminophenoxy)pyridine-2-yl)thiophene-2-carboxylate (6.1 g, 82% yield).

Example 42

methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylate




To a stirred solution of methyl 4-[4-(4-aminophenoxy)pyridin-2-yl]thiophene-2-carboxylate (500 mg, 1.53 mmol) in anhydrous THF (10ml) was added 2-fluoro-5-methyl-phenylisocyanate (255mg, 1.68mmol). The mixture was stirred at room temperature for one hour and poured into 200ml of water. The resulting precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 3-5% $MeOH/CHCl_3$ to give methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylate as off-white solid. Yield: 560mg, 76%.

18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 9.14 (s, 1H), 8.51 (d, J = 1.5 Hz, 1H), 8.41 - 8.47 (m, 2H), 8.33 (d, J = 1.8 Hz, 1H), 7.96 (d, J = 6.2 Hz, 1H), 7.48 - 7.57 (m, 3H), 7.13 (d, J = 9.1 Hz, 2H), 7.08 (dd, J = 11.4, 8.5 Hz, 1H), 6.76 - 6.81 (m, 1H), 6.74 (dd, J = 5.6, 2.3 Hz, 1H), 3.83 (s, 3H), 2.25 (s, 3H)
LR MS (ES+): 500 ($M+Na^+$)
LR MS (ES-): 476 (M-H)

Example 43

(4S)-5-(ethylamino)-4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid




To a stirred solution of tert-butyl (4S)-5-(ethylamino)-4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoate (30mg, 0.046mmol) in 5ml of methylene chloride was added 2ml of TFA. The mixture was stirred at room temperature for 1 hour, and evaporated to dryness. The residue was dissolved in MeOH (3ml), which was added dropwise into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried to give (4S)-5-(ethylamino)-4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid as white solid. Yield: 20mg, 74%.

^{1}H NMR (DMSO-d_6): 12.04 (br. s., 1H), 11.86 (br. s., 1H), 8.97 (s, 1H), 8.57 (d, J = 2.1 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 8.20 (t, J = 9.1 Hz, 1H), 7.82 (t, J = 5.6 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.46 (br. s., 1H), 7.12 - 7.29 (m, 5H), 6.99 - 7.04 (m, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.74 (d, J = 4.7 Hz, 1H), 4.31 (td, J = 8.6, 5.4 Hz, 1H), 2.97 - 3.11 (m, 2H), 2.26 (s, 3H), 2.17 - 2.25 (m, 2H), 1.87 - 1.98 (m, 1H), 1.74 - 1.84 (m, 1H), 0.97 (t, J = 7.2 Hz, 3H)
LR MS (ES-): 601 (M-H)

18572 CIP PCT (AP)

Example 44

tert-butyl (4S)-5-(ethylamino)-4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoate



A mixture of (2S)-5-tert-butoxy-2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid (80mg, 0.13mmol), HATU (57mg, 0.15mmol) and *N,N*-diisopropylethylamine (49mg, 0.38mmol) in anhydrous DMF (8ml) was stirred at room temperature for 10 minutes, followed by addition of 2M ethylamine in THF solution (0.1ml, 0.2mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. 2M HCl was added dropwise until pH = 5. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 4~5% MeOH/$CHCl_3$ to give tert-butyl (4S)-5-(ethylamino)-4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoate as white solid. Yield: 40mg, 48%.

^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 8.95 (s, 1H), 8.56 (br. s., 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.20 (t, J = 9.1 Hz, 1H), 7.81 (t, J = 5.3 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.45 (d, J = 1.5 Hz, 1H), 7.23 - 7.30 (m, 2H), 7.18 - 7.23 (m, 2H), 7.12 - 7.18 (m, 2H), 6.98 - 7.04 (m, 1H), 6.79 (d, J = 7.6 Hz, 1H), 6.73 (dd, J = 5.6, 2.3 Hz, 1H), 4.27 - 4.35 (m, 1H), 3.01 - 3.08 (m, 2H), 2.26 (s, 3H), 2.17 - 2.23 (m, 2H), 1.87 - 1.95 (m, 1H), 1.78 (m, 1H), 1.34 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H)


LR MS (ES+): 681 ($M+Na^+$)

LR MS (ES-): 657 (M-H)

18572 CIP PCT (AP)

Example 45

(2S)-5-tert-butoxy-2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid



To a stirred solution of (S)-5-tert-butyl 1-methyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate (120mg, 0.19mmol) in a mixture of solvents THF/MeOH (5ml/5ml) was added 1ml of 1M NaOH (1mmol) solution. The mixture was stirred at room temperature for 30 minutes, and poured into 100ml of water. 2M HCl was added dropwise until pH = 4. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give (2S)-5-tert-butoxy-2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-oxopentanoic acid as white solid. Yield: 100mg, 85%.

^{1}H NMR (DMSO-d_6): 12.49 (br. s., 1H), 11.84 (br. s., 1H), 8.98 (s, 1H), 8.58 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.20 (t, J = 9.1 Hz, 1H), 7.89 (br. s., 1H), 7.42 (br. s., 1H), 7.28 (s, 1H), 7.25 (dd, J = 11.7, 2.6 Hz, 1H), 7.20 - 7.23 (m, 2H), 7.11 - 7.18 (m, 2H), 7.01 (dd, J = 9.0, 1.6 Hz, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.73 (dd, J = 5.6, 2.3 Hz, 1H), 4.23 - 4.34 (m, 1H), 2.23 - 2.28 (m, 2H), 2.26 (s, 3H), 1.95 - 2.03 (m, 1H), 1.80 - 1.88 (m, 1H), 1.35 (s, 9H)


LR MS (ES+): 654 ($M+Na^+$)

LR MS (ES-): 630 (M-H)

Example 46

(S)-5-tert-butyl 1-methyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate

18572 CIP PCT (AP)



A mixture of 5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (500mg, 1.1mmol), HATU (500mg, 1.32mmol) and *N,N*-diisopropylethylamine (426mg, 3.3mmol) in anhydrous DMF (8ml) was stirred at room temperature for 10 minutes, followed by addition of L-Glutamic acid 5-tert-butyl 1-methyl ester hydrochloride (334mg, 1.32mmol). The mixture was stirred for another 10 minutes and poured into 200ml of water. 2M HCl was added dropwise until pH = 5. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 3~5% MeOH/$CHCl_3$ to give (S)-5-tert-butyl 1-methyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate as off-white solid. Yield: 380mg, 52%.

^{1}H NMR (DMSO-d_6): 11.87 (br. s., 1H), 8.96 (s, 1H), 8.56 (br. s., 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.20 (t, J = 8.9 Hz, 1H), 8.08 (d, J = 7.0 Hz, 1H), 7.44 (br. s., 1H), 7.23 - 7.29 (m, 2H), 7.18 - 7.23 (m, 2H), 7.11 - 7.17 (m, 2H), 7.01 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 7.0 Hz, 1H), 6.70 - 6.76 (m, 1H), 4.32 - 4.41 (m, 1H), 3.60 (s, 3H), 2.23 - 2.31 (m, 5H), 1.93 - 2.03 (m, 1H), 1.81 - 1.91 (m, 1H), 1.35 (s, 9H)


LR MS (ES+): 646 (MH), 668 ($M+Na^+$)

LR MS (ES-): 644 (M-H)

Example 47

bis(2-hydroxyethyl) 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate

18572 CIP PCT (AP)




Similar procedure as Example 131.

LR MS (ES+): 686 ($M+Na^+$)

LR MS (ES-): 662 (M-H), 561

Example 48

3-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoic acid



Similar procedure as Example 132.


^{1}H NMR (DMSO-d_6): 11.90 (br. s., 1H), 8.99 (s, 1H), 8.59 (br. s., 1H), 8.40 (d, J = 5.9 Hz, 1H), 8.22 (t, J = 9.0 Hz, 1H), 7.90 - 7.96 (m, 1H), 7.40 (br. s., 1H), 7.25 - 7.30 (m, 2H), 7.21 (d, J = 7.0 Hz, 2H), 7.15 (t, J = 7.8 Hz, 2H), 7.03 (d, J = 9.1 Hz, 1H), 6.79 (d, J = 7.0 Hz, 2H), 3.32 - 3.37 (m, 2H), 2.43 (t, J = 7.0 Hz, 2H), 2.26 (s, 3H)

LR MS (ES-): 516 (M-H)

Example 49

2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid

18572 CIP PCT (AP)




^{1}H NMR (DMSO-d_6): 12.43 (br. s., 2H), 11.89 (br. s., 1H), 8.97 (br. s., 1H), 8.57 (br. s., 1H), 8.39 (d, J = 5.3 Hz, 1H), 8.20 (t, J = 8.8 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.46 (br. s., 1H), 7.11 - 7.31 (m, 4H), 7.02 (d, J = 9.1 Hz, 1H), 6.79 (d, J = 7.0 Hz, 1H), 6.75 (br. s., 1H), 4.32 (br. s., 1H), 2.30 (t, J = 7.2 Hz, 2H), 2.26 (s, 3H), 2.01 (m, 2H), 1.86 (m, 2H)

LR MS (ES-): 574 (M-H)

Example 50

methyl 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylate



Similar procedure as Example 132


LR MS (ES+): 615 (MH), 637 (M+Na^+)

LR MS (ES-): 613 (M-H)

Example 51

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{2-[(3S)-3-hydroxypyrrolidin-1-yl]-2-oxoethyl}-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)




Similar procedure as Example 132.

LR MS (ES+): 573 (MH), 595 ($M+Na^+$)

LR MS (ES-): 571 (M-H)

Example 52

N-{4-[(2,3-dihydroxypropyl)(methyl)amino]-4-oxobutyl}-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 61.

^1H NMR (DMSO-d_6): 11.70 - 11.82 (m, 1H), 9.24 (s, 1H), 8.50 (d, J = 2.1 Hz, 1H), 8.35 (d, J = 5.9 Hz, 1H), 7.93 - 7.98 (m, 1H), 7.85 (dt, J = 14.5, 5.5 Hz, 1H), 7.54 (d, J = 9.1 Hz, 2H), 7.34 (br. s., 1H), 7.10 - 7.15 (m, 3H), 7.08 (dd, J = 11.2, 8.5 Hz, 1H), 7.01 - 7.05 (m, 1H), 6.73 - 6.82 (m, 1H), 6.67 (dd, J = 5.6, 2.3 Hz, 1H), 4.87 (d, J = 5.3 Hz, 1H), 4.60 - 4.69 (m, 1H), 4.46 (t, J = 5.9 Hz, 1H), 3.55 - 3.65 (m, 2H), 3.20 - 3.27 (m, 2H), 3.10 - 3.19 (m, 2H), 2.96 (s, 1H), 2.79 (s, 2H), 2.27 - 2.35 (m, 1H), 2.24 (s, 3H), 1.62 - 1.72 (m, 2H)


LR MS (ES+): 619 (MH), 641 ($M+Na^+$)

LR MS (ES-): 617 (M-H)

Example 53

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[4-(3-hydroxypiperidin-1-yl)-4-oxobutyl]-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)




Similar procedure as Example 61.

LR MS (ES+): 637 ($M+Na^+$)

LR MS (ES-): 613 (M-H)

Example 54

N-{4-[(2,3-dihydroxypropyl)amino]-4-oxobutyl}-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 61.

^1H NMR (DMSO-d_6): 11.77 (br. s., 1H), 9.14 (s, 1H), 8.46 (d, J = 2.3 Hz, 1H), 8.35 (d, J = 5.9 Hz, 1H), 7.96 (dd, J = 7.9, 2.1 Hz, 1H), 7.84 (t, J = 5.6 Hz, 1H), 7.77 (t, J = 5.9 Hz, 1H), 7.51 - 7.57 (m, 2H), 7.33 (dd, J = 3.1, 1.6 Hz, 1H), 7.11 - 7.16 (m, 3H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 7.01 - 7.05 (m, 1H), 6.75 - 6.82 (m, 1H), 6.68 (dd, J = 5.7, 2.5 Hz, 1H), 4.68 (d, J = 5.0 Hz, 1H), 4.46 (t, J = 5.9 Hz, 1H), 3.41 - 3.47 (m, 1H), 3.20 - 3.26 (m, 2H), 3.09 - 3.19 (m, 3H), 2.90 - 2.97 (m, 1H), 2.25 (s, 3H), 2.10 (t, J = 7.6 Hz, 2H), 1.66 (quin, J = 7.3 Hz, 2H)


LR MS (ES+): 605 (MH), 627 ($M+Na^+$)

LR MS (ES-): 603 (M-H)

18572 CIP PCT (AP)

Example 55

N-(4-amino-4-oxobutyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 61.


^{1}H NMR (DMSO-d_6): 11.92 (br. s., 1H), 9.20 (br. s., 1H), 8.48 (d, J = 1.8 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.95 (dd, J = 7.8, 1.9 Hz, 1H), 7.89 (br. s., 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.42 (br. s., 1H), 7.18 - 7.28 (m, 2H), 7.15 (d, J = 8.8 Hz, 2H), 7.08 (dd, J = 11.4, 8.5 Hz, 1H), 6.78 (ddd, J = 7.5, 5.0, 2.2 Hz, 2H), 6.68 (br. s., 1H), 3.14 (q, J = 6.7 Hz, 2H), 2.25 (s, 3H), 2.05 (t, J = 7.5 Hz, 2H), 1.66 (quin, J = 7.3 Hz, 2H)

LR MS (ES+): 553 ($M+Na^+$)

LR MS (ES-): 529 (M-H)

Example 56

N-{2-[(2,3-dihydroxypropyl)amino]-2-oxoethyl}-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 9.15 (s, 1H), 8.46 (br. s., 1H), 8.36 (d, J = 5.9 Hz, 1H), 8.14 (t, J = 6.0 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.67 (t, J = 5.6 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.38 (br. s., 1H), 7.13 (d, J = 8.8 Hz, 3H), 7.03 - 7.11 (m, 2H), 6.75 - 6.82 (m, 1H), 6.69


(dd, J = 5.6, 2.3 Hz, 1H), 4.70 (d, J = 5.0 Hz, 1H), 4.47 (t, J = 5.7 Hz, 1H), 3.76 (d, J = 5.6 Hz, 2H), 3.45 (dq, J = 11.2, 5.5 Hz, 1H), 3.16 - 3.27 (m, 3H), 2.93 - 3.00 (m, 1H), 2.25 (s, 3H)

LR MS (ES+): 577 (MH), 599 ($M+Na^+$)

LR MS (ES-): 575 (M-H)

Example 57

5-(2,3-dihydroxypropyl) 1-methyl 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate



Similar procedure as Example 58.


^1H NMR (DMSO-d_6): 11.86 (br. s., 1H), 9.14 (s, 1H), 8.46 (d, J = 2.3 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 8.08 - 8.17 (m, 1H), 7.96 (dd, J = 7.9, 1.8 Hz, 1H), 7.54 (d, J = 8.5 Hz, 2H), 7.43 (br. s., 1H), 7.04 - 7.21 (m, 4H), 6.78 (dt, J = 5.7, 2.7 Hz, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 4.83 (d, J = 5.3 Hz, 1H), 4.58 (t, J = 5.7 Hz, 1H), 4.36 - 4.45 (m, 1H), 3.95 - 4.06 (m, 2H), 3.88 (dd, J = 11.0, 6.6 Hz, 1H), 3.60 (s, 3H), 3.28 - 3.35 (m, 2H), 2.40 (t, J = 7.6 Hz, 2H), 2.25 (s, 3H), 1.99 - 2.10 (m, 1H), 1.88 - 1.95 (m, 1H), 1.15 (t, J = 7.0 Hz, 1H)

LR MS (ES+): 664 (MH), 686 ($M+Na^+$)

Example 58

bis(2,3-dihydroxypropyl) 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate

18572 CIP PCT (AP)




A mixture of 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid (60mg, 0.10mmol), glycerol (0.5ml), 1-Ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (EDC• HCl, 37mg, 0.19mmol) and 4-dimethylaminopyridine (DMAP, 5mg, 0.04mmol) in anhydrous THF (10ml) was stirred at 60°C for 3 hours. The mixture was cooled to room temperature, concentrated and purified by silica gel chromatography eluting with a gradient of 10~15% MeOH/$CHCl_3$ to give bis(2,3-dihydroxypropyl) 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate as colorless oil. Yield: 40mg, 53%.

LR MS (ES+): 746 ($M+Na^+$)

LR MS (ES-): 722 (M-H)

Example 59

4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}-5-methoxy-5-oxopentanoic acid




Similar procedure as Example 132.

^1H NMR (DMSO-d_6): 11.98 (br. s., 1H), 9.19 (s, 1H), 8.48 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 8.13 (d, J = 7.3 Hz, 1H), 7.95 (dd, J = 7.8, 1.9 Hz, 1H), 7.53 - 7.57 (m, 2H), 7.47 - 7.52

(m, 1H), 7.24 (br. s., 1H), 7.19 (br. s., 1H), 7.15 (d, J = 8.8 Hz, 2H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.72 - 6.81 (m, 2H), 4.38 (ddd, J = 9.5, 7.5, 5.3 Hz, 1H), 3.60 (s, 3H), 2.31 (t, J = 7.6 Hz, 2H), 2.25 (s, 3H), 1.95 - 2.05 (m, 1H), 1.82 - 1.93 (m, J = 14.0, 9.6, 7.0, 7.0 Hz, 1H)
LR MS (ES-): 588 (M-H)

Example 60


N-[4-(ethylamino)-4-oxobutyl]-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 61.
^{1}H NMR (DMSO-d_6): 11.96 (br. s., 1H), 9.20 (s, 1H), 8.48 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.95 (dd, J = 7.8, 1.9 Hz, 1H), 7.89 (br. s., 1H), 7.76 (t, J = 5.3 Hz, 1H), 7.53 - 7.58 (m, 2H), 7.44 (br. s., 1H), 7.23 (br. s., 1H), 7.13 - 7.19 (m, 3H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.75 - 6.84 (m, 2H), 3.11 - 3.17 (m, 2H), 3.01 (qd, J = 7.2, 5.6 Hz, 2H), 2.25 (s, 3H), 2.05 (t, J = 7.5 Hz, 2H), 1.66 (quin, J = 7.3 Hz, 2H), 0.96 (t, J = 7.2 Hz, 3H)
LR MS (ES+): 559 (MH), 581 (M+Na^+)
LR MS (ES-): 557 (M-H)

Example 61

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[4-(3-hydroxypyrrolidin-1-yl)-4-oxobutyl]-1H-pyrrole-3-carboxamide



18572 CIP PCT (AP)

A mixture of 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid (60mg, 0.11mmol), HATU (50mg, 0.13mmol) and *N,N*-diisopropylethylamine (43mg, 0.33mmol) in anhydrous DMF (8ml) was stirred at room temperature for 10 minutes, followed by addition of (R)-3-pyrrolidinol (14mg, 0.16mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. 2M HCl was added dropwise until pH = 4~5. The precipitates were filtered, washed with water and dried *in vacuo* to give 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[4-(3-hydroxypyrrolidin-1-yl)-4-oxobutyl]-1H-pyrrole-3-carboxamide as white solid. Yield: 40mg, 59%.


^{1}H NMR (DMSO-d_6): 11.97 (br. s., 1H), 9.31 (s, 1H), 8.53 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.95 (dd, J = 7.8, 1.9 Hz, 1H), 7.91 (d, J = 4.4 Hz, 1H), 7.54 - 7.59 (m, 2H), 7.42 - 7.48 (m, 1H), 7.24 (br. s., 1H), 7.16 (d, J = 8.8 Hz, 2H), 7.05 - 7.10 (m, 1H), 6.78 (ddd, J = 7.5, 5.0, 2.2 Hz, 2H), 4.24 - 4.28 (m, 0H), 4.16 - 4.21 (m, 1H), 3.40 - 3.48 (m, 2H), 3.35 (ddd, J = 11.6, 8.4, 3.5 Hz, 1H), 3.25 - 3.30 (m, 1H), 3.14 - 3.25 (m, 4H), 2.25 (s, 3H), 2.23- 2.27 (m, 1H), 2.20 (t, J = 7.9 Hz, 1H), 1.84 - 1.92 (m, 1H), 1.75 - 1.82 (m, 1H), 1.65 - 1.73 (m, 2H)

LR MS (ES+): 601 (MH), 623 ($M+Na^+$)

LR MS (ES-): 599 (M-H)

Example 62

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[4-(hydroxyamino)-4-oxobutyl]-1H-pyrrole-3-carboxamide




Similar procedure as Example 61.

^{1}H NMR (DMSO-d_6): 11.92 (br. s., 1H), 10.33 (s, 1H), 9.18 (s, 1H), 8.47 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.95 (dd, J = 7.9, 1.8 Hz, 1H), 7.87 - 7.92 (m, 1H), 7.51 - 7.58 (m, 2H),

7.38 - 7.46 (m, 1H), 7.21 (br. s., 1H), 7.11 - 7.18 (m, 3H), 7.05 - 7.11 (m, 1H), 6.72 - 6.82 (m, 2H), 3.14 (q, J = 6.7 Hz, 2H), 2.25 (s, 3H), 1.96 (t, J = 7.6 Hz, 2H), 1.66 (quin, J = 7.3 Hz, 2H)
LR MS (ES+): 547 (MH), 569 ($M+Na^+$)
LR MS (ES-): 545 (M-H)

Example 63


2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid



Similar procedure as Example 132.
^1H NMR (DMSO-d_6): 12.42 (br. s., 1H), 12.12 (br. s., 1H), 11.86 (br. s., 1H), 9.15 (s, 1H), 8.46 (d, J = 2.6 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 7.93 - 8.01 (m, 2H), 7.51 - 7.58 (m, 2H), 7.44 (br. s., 1H), 7.18 (s, 1H), 7.11 - 7.16 (m, 3H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.75 - 6.82 (m, 1H), 6.69 (d, J = 3.8 Hz, 1H), 4.32 (ddd, J = 9.7, 7.9, 5.0 Hz, 1H), 2.30 (t, J = 7.6 Hz, 2H), 2.25 (s, 3H), 1.96 - 2.05 (m, 1H), 1.80 - 1.91 (m, J = 14.0, 9.8, 7.2, 7.2 Hz, 1H)
LR MS (ES-): 574 (M-H)

Example 64

dimethyl 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate



18572 CIP PCT (AP)

Similar procedure as Example 132.


^{1}H NMR (DMSO-d_6): 12.27 (br. s., 1H), 9.33 (br. s., 1H), 8.50 - 8.57 (m, 1H), 8.44 (d, J = 6.2 Hz, 1H), 8.23 (d, J = 6.7 Hz, 1H), 7.95 (d, J = 6.5 Hz, 1H), 7.64 (br. s., 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.39 (br. s., 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.08 (dd, J = 11.2, 8.2 Hz, 1H), 6.92 (br. s., 1H), 6.79 (d, J = 5.6 Hz, 1H), 4.35 - 4.43 (m, 1H), 3.60 (s, 3H), 3.55 (s, 3H), 2.40 (t, J = 7.5 Hz, 2H), 2.22 - 2.28 (m, 3H), 2.00 - 2.10 (m, 1H), 1.88 - 1.97 (m, 1H)

LR MS (ES+): 626 ($M+Na^+$)

LR MS (ES-): 602 (M-H)

Example 65

1-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]pyrrolidine-3-carboxylic acid



Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 12.47 (br. s., 1H), 11.85 - 12.01 (m, 1H), 9.05 (d, J = 1.8 Hz, 1H), 8.94 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 8.22 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.8, 1.9 Hz, 1H), 7.41 (br. s., 1H), 7.21 - 7.32 (m, 2H), 7.06 - 7.14 (m, 2H), 7.01 (dd, J = 9.0, 1.6 Hz, 1H), 6.79 (ddd, J = 7.6, 5.1, 1.9 Hz, 1H), 6.65 - 6.76 (m, 1H), 2.97 - 3.93 (m, 5H), 2.25 (s, 3H), 1.93 - 2.19 (m, 2H)


LR MS (ES+): 562 (MH), 584 ($M+Na^+$)

LR MS (ES-): 560 (M-H)

Example 66

4-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid

18572 CIP PCT (AP)




To a stirred solution of ethyl 4-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate (45mg, 0.078mmol) in 10ml of THF was added 3ml of 1M NaOH (3.0mmol). The mixture was heated at 60°C for 3 hours, cooled to room temperature and poured into 100ml of water. 2M HCl was added until pH = 5. The precipitates were filtered, washed with water, and dried to give 4-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid as grey solid. Yield: 40mg, 93%.

^{1}H NMR (DMSO-d_6): 11.99 (br. s., 1H), 11.82 (br. s., 1H), 9.06 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.1 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.37 (br. s., 1H), 7.27 (dd, J = 11.7, 2.6 Hz, 1H), 7.19 (s, 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 2H), 7.02 (dd, J = 8.9, 1.6 Hz, 1H), 6.77 - 6.82 (m, 1H), 6.73 - 6.77 (m, 1H), 3.16 (q, J = 6.7 Hz, 2H), 2.25 (s, 3H), 2.22 (t, J = 7.3 Hz, 2H), 1.67 (quin, J = 7.2 Hz, 2H)

LR MS (ES-): 548 (M-H)

Example 67

ethyl 4-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate



Similar procedure as Example 132.

18572 CIP PCT (AP)


^{1}H NMR (DMSO-d_6): 11.99 (br. s., 1H), 9.09 (d, J = 1.5 Hz, 1H), 8.96 (d, J = 2.3 Hz, 1H), 8.42 (d, J = 6.2 Hz, 1H), 8.26 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.8, 2.2 Hz, 1H), 7.86 - 7.94 (m, 1H), 7.46 (br. s., 1H), 7.25 - 7.34 (m, 2H), 7.22 (br. s., 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.87 (br. s., 1H), 6.76 - 6.82 (m, 1H), 4.01 (q, J = 7.1 Hz, 2H), 3.13 - 3.21 (m, 2H), 2.30 (t, J = 7.5 Hz, 2H), 2.25 (s, 3H), 1.70 (quin, J = 7.2 Hz, 2H), 1.14 (t, J = 7.04 Hz, 3H)

LR MS (ES+): 578 (MH), 600 ($M+Na^+$)

LR MS (ES-): 576 (M-H)

Example 68

4-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid



Similar procedure as Example 66.

^{1}H NMR (DMSO-d_6): 12.00 (br. s., 1H), 11.82 (br. s., 1H), 8.97 (s, 1H), 8.57 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 8.21 (t, J = 9.1 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.37 (br. s., 1H), 7.24 - 7.29 (m, 2H), 7.17 - 7.23 (m, 2H), 7.13 - 7.17 (m, 1H), 7.10 (br. s., 1H), 7.02 (dd, J = 8.8, 1.8 Hz, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.75 (br. s., 1H), 3.16 (q, J = 6.7 Hz, 2H), 2.26 (s, 3H), 2.22 (t, J = 7.3 Hz, 2H), 1.67 (quin, J = 7.2 Hz, 2H)


LR MS (ES+): 532 (MH), 554 ($M+Na^+$)

LR MS (ES-): 530 (M-H)

Example 69

3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoic acid

18572 CIP PCT (AP)




Similar procedure as Example 66.

^{1}H NMR (DMSO-d_6): 11.93 (br. s., 2H), 9.08 (br. s., 1H), 8.96 (d, J = 1.8 Hz, 1H), 8.41 (d, J = 5.9 Hz, 1H), 8.25 (t, J = 8.9 Hz, 1H), 7.98 (d, J = 7.9 Hz, 1H), 7.94 (br. s., 1H), 7.43 (d, J = 2.1 Hz, 1H), 7.29 (d, J = 10.3 Hz, 1H), 7.24 (br. s., 1H), 7.17 (br. s., 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 6.83 (br. s., 1H), 6.76 - 6.81 (m, 1H), 3.33 - 3.38 (m, 2H), 2.44 (t, J = 7.0 Hz, 2H), 2.25 (s, 3H)

LR MS (ES-): 534 (M-H)

Example 70

N-ethyl-5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 11.98 (br. s., 1H), 9.11 (s, 1H), 8.67 (br. s., 1H), 8.41 (d, J = 5.9 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.87 (t, J = 5.0 Hz, 1H), 7.44 (br. s., 1H), 7.25 - 7.32 (m, 3H), 7.18 - 7.25 (m, 2H), 7.12 - 7.17 (m, 1H), 7.04 (dd, J = 9.0, 1.6 Hz, 1H), 6.85 (br. s., 1H), 6.79 (d, J = 7.3 Hz, 1H), 3.15 - 3.22 (m, 2H), 2.26 (s, 3H), 1.05 (t, J = 7.2 Hz, 3H)


LR MS (ES+): 474 (MH), 496 ($M+Na^+$)

LR MS (ES-): 472 (M-H)

Example 71

{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid

18572 CIP PCT (AP)




Similar procedure as Example 66.

^{1}H NMR (DMSO-d_6): 11.84 (br. s., 1H), 9.23 (s, 1H), 8.73 (d, J = 1.5 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.18 (t, J = 9.1 Hz, 1H), 8.12 (t, J = 5.4 Hz, 1H), 7.38 (dd, J = 2.9, 1.8 Hz, 1H), 7.28 (s, 1H), 7.21 - 7.26 (m, 2H), 7.19 (d, J = 2.3 Hz, 1H), 7.14 (t, J = 7.8 Hz, 1H), 7.08 - 7.11 (m, 1H), 7.01 (dd, J = 9.0, 2.5 Hz, 1H), 6.78 (d, J = 7.3 Hz, 1H), 6.73 (dd, J = 5.9, 2.3 Hz, 1H), 3.78 (d, J = 5.9 Hz, 2H), 2.25 (s, 3H)

LR MS (ES-): 502 (M-H)

Example 72

methyl {[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate



Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 11.87 (br. s., 1H), 8.96 (s, 1H), 8.56 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 8.31 (t, J = 6.0 Hz, 1H), 8.20 (t, J = 9.1 Hz, 1H), 7.39 (dd, J = 3.2, 1.8 Hz, 1H), 7.24 - 7.29 (m, 2H), 7.21 (d, J = 8.2 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.13 - 7.17 (m, 1H), 7.08 - 7.10 (m, 1H), 7.01 (dd, J = 8.5, 2.1 Hz, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.74 (dd, J = 5.9, 2.3 Hz, 1H), 3.90 (d, J = 5.9 Hz, 2H), 3.60 (s, 3H), 2.26 (s, 3H)


LR MS (ES+): 518 (MH), 540 ($M+Na^+$)

LR MS (ES-): 516 (M-H)

18572 CIP PCT (AP)

Example 73

1-(2-fluoro-4-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-(3-methylphenyl)urea



Similar procedure as Example 132.


^{1}H NMR (DMSO-d_6): 11.87 (br. s., 1H), 8.97 (s, 1H), 8.56 (d, J = 2.1 Hz, 1H), 8.37 (d, J = 5.9 Hz, 1H), 8.18 (t, J = 9.1 Hz, 1H), 7.38 (d, J = 2.3 Hz, 1H), 7.18 - 7.30 (m, 4H), 7.12 - 7.17 (m, 1H), 7.08 (d, J = 18.8 Hz, 1H), 6.99 (dt, J = 7.6, 1.5 Hz, 1H), 6.78 (d, J = 7.6 Hz, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 4.90 (d, J = 9.4 Hz, 1H), 4.30 (br. s., 1H), 3.68 - 3.82 (m, 2H), 3.42 - 3.54 (m, 2H), 2.26 (s, 3H), 1.72 - 1.97 (m, 2H)

LR MS (ES+): 516 (MH), 538 ($M+Na^+$)

LR MS (ES-): 514 (M-H)

Example 74

1-{2-fluoro-4-[(2-{4-[(3-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}-3-(3-methylphenyl)urea



Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 8.96 (s, 1H), 8.55 (d, J = 2.3 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.19 (t, J = 9.1 Hz, 1H), 7.34 (d, J = 2.3 Hz, 1H), 7.27 (s, 1H), 7.19 - 7.25 (m, 2H), 7.15 (t, J = 7.8 Hz, 1H), 7.12 (br. s., 1H), 6.97 - 7.01 (m, 1H), 6.90 (s, 1H), 6.79 (d, J = 7.6 Hz, 1H), 6.68 (dd, J = 5.7, 2.2 Hz, 1H), 4.87 (br. s., 1H), 4.04 (br. s., 1H), 3.85 (br. s., 1H), 3.41 - 3.52 (m,

18572 CIP PCT (AP)


1H), 3.07 (t, J = 10.1 Hz, 1H), 2.26 (s, 3H), 1.78 - 1.90 (m, 1H), 1.67 (td, J = 8.8, 4.7 Hz, 1H), 1.30 - 1.43 (m, 2H)

LR MS (ES+): 530 (MH), 552 ($M+Na^+$)

LR MS (ES-): 528 (M-H)

Example 75

5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid




Similar procedure as Example 134.

^{1}H NMR (DMSO-d_6): 12.04 (br. s., 1H), 11.87 (br. s., 1H), 8.97 (br. s., 1H), 8.56 (br. s., 1H), 8.39 (d, J = 5.9 Hz, 1H), 8.20 (t, J = 9.1 Hz, 1H), 7.36 (br. s., 2H), 7.19 - 7.30 (m, 3H), 7.12 - 7.17 (m, 1H), 7.08 (br. s., 1H), 7.00 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.73 (br. s., 1H), 2.26 (s, 3H)

LR MS (ES+): 469 (MH)

Example 76

methyl 5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



Similar procedure as Example 135.

^{1}H NMR (DMSO-d_6): 12.11 (br. s., 1H), 8.96 (s, 1H), 8.55 (s, 1H), 8.38 (d, J = 5.9 Hz, 1H), 8.19 (t, J = 9.1 Hz, 1H), 7.42 (dd, J = 3.1, 1.6 Hz, 1H), 7.37 (d, J = 2.1 Hz, 1H), 7.28 (s, 1H), 7.19 - 7.26 (m, 2H), 7.12 - 7.17 (m, 1H), 7.09 - 7.12 (m, 1H), 7.00 (dd, J = 9.1, 2.3 Hz, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.72 (dd, J = 5.6, 2.3 Hz, 1H), 3.69 (s, 3H), 2.26 (s, 3H)


18572 CIP PCT (AP)

LR MS (ES+): 461 (MH), 483 ($M+Na^+$)

LR MS (ES-): 459 (M-H)

Example 77

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.


^1H NMR (DMSO-d_6): 11.92 (br. s., 1H), 9.20 (s, 1H), 8.48 (br. s., 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.92 (br. s., 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.43 (br. s., 1H), 7.20 (br. s., 1H), 7.11 - 7.17 (m, 3H), 7.08 (dd, J = 11.2, 8.5 Hz, 1H), 6.73 - 6.81 (m, 2H), 3.41 - 3.48 (m, 12H), 3.34 - 3.39 (m, 2H), 3.31 (q, J = 5.8 Hz, 2H), 2.25 (s, 3H)

LR MS (ES+): 622 (MH), 644 ($M+Na^+$)

LR MS (ES-): 620 (M-H)

Example 78

4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid



Similar procedure as Example 66.

^1H NMR (DMSO-d_6): 11.83 (br. s., 1H), 9.17 (s, 1H), 8.49 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.95 - 8.02 (m, 1H), 7.88 (t, J = 5.6 Hz, 1H), 7.57 (d, J = 9.1 Hz, 2H), 7.38 (br. s., 1H),

18572 CIP PCT (AP)


7.16 (d, J = 9.1 Hz, 2H), 7.06 - 7.17 (m, 3H), 6.77 - 6.85 (m, 1H), 6.67 - 6.76 (m, 1H), 3.16 - 3.22 (m, 2H), 2.28 (s, 3H), 2.25 (t, J = 7.3 Hz, 2H), 1.70 (quin, J = 7.2 Hz, 2H)

LR MS (ES+): 532 (MH)

LR MS (ES-): 530 (M-H)

Example 79

ethyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate




Similar procedure as Example 132.

LR MS (ES+): 560 (MH), 582 ($M+Na^+$)

LR MS (ES-): 558 (M-H)


Preparation of 4-(2-Chloro-pyridin-4-ylsulfanyl)-phenylamine



2,4-Dichloropyrdine (4.44 g, 30.0 mmol) and potassium carbonate (8.28 g, 60.0 mmol) in dimethylformamide (60 mL) was purged with nitrogen for 10 min. 4-Aminothiophenol (3.76 g, 30.0 mmol) was added and the mixture stirred under nitrogen at room temperature for 18 h. Water (300 mL) was added and the slurry stirred for 30 min. The resulting solid was filtered, washed with water and vacuum dried at room temperature. Recrystallization from ethyl acetate (35 mL), filtered hot, then cooled gave 4-(2-Chloro-pyridin-4-ylsulfanyl)-phenylamine (3.946 g, 56% yield).

Preparation of 1-[4-(2-Chloro-pyridin-4-ylsulfanyl)-phenyl]-3-(2-fluoro-5-methyl-phenyl)-urea


18572 CIP PCT (AP)



To a stirred solution of 4-(2-Chloro-pyridin-4-ylsulfanyl)-phenylamine (300 mg, 1.27 mmol) in anhydrous THF (10ml) was added 2-fluoro-5-methyl-phenylisocyanate (210mg, 1.39mmol). The mixture was stirred at 60°C for 5 hours, and poured into 100ml of water. The precipitates were filtered, washed with water (50ml), and dried to give the crude, which was purified by silica gel chromatography eluting with 2-3% MeOH/$CHCl_3$ to give 1-[4-(2-Chloro-pyridin-4-ylsulfanyl)-phenyl]-3-(2-fluoro-5-methyl-phenyl)-urea as white solid. Yield: 410mg, 83%. ^{1}H NMR (DMSO-d_6): 9.37 (s, 1H), 8.57 (d, J = 2.1 Hz, 1H), 8.17 (d, J = 5.9 Hz, 1H), 7.89 - 8.01 (m, 1H), 7.58 - 7.70 (m, 2H), 7.47 - 7.59 (m, 2H), 7.10 (dd, J = 11.4, 8.2 Hz, 1H), 6.94 - 7.03 (m, 2H), 6.82 (dd, J = 4.8, 2.2 Hz, 1H), 2.26 (s, 3H)

Example 80

5-(4-{[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]thio}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid



To a stirred solution of methyl 5-(4-{[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]thio}pyridin-2-yl)-1H-pyrrole-3-carboxylate (86mg, 0.18mmol) in a mixture of solvents THF/MeOH (5ml/5ml) was added 2ml of 1M NaOH (2mmol) solution. The mixture was heated in a 66°C bath for 7 hours, cooled to room temperature and poured into 100ml of water. 2M HCl was added until pH = 3. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give 5-(4-{[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]thio}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid as light brown solid. Yield: 73mg, 88%.


18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 12.01 (br. s., 1H), 9.37 (s, 1H), 8.56 (d, J = 1.8 Hz, 1H), 8.27 (d, J = 5.6 Hz, 1H), 7.95 (s, 1H), 7.44 - 7.68 (m, 5H), 7.36 (br. s., 1H), 7.10 (dd, J = 11.1, 8.5 Hz, 1H), 6.94 (br. s., 1H), 6.81 (br. s., 1H), 6.69 (d, J = 5.3 Hz, 1H), 2.26 (s, 3H)

LR MS (ES-): 461 (M-H)

Example 81

3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoic acid



Similar procedure as Example 66.


^{1}H NMR (DMSO-d_6): 12.12 (br. s., 1H), 11.81 (br. s., 1H), 9.15 (s, 1H), 8.46 (br. s., 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.92 (t, J = 5.3 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.35 (br. s., 1H), 7.13 (dd, J = 6.6, 2.2 Hz, 3H), 7.08 (dd, J = 11.2, 8.5 Hz, 1H), 7.04 (br. s., 1H), 6.75 - 6.82 (m, 1H), 6.70 (d, J = 3.2 Hz, 1H), 3.32 - 3.41 (m, 2H), 2.43 (t, J = 7.0 Hz, 2H), 2.25 (s, 3H)

LR MS (ES+): 518 (MH), 540 ($M+Na^+$)

LR MS (ES-): 516 (M-H)

Example 82

4-{S-methyl-N-[(5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]sulfonimidoyl}butanoic acid



18572 CIP PCT (AP)


To a stirred solution of methyl 4-{S-methyl-N-[(5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]sulfonimidoyl}butanoate (5mg, 0.0087mol) in MeOH (3ml) was added 1M NaOH (0.5ml, 0.5mmol). The mixture was stirred at room temperature for 30 minutes, and poured into 30ml of water. 2M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried to give 4-{S-methyl-N-[(5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]sulfonimidoyl}butanoic acid as off-white solid. Yield: 5mg, 100%.

LR MS (ES+): 576 (MH), 598 ($M+Na^+$)

LR MS (ES-): 574 (M-H)

Example 83

1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]pyrrolidine-3-carboxylic acid



Similar procedure as Example 132.

^1H NMR (DMSO-d_6): 12.04 (br. s., 1H), 9.16 (s, 1H), 8.46 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.93 - 7.99 (m, 1H), 7.54 (d, J = 9.1 Hz, 2H), 7.41 (br. s., 1H), 7.33 (br. s., 1H), 7.14 (d, J = 8.8 Hz, 2H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.75 - 6.82 (m, 1H), 6.72 (br. s., 1H), 2.98 - 3.93 (m, 5H), 2.25 (s, 3H), 1.93 - 2.19 (m, 2H)


LR MS (ES+): 544 (MH), 566 ($M+Na^+$)

LR MS (ES-): 542 (M-H)

Example 84

{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid

18572 CIP PCT (AP)



Similar procedure as Example 66.


^{1}H NMR (DMSO-d_6): 12.42 (br. s., 1H), 11.85 (br. s., 1H), 9.15 (s, 1H), 8.47 (d, J = 2.1 Hz, 1H), 8.37 (d, J = 5.9 Hz, 1H), 8.21 (t, J = 6.0 Hz, 1H), 7.90 - 8.03 (m, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.38 (br. s., 1H), 7.02 - 7.21 (m, 5H), 6.74 - 6.84 (m, 1H), 6.70 (dd, J = 5.6, 2.3 Hz, 1H), 3.82 (d, J = 5.9 Hz, 2H), 2.26 (s, 3H)

LR MS (ES+): 504 (MH), 526 ($M+Na^+$)

LR MS (ES-): 502 (M-H)

Example 85

methyl {[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate



Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 12.00 (br. s., 1H), 9.18 (s, 1H), 8.48 (d, J = 2.1 Hz, 1H), 8.29 - 8.44 (m, 2H), 7.97 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 9.1 Hz, 2H), 7.46 (br. s., 1H), 7.02 - 7.27 (m, 5H), 6.79 (d, J = 2.1 Hz, 2H), 3.91 (d, J = 6.2 Hz, 2H), 3.61 (s, 3H), 2.26 (s, 3H)


LR MS (ES+): 518 (MH), 540 ($M+Na^+$)

LR MS (ES-): 516 (M-H)

18572 CIP PCT (AP)

Example 86

1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidine-4-sulfonic acid



Similar procedure as Example 132.


^{1}H NMR (DMSO-d_6): 12.41 (br. s., 1H), 9.24 (s, 1H), 8.46 - 8.53 (m, 2H), 7.91 - 7.98 (m, 1H), 7.54 - 7.64 (m, 3H), 7.45 (br. s., 1H), 7.30 (br. s., 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.08 (dd, J = 11.2, 8.2 Hz, 1H), 7.02 (br. s., 1H), 6.75 - 6.82 (m, 1H), 4.29 (br. s., 2H), 3.52 (br. s., 2H), 2.48 - 2.56 (m, 1H), 2.25 (s, 3H), 1.93 (d, J = 12.6 Hz, 2H), 1.45 (br. s., 2H)

LR MS (ES+): 616 ($M+Na^+$)

LR MS (ES-): 592 (M-H)

Example 87

methyl 4-{S-methyl-N-[(5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]sulfonimidoyl}butanoate




Similar procedure as Example 101.

LR MS (ES+): 590 (MH), 612 ($M+Na^+$)

Example 88

18572 CIP PCT (AP)

methyl 5-(4-{[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]thio}pyridin-2-yl)-1H-pyrrole-3-carboxylate




A mixture of 1-[4-(2-Chloro-pyridin-4-ylsulfanyl)-phenyl]-3-(2-fluoro-5-methyl-phenyl)-urea (410mg, 1.06 mmol), methyl-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-3-carboxylate (532mg, 2.12 mmol) and $PdCl_2(dppf)\cdot CH_2Cl_2$ (10mg, 0.012 mmol) was added to a thick-walled reaction vessel and purged with N_2. A solution of 2M Na_2CO_3 (1.0 mL) was added, followed by DMSO (10 mL). The reaction vessel was sealed and the mixture stirred at 95°C for 16 h. The reaction vessel was cooled to room temperature and the mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified via silica gel chromatography eluting with 2-5% MeOH/$CHCl_3$ to afford methyl 5-(4-{[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]thio}pyridin-2-yl)-1H-pyrrole-3-carboxylate as off-white solid. Yield: 100mg, 20% yield.

LR MS (ES+): 477 (MH), 499 ($M+Na^+$)

Example 89

N-methyl-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^1H NMR (DMSO-d_6): 11.88 (br. s., 1H), 8.89 (s, 1H), 8.69 (s, 1H), 8.37 (d, J = 5.9 Hz, 1H), 7.82 (d, J = 4.4 Hz, 1H), 7.52 - 7.58 (m, 2H), 7.37 (br. s., 1H), 7.27 (s, 1H), 7.22 (d, J = 8.2 Hz, 1H), 7.18 (br. s., 1H), 7.11 - 7.15 (m, 3H), 7.08 (br. s., 1H), 6.71 - 6.80 (m, 2H), 2.67 (d, J = 4.7 Hz, 3H), 2.25 (s, 3H)


LR MS (ES+): 442 (MH), 464 ($M+Na^+$)

18572 CIP PCT (AP)

LR MS (ES-): 440 (M-H)

Example 90

1-{4-[(2-{4-[(3-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}-3-(3-methylphenyl)urea




Similar procedure as Example 132.

LR MS (ES+): 512 (MH), 534 ($M+Na^+$)

LR MS (ES-): 510 (M-H)

Example 91

1-{4-[(2-{4-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}-3-(3-methylphenyl)urea



Similar procedure as Example 132.


^1H NMR (DMSO-d_6): 11.88 (br. s., 1H), 8.74 (s, 1H), 8.58 (s, 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 6.99 - 7.39 (m, 8H), 6.78 (d, J = 7.0 Hz, 1H), 6.62 (dd, J = 5.6, 2.3 Hz, 1H), 4.91 (br. s., 1H), 4.31 (br. s., 1H), 3.67 - 3.87 (m, 2H), 3.49 (br. s., 2H), 2.26 (s, 3H), 1.88 (br. s., 2H)

LR MS (ES+): 520 ($M+Na^+$)

Example 92

18572 CIP PCT (AP)

N-(2,3-dihydroxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide




Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 11.86 (br. s., 1H), 8.78 (s, 1H), 8.61 (s, 1H), 8.37 (d, J = 5.9 Hz, 1H), 7.87 (t, J = 5.7 Hz, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.41 (br. s., 1H), 7.05 - 7.32 (m, 7H), 6.75 (dd, J = 17.7, 6.6 Hz, 2H), 3.49 - 3.61 (m, 1H), 3.22 - 3.35 (m, 3H), 3.04 - 3.18 (m, 1H), 2.26 (s, 3H)

LR MS (ES+): 524 ($M+Na^+$)

Example 93

N-ethyl-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^{1}H NMR (DMSO-d_6): 12.09 (br. s., 1H), 8.98 (s, 1H), 8.76 (s, 1H), 8.42 (d, J = 5.9 Hz, 1H), 7.91 (br. s., 1H), 7.45 - 7.65 (m, 3H), 7.05 - 7.38 (m, 7H), 6.82 - 6.94 (m, 1H), 6.78 (d, J = 7.6 Hz, 1H), 3.09 - 3.27 (m, 2H), 2.26 (s, 3H), 1.06 (t, J = 7.2 Hz, 3H)


LR MS (ES+): 478 ($M+Na^+$)

LR MS (ES-): 454 (M-H)

Example 94

5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)



Similar procedure as Example 132.


^{1}H NMR (d_6-DMSO,300MHz): 11.81 (br. s., 1H), 8.76 (s, 1H), 8.59 (s, 1H), 8.37 (d, J = 5.6 Hz, 1H), 7.55 (d, J = 9.1 Hz, 2H), 7.37 (br. s., 2H), 7.28 (s, 1H), 7.19 - 7.26 (m, 1H), 7.09 - 7.18 (m, 4H), 7.04 (br. s., 1H), 6.78 (d, J = 7.3 Hz, 2H), 6.69 (dd, J = 5.4, 1.9 Hz, 1H), 2.26 (s, 3H)

LR MS (ES+): 428 (MH), 450 ($M+Na^+$)

LR MS (ES-): 426 (M-H)

Example 95

N-hydroxy-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^{1}H NMR (d_6-DMSO,300MHz): 11.98 (br. s., 1H), 10.62 (br. s., 1H), 8.87 (s, 1H), 8.68 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.58 (d, J = 9.1 Hz, 2H), 7.04 - 7.46 (m, 8H), 6.80 (d, J = 7.6 Hz, 2H), 2.28 (s, 3H)


LR MS (ES+): 444 (MH), 466 ($M+Na^+$)

LR MS (ES-): 442 (M-H)

Example 96

5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid

18572 CIP PCT (AP)




Similar procedure as Example 134.

^{1}H NMR (d_6-DMSO,300MHz): 12.04 (br. s., 1H), 11.88 (br. s., 1H), 9.08 (s, 1H), 8.97 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 8.25 (t, J = 9.2 Hz, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.38 (s, 2H), 7.27 (dd, J = 11.9, 2.5 Hz, 1H), 6.95 - 7.18 (m, 3H), 6.78 - 6.88 (m, 1H), 6.74 (dd, J = 5.6, 2.1 Hz, 1H), 2.28 (s, 3H)

LR MS (ES+): 465 (MH), 487 ($M+Na^+$)

LR MS (ES-): 463 (M-H)

Example 97



N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

Similar procedure as Example 101.

^{1}H NMR (d_6-DMSO,300MHz): 11.82 (none, 1H), 11.83 (br. s., 1H), 8.76 (s, 1H), 8.60 (s, 1H), 8.37 (d, J = 5.9 Hz, 1H), 7.56 (d, J = 9.1 Hz, 2H), 7.21 - 7.35 (m, 4H), 7.08 - 7.20 (m, 3H), 6.95 (s, 1H), 6.79 (d, J = 7.0 Hz, 1H), 6.66 (dd, J = 5.6, 2.3 Hz, 1H), 3.37 (s, 6H), 2.28 (s, 3H)


LR MS (ES+): 526 ($M+Na^+$)

LR MS (ES-): 502 (M-H)

Example 98

2-hydroxyethyl 5-{4-[4-({[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate

18572 CIP PCT (AP)



Similar procedure as Example 131.


^{1}H NMR (d_6-DMSO,300MHz): 12.12 (br. s., 1 H), 9.19 (s, 1 H), 8.97 (s, 1 H), 8.40 (d, *J*=5.9 Hz, 1 H), 8.12 (d, *J*=2.1 Hz, 1 H), 7.53 - 7.70 (m, 4 H), 7.48 (dd, *J*=3.1, 1.6 Hz, 1 H), 7.35 (d, *J*=2.1 Hz, 1 H), 7.16 (d, *J*=9.1 Hz, 2 H), 7.09 (d, *J*=2.3 Hz, 1 H), 6.68 (dd, *J*=5.6, 2.3 Hz, 1 H), 4.83 (t, *J*=5.9 Hz, 1 H), 4.15 (t, *J*=5.0 Hz, 2 H), 3.59 - 3.69 (m, 2 H)

LR MS (ES+): 583 ($M+Na^+$), 585

LR MS (ES-): 559 (M-H), 561

Example 99

N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-{4-[4-({[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 101.


^{1}H NMR (d_6-DMSO,300MHz) 11.83 (br. s., 1 H), 9.19 (s, 1 H), 8.97 (s, 1 H), 8.37 (d, *J*=5.9 Hz, 1 H), 8.12 (d, *J*=2.3 Hz, 1 H), 7.54 - 7.69 (m, 4 H), 7.23 - 7.31 (m, 2 H), 7.12 - 7.19 (m, 2 H), 6.93 - 6.97 (m, 1 H), 6.67 (dd, *J*=5.9, 2.3 Hz, 1 H), 3.37 (s, 6 H)

LR MS (ES-): 590 (M-H)

Example 100

methy 4-(N-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxyl)-S-methylsulfonimidoyl)butanoate

18572 CIP PCT (AP)




Similar procedure as Example 101.

LR MS (ES+): 630 ($M+Na^+$)

LR MS (ES-): 606 (M-H)

Example 101

N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



A mixture of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (60mg, 0.13mmol), HATU (60mg, 0.16mmol), sulfonimidoyldimethane (24mg, 0.26mmol), *N,N*-diisopropylethylamine (37mg, 0.29mmol), 200mg of 4Å molecular sieves and 5ml of anhydrous 1,4-dioxane was added to a thick walled reaction vessel and purged with N_2. The reaction vessel was sealed and the mixture stirred at 90°C for 18 hours. The reaction vessel was cooled to room temperature and the mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel chromatography eluting with 3~5% MeOH/$CHCl_3$ to give N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as white solid. Yield: 38mg, 54%.

^1H NMR (d_6-DMSO): 11.83 (br. s., 1H), 9.16 (s, 1H), 8.48 (br. s., 1H), 8.37 (d, J = 5.9 Hz, 1H), 7.98 (d, J = 6.7 Hz, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.26 (dd, J = 8.6, 1.6 Hz, 2H), 7.05 - 7.19 (m, 3H), 6.96 (s, 1H), 6.75 - 6.85 (m, 1H), 6.66 (dd, J = 5.4, 1.6 Hz, 1H), 3.37 (s, 6H), 2.27 (s, 3H)


18572 CIP PCT (AP)

LR MS (ES+): 544 ($M+Na^+$)

LR MS (ES-): 520 (M-H)

Example 102

methyl (2S)-1-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)pyrrolidine-2-carboxylate




Similar procedure as Example 132.

LR MS (ES+): 623 ($M+Na^+$)

LR MS (ES-): 599 (M-H)

Example 103

N,N-diethyl-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^1H NMR (d_6-DMSO): 11.97 (br. s., 1H), 9.19 (s, 1H), 8.49 (d, J = 2.6 Hz, 1H), 8.40 (d, J = 6.2 Hz, 1H), 7.98 (dd, J = 7.8, 1.9 Hz, 1H), 7.53 - 7.61 (m, 2H), 7.40 (d, J = 1.5 Hz, 1H), 7.05 - 7.25 (m, 4H), 7.01 (br. s., 1H), 6.76 - 6.86 (m, 1H), 6.67 - 6.76 (m, 1H), 3.26 - 3.64 (m, 4H), 2.27 (s, 3H), 1.13 (t, J = 7.0 Hz, 6H)


LR MS (ES+): 524 ($M+Na^+$)

LR MS (ES-): 500 (M-H)

18572 CIP PCT (AP)

Example 104

1-(2-fluoro-5-methylphenyl)-3-{4-[(2-{4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}urea



Similar procedure as Example 132.


^{1}H NMR (d_6-DMSO): 11.87 (br. s., 1H), 9.16 (s, 1H), 8.47 (d, J = 2.6 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 7.98 (dd, J = 8.1, 1.9 Hz, 1H), 7.50 - 7.59 (m, 2H), 7.35 (d, J = 2.3 Hz, 1H), 7.08 - 7.19 (m, 4H), 6.87 - 6.95 (m, 1H), 6.80 (ddd, J = 7.7, 5.1, 2.2 Hz, 1H), 6.63 (dd, J = 5.9, 2.3 Hz, 1H), 3.60 (d, J = 4.1 Hz, 4H), 2.23 - 2.35 (m, 7H), 2.18 (s, 3H)

LR MS (ES+): 551 ($M+Na^+$)

LR MS (ES-): 527 (M-H)

Example 105

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^{1}H NMR (d_6-DMSO): 11.80 (br. s., 1H), 9.17 (s, 1H), 8.48 (d, J = 2.6 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 7.98 (dd, J = 7.9, 2.1 Hz, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.50 - 7.63 (m, 2H), 7.35 (dd, J = 2.9, 1.8 Hz, 1H), 7.00 - 7.20 (m, 5H), 6.80 (dt, J = 7.9, 2.2 Hz, 1H), 6.70 (dd, J = 5.9, 2.3 Hz, 1H), 3.21 - 3.35 (m, 2H), 2.37 - 2.57 (m, 6H), 2.27 (s, 3H), 1.65 (dt, J = 6.6, 3.1 Hz, 4H)


LR MS (ES+): 565 ($M+Na^+$)

18572 CIP PCT (AP)

LR MS (ES-): 541 (M-H)

Example 106

1-(4-((2-(4-(4,5-dihydrooxazol-2-yl)-1H-pyrrol-2-yl)pyridin-4-yl)oxy)phenyl)-3-(2-fluoro-5-methylphenyl)urea



Similar procedure as Example 132.


^{1}H NMR (d_6-DMSO): 11.90 (br. s., 1H), 9.15 (s, 1H), 8.47 (d, J = 2.6 Hz, 1H), 8.36 (d, J = 5.9 Hz, 1H), 7.97 (dd, J = 8.2, 2.1 Hz, 1H), 7.50 - 7.58 (m, 2H), 7.28 (d, J = 2.1 Hz, 1H), 7.23 (br. s., 1H), 7.04 - 7.17 (m, 3H), 6.97 (br. s., 1H), 6.79 (ddd, J = 7.5, 5.1, 2.3 Hz, 1H), 6.65 (dd, J = 5.7, 2.5 Hz, 1H), 4.17 - 4.31 (m, 2H), 3.82 (t, J = 9.2 Hz, 2H), 2.26 (s, 3H)

LR MS (ES+): 494 ($M+Na^+$)

LR MS (ES-): 470 (M-H)

Example 107

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^{1}H NMR (d_6-DMSO): 11.89 (br. s., 1H), 9.21 (s, 1H), 8.50 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.98 (dd, J = 8.1, 1.9 Hz, 1H), 7.53 - 7.62 (m, 2H), 7.43 (br. s., 2H), 7.05 - 7.24 (m, 5H), 6.71 - 6.86 (m, 3H), 2.27 (s, 3H)


LR MS (ES+): 468 ($M+Na^+$)

LR MS (ES-): 444 (M-H)

18572 CIP PCT (AP)

Example 108

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-hydroxy-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.


^{1}H NMR (d_6-DMSO): 12.10 (br. s., 1H), 10.66 (br. s., 1H), 9.29 (s, 1H), 8.53 (br. s., 1H), 8.43 (d, J = 6.2 Hz, 1H), 7.93 - 8.03 (m, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.39 - 7.50 (m, 1H), 7.30 (br. s., 1H), 7.05 - 7.26 (m, 4H), 6.75 - 6.91 (m, 2H), 2.27 (s, 3H)

LR MS (ES+): 484 ($M+Na^+$)

LR MS (ES-): 460 (M-H)

Example 109

1-(4-((2-(4-(5,6-dihydro-4H-1,3-oxazin-2-yl)-1H-pyrrol-2-yl)pyridin-4-yl)oxy)phenyl)-3-(2-fluoro-5-methylphenyl)urea



Similar procedure as Example 132.

^{1}H NMR (d_6-DMSO): 11.67 (br. s., 1H), 9.16 (s, 1H), 8.47 (d, J = 2.1 Hz, 1H), 8.34 (d, J = 5.6 Hz, 1H), 7.97 (d, J = 5.9 Hz, 1H), 7.54 (d, J = 9.1 Hz, 2H), 7.02 - 7.23 (m, 5H), 6.86 (br. s., 1H), 6.74 - 6.83 (m, 1H), 6.64 (dd, J = 5.9, 2.3 Hz, 1H), 4.14 - 4.28 (m, 2H), 3.33 - 3.42 (m, 2H), 2.26 (s, 3H), 1.83 (br. s., 2H)


LR MS (ES+): 486 (M+H)

LR MS (ES-): 484 (M-H)

Example 110

18572 CIP PCT (AP)

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-hydroxypropyl)-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.


^{1}H NMR (d_6-DMSO): 11.78 (br. s., 1H), 9.20 (s, 1H), 8.51 (d, J = 2.1 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.96 (dd, J = 7.9, 1.8 Hz, 1H), 7.83 (t, J = 5.7 Hz, 1H), 7.55 (d, J = 9.1 Hz, 2H), 7.32 - 7.36 (m, 1H), 7.02 - 7.17 (m, 5H), 6.78 (td, J = 5.3, 2.6 Hz, 1H), 6.69 (dd, J = 5.6, 2.3 Hz, 1H), 4.42 (t, J = 5.3 Hz, 1H), 3.41 (q, J = 6.2 Hz, 2H), 3.15 - 3.26 (m, 2H), 2.26 (s, 3H), 1.60 (quin, J = 6.7 Hz, 2H)

LR MS (ES+): 526 ($M+Na^+$)

LR MS (ES-): 502 (M-H)

Example 111

2-(2-methoxyethoxy)ethyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



Similar procedure as Example 131.

^{1}H NMR (d_6-DMSO): 12.12 (br. s., 1H), 9.15 (s, 1H), 8.47 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 7.97 (dd, J = 8.1, 1.9 Hz, 1H), 7.49 - 7.59 (m, 2H), 7.41 (dd, J = 3.1, 1.6 Hz, 1H), 7.34 (d, J = 2.3 Hz, 1H), 7.03 - 7.17 (m, 4H), 6.74 - 6.84 (m, 1H), 6.67 (dd, J = 5.7, 2.5 Hz, 1H), 4.20 - 4.28 (m, 2H), 3.62 - 3.70 (m, 2H), 3.51 - 3.59 (m, 2H), 3.39 - 3.46 (m, 2H), 3.18 - 3.24 (m, 3H), 2.26 (s, 3H)


18572 CIP PCT (AP)

LR MS (ES+): 571 ($M+Na^+$)

LR MS (ES-): 547 (M-H)

Example 112

N-ethyl-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.


^1H NMR (d_6-DMSO): 11.93 (br. s., 1H), 9.23 (s, 1H), 8.50 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 6.2 Hz, 1H), 7.96 (dd, J = 7.9, 1.8 Hz, 1H), 7.87 (t, J = 5.6 Hz, 1H), 7.57 (d, J = 8.8 Hz, 2H), 7.42 (br. s., 1H), 7.02 - 7.27 (m, 5H), 6.72 - 6.86 (m, 2H), 3.09 - 3.25 (m, 2H), 2.26 (s, 3H), 1.06 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 496 ($M+Na^+$)

LR MS (ES-): 472 (M-H)

Example 113

2-methoxyethyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



Similar procedure as Example 131.

^1H NMR (d_6-DMSO): 12.12 (br. s., 1H), 9.15 (s, 1H), 8.46 (br. s., 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.98 (s, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.41 (d, J = 1.2 Hz, 1H), 7.35 (d, J = 1.8 Hz, 1H), 7.01 - 7.19 (m, 4H), 6.78 (d, J = 5.9 Hz, 1H), 6.66 (dd, J = 5.9, 2.1 Hz, 1H), 4.17 - 4.32 (m, 2H), 3.51 - 3.65 (m, 2H), 3.29 (s, 3H), 2.26 (s, 3H)


18572 CIP PCT (AP)

LR MS (ES+): 527 ($M+Na^+$)

LR MS (ES-): 503 (M-H)

Example 114

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-methoxyethyl)-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.


^1H NMR (d_6-DMSO): 11.86 (br. s., 1H), 9.17 (s, 1H), 8.48 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 7.86 - 8.02 (m, 2H), 7.56 (d, J = 8.8 Hz, 2H), 7.40 (br. s., 1H), 7.02 - 7.21 (m, 5H), 6.67 - 6.84 (m, 2H), 3.26 - 3.50 (m, 7H), 2.26 (s, 3H)

LR MS (ES+): 526 ($M+Na^+$)

LR MS (ES-): 502 (M-H)

Example 115

5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid



Similar procedure as Example 134.


^1H NMR (d_6-DMSO): 12.05 (br. s., 1H), 8.79 (s, 1H), 8.62 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.52 - 7.61 (m, 2H), 7.39 (dd, J = 3.1, 1.6 Hz, 1H), 7.34 (d, J = 2.3 Hz, 1H), 7.30 (s, 1H), 7.21 - 7.27 (m, 1H), 7.10 - 7.20 (m, 3H), 7.05 (s, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 2.28 (s, 3H)

LR MS (ES-): 427 (M-H)

18572 CIP PCT (AP)

Example 116

methyl 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



Similar procedure as Example 135.


^{1}H NMR (d_6-DMSO): 12.12 (br. s., 1H), 9.02 (br. s., 1H), 8.85 (br. s., 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.50 - 7.59 (m, 2H), 7.41 (d, J = 1.5 Hz, 1H), 7.33 (d, J = 2.3 Hz, 1H), 7.29 (s, 1H), 7.24 (d, J = 7.9 Hz, 1H), 7.08 - 7.18 (m, 3H), 7.06 (d, J = 1.5 Hz, 1H), 6.77 (d, J = 7.6 Hz, 1H), 6.65 (dd, J = 5.6, 2.3 Hz, 1H), 3.69 (s, 3H), 2.26 (s, 3H)

LR MS (ES+): 465 ($M+Na^+$)

LR MS (ES-): 441 (M-H)

Example 117

5-{4-[2-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid



Similar procedure as Example 134.

^{1}H NMR (d_6-DMSO): 12.03 (br. s., 1H), 11.86 (br. s., 1H), 9.62 (s, 1H), 8.65 (s, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.94 (dd, J = 7.9, 1.8 Hz, 1H), 7.72 (dd, J = 13.2, 2.3 Hz, 1H), 7.26 - 7.40 (m, 3H), 7.15 - 7.24 (m, 1H), 7.01 - 7.14 (m, 2H), 6.81 (td, J = 5.3, 2.3 Hz, 1H), 6.68 (dd, J = 5.7, 2.2 Hz, 1H), 2.26 (s, 3H)


LR MS (ES+): 487 ($M+Na^+$)

LR MS (ES-): 463 (M-H)

18572 CIP PCT (AP)

Example 118

methyl 5-{4-[2-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



Similar procedure as Example 135.


^{1}H NMR (d_6-DMSO): 12.13 (br. s., 1H), 9.34 (s, 1H), 8.55 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.94 (dd, J = 7.8, 1.6 Hz, 1H), 7.72 (dd, J = 13.5, 2.3 Hz, 1H), 7.43 (dd, J = 3.2, 1.8 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.26 - 7.36 (m, 1H), 7.18 (dd, J = 8.9, 1.6 Hz, 1H), 7.05 - 7.15 (m, 2H), 6.77 - 6.87 (m, 1H), 6.70 (dd, J = 5.6, 2.3 Hz, 1H), 3.70 (s, 3H), 2.26 (s, 3H)

LR MS (ES+): 501 ($M+Na^+$)

LR MS (ES-): 477 (M-H)

Example 119

5-(4-{4-[({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid



Similar procedure as Example 134.


^{1}H NMR (d_6-DMSO): 12.05 (d, 1H), 9.11 (s, 1H), 8.96 (s, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 6.4, 2.3 Hz, 1H), 7.60 - 7.72 (m, 1H), 7.56 (d, J = 9.1 Hz, 2H), 7.27 - 7.49 (m, 3H), 7.14 (d, J = 9.1 Hz, 2H), 7.03 (br. s., 1H), 6.67 (dd, J = 5.7, 2.2 Hz, 1H)

LR MS (ES-): 499 (M-H)

Example 120

18572 CIP PCT (AP)

methyl 5-(4-{4-[({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate



Similar procedure as Example 135.


^{1}H NMR (d_6-DMSO): 12.12 (br. s., 1H), 9.04 (s, 1H), 8.91 (s, 1H), 8.37 (d, J = 6.2 Hz, 1H), 7.99 (dd, J = 6.4, 2.6 Hz, 1H), 7.60 - 7.69 (m, 1H), 7.51 - 7.61 (m, 2H), 7.37 - 7.49 (m, 2H), 7.34 (d, J = 2.1 Hz, 1H), 7.09 - 7.18 (m, 2H), 7.01 - 7.09 (m, 1H), 6.66 (dd, J = 5.6, 2.3 Hz, 1H), 3.70 (s, 3H)

LR MS (ES+): 537 ($M+Na^+$)

LR MS (ES-): 513 (M-H)

Example 121

5-(4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid



Similar procedure as Example 134.


^{1}H NMR (d_6-DMSO): 12.08 (br. s., 1H), 9.23 (s, 1H), 9.00 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.10 (s, 1H), 7.48 - 7.72 (m, 4H), 7.27 - 7.47 (m, 2H), 7.00 - 7.23 (m, 3H), 6.69 (br. s., 1H)

LR MS (ES-): 515 (M-H)

Example 122

methyl 5-(4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylate

18572 CIP PCT (AP)



Similar procedure as Example 135.


^{1}H NMR (d_6-DMSO): 12.12 (br. s., 1H), 9.17 (s, 1H), 8.94 (s, 1H), 8.38 (d, J = 5.9 Hz, 1H), 8.10 (d, J = 2.1 Hz, 1H), 7.51 - 7.69 (m, 4H), 7.42 (dd, J = 3.2, 1.8 Hz, 1H), 7.34 (d, J = 2.3 Hz, 1H), 7.10 - 7.18 (m, 2H), 7.03 - 7.09 (m, 1H), 6.66 (dd, J = 5.9, 2.3 Hz, 1H), 3.70 (s, 3H)

LR MS (ES+): 553 ($M+Na^+$)

LR MS (ES-): 529 (M-H)

Example 123

4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylic acid



To a stirred solution of methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylate (550mg, 1.15mmol) in a mixture of solvents - THF/MeOH (20ml/20ml) was added 1ml of 5M NaOH (5mmol) solution. The mixture was heated in a 66°C bath for 2 hours, cooled to room temperature and poured into 200ml of water. 2M HCl was added until pH = 5. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylic acid as off-white solid. Yield: 520mg, 97%.


^{1}H NMR (d_6-DMSO): 9.30 (s, 1H), 8.59 (d, J = 2.6 Hz, 1H), 8.43 (d, J = 5.9 Hz, 1H), 8.35 (br. s., 1H), 8.13 (br. s., 1H), 7.95 (dd, J = 7.8, 1.9 Hz, 1H), 7.51 - 7.59 (m, 2H), 7.45 (s, 1H), 7.03 - 7.18 (m, 3H), 6.75 - 6.83 (m, 1H), 6.72 (dd, J = 5.6, 2.3 Hz, 1H), 2.25 (s, 3H)

LR MS (ES-): 462 (M-H)

18572 CIP PCT (AP)

Example 124

2-hydroxyethyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate



Similar procedure as Example 131.


^{1}H NMR (DMSO-d_6) δ: 12.11 (br. s., 1H), 9.15 (s, 1H), 8.47 (d, J = 2.1 Hz, 1H), 8.33 (d, J = 5.6 Hz, 1H), 7.97 (dd, J = 7.9, 1.8 Hz, 1H), 7.63 (dd, J = 2.9, 1.8 Hz, 1H), 7.53 (d, J = 8.8 Hz, 2H), 7.22 - 7.37 (m, 2H), 7.01 - 7.18 (m, 3H), 6.72 - 6.85 (m, 1H), 6.58 (dd, J = 5.6, 2.3 Hz, 1H), 4.83 (t, J = 5.9 Hz, 1H), 4.19 (t, J = 5.1 Hz, 2H), 3.57 - 3.73 (m, 2H), 2.25 (s, 3H)

LR MS (ES+): 491 (MH), 513 ($M+Na^+$)

LR MS (ES-): 489 (M-H)

Example 125

{1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidin-4-yl}acetic acid




To a stirred solution of methyl {1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidin-4-yl}acetate (50mg, 0.085mmol) in THF/MeOH (5ml/5ml) was added 1M NaOH solution (3ml, 3mmol). The mixture was stirred at room temperature for one hour, and poured into 50ml of water. 2M HCl was added until pH = 4. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give {1-[(5-{4-[4-({[(2-fluoro-5-

methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidin-4-yl}acetic acid as white solid. Yield: 47mg, 96%.
LR MS (ES-): 570 (M-H)

Example 126

methyl {1-[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperidin-4-yl}acetate




Similar procedure as Example 132.

^{1}H NMR (d_6-DMSO): 11.83 (br. s., 1H), 9.14 (s, 1H), 8.46 (br. s., 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.97 (d, J = 8.2 Hz, 1H), 7.53 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 1.8 Hz, 1H), 7.01 - 7.18 (m, 4H), 6.86 (s, 1H), 6.80 (d, J = 4.4 Hz, 1H), 6.61 (dd, J = 5.9, 2.1 Hz, 1H), 4.26 (br. s., 2H), 3.57 (s, 3H), 2.87 (br. s., 2H), 2.18 - 2.32 (m, 5H), 1.93 (br. s., 1H), 1.65 (br. s., 2H), 1.14 (br. s., 2H)
LR MS (ES+): 608 ($M+Na^+$)
LR MS (ES-): 584 (M-H)

Example 127

N-(2,3-dihydroxypropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

18572 CIP PCT (AP)


^{1}H NMR (d_6-DMSO): 11.81 (br. s., 1H), 9.17 (s, 1H), 8.48 (d, J = 2.3 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.97 (dd, J = 7.8, 1.9 Hz, 1H), 7.86 (t, J = 5.7 Hz, 1H), 7.51 - 7.60 (m, 2H), 7.38 (dd, J = 3.1, 1.6 Hz, 1H), 7.10 - 7.19 (m, 3H), 7.07 (td, J = 4.3, 2.5 Hz, 2H), 6.74 - 6.84 (m, 1H), 6.69 (dd, J = 5.6, 2.3 Hz, 1H), 4.78 (d, J = 5.0 Hz, 1H), 4.54 (t, J = 5.9 Hz, 1H), 3.48 - 3.60 (m, 1H), 3.23 - 3.36 (m, 3H), 3.05 - 3.18 (m, 1H), 2.26 (s, 3H)

LR MS (ES+): 542 ($M+Na^+$)

LR MS (ES-): 518 (M-H)

Example 128

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide



Similar procedure as Example 132.

^{1}H NMR (d_6-DMSO): 11.79 (br. s., 1H), 9.30 (s, 1H), 8.57 (d, J = 1.5 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.95 (dd, J = 7.9, 1.8 Hz, 1H), 7.84 (t, J = 5.6 Hz, 1H), 7.50 - 7.63 (m, 2H), 7.35 (d, J = 1.5 Hz, 1H), 7.00 - 7.21 (m, 5H), 6.79 (td, J = 5.3, 2.5 Hz, 1H), 6.69 (dd, J = 5.6, 2.3 Hz, 1H), 4.66 (t, J = 5.6 Hz, 1H), 3.38 - 3.51 (m, 2H), 3.22 (q, J = 6.1 Hz, 2H), 2.25 (s, 3H)


LR MS (ES+): 512 ($M+Na^+$)

LR MS (ES-): 488 (M-H)

Example 129

1-(2-fluoro-5-methylphenyl)-3-{4-[(2-{4-[(4-hydroxypiperidin-1-yl)carbonyl]-1H-pyrrol-2-yl}pyridin-4-yl)oxy]phenyl}urea

18572 CIP PCT (AP)



Similar procedure as Example 132.


^{1}H NMR (d_6-DMSO): 11.84 (br. s., 1H), 9.17 (s, 1H), 8.48 (d, J = 2.3 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.9, 1.8 Hz, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 2.3 Hz, 1H), 7.04 - 7.20 (m, 4H), 6.89 (s, 1H), 6.81 (td, J = 5.3, 2.3 Hz, 1H), 6.63 (dd, J = 5.9, 2.3 Hz, 1H), 4.73 (d, J = 4.1 Hz, 1H), 3.90 - 4.06 (m, 2H), 3.71 (dt, J = 8.4, 4.3 Hz, 1H), 3.25 (d, J = 2.6 Hz, 2H), 2.27 (s, 3H), 1.73 (d, J = 4.1 Hz, 2H), 1.21 - 1.44 (m, 2H)

LR MS (ES+): 552 ($M+Na^+$)

LR MS (ES-): 528 (M-H)

Example 130

2,3-dihydroxypropyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



Similar procedure as Example 131.

^{1}H NMR (d_6-DMSO): 12.12 (br. s., 1H), 9.24 (s, 1H), 8.54 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.98 (dd, J = 7.8, 1.9 Hz, 1H), 7.51 - 7.62 (m, 2H), 7.48 (dd, J = 3.1, 1.6 Hz, 1H), 7.34 - 7.40 (m, 1H), 7.05 - 7.20 (m, 4H), 6.75 - 6.87 (m, 1H), 6.68 (dd, J = 5.9, 2.3 Hz, 1H), 4.92 (d, J = 5.3 Hz, 1H), 4.64 (t, J = 5.7 Hz, 1H), 4.11 - 4.22 (m, 1H), 3.97 - 4.09 (m, 1H), 3.67 - 3.79 (m, 1H), 3.38 - 3.46 (m, 2H), 2.28 (s, 3H)


LR MS (ES+): 543 ($M+Na^+$)

LR MS (ES-): 519 (M-H)

18572 CIP PCT (AP)

Example 131

2-hydroxyethyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



A mixture of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (50mg, 0.11mmol), ethylene glycol (1ml), 1-Ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (EDC• HCl, 25mg, 0.13mmol) and 4-dimethylaminopyridine (DMAP, 5mg, 0.04mmol) in anhydrous THF (10ml) was stirred at 60°C for 16 hours. The mixture was poured into 100ml of water. 2M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography with a gradient of 3~5% MeOH/$CHCl_3$ to give 2-hydroxyethyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate as white solid. Yield: 36mg, 67%.

^{1}H NMR (d_6-DMSO): 12.12 (br. s., 1H), 9.18 (s, 1H), 8.49 (d, J = 1.8 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.94 - 8.05 (m, 1H), 7.56 (d, J = 9.1 Hz, 2H), 7.48 (d, J = 1.5 Hz, 1H), 7.35 (d, J = 2.1 Hz, 1H), 7.03 - 7.23 (m, 4H), 6.75 - 6.86 (m, 1H), 6.69 (dd, J = 5.7, 2.2 Hz, 1H), 4.83 (t, J = 5.7 Hz, 1H), 4.15 (t, J = 5.1 Hz, 2H), 3.64 (q, J = 5.4 Hz, 2H), 2.27 (s, 3H)


LR MS (ES+): 513 ($M+Na^+$)

LR MS (ES-): 489 (M-H)

Example 132

1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea

18572 CIP PCT (AP)



A mixture of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (50mg, 0.11mmol), HATU (51mg, 0.13mmol) and *N,N*-diisopropylethylamine (31mg, 0.24mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of (R)-3-pyrrolidinol (14mg, 0.16mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. 2M HCl was added dropwise until pH = 4~5. The precipitates were filtered, washed with water and dried *in vacuo* to give 1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea as white solid. Yield: 40mg, 71%.


^{1}H NMR (d_6-DMSO): 11.90 (br. s., 1H), 9.17 (s, 1H), 8.49 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 7.99 (dd, J = 7.8, 1.9 Hz, 1H), 7.51 - 7.62 (m, 2H), 7.37 (d, J = 2.3 Hz, 1H), 7.25 (br. s., 1H), 7.02 - 7.19 (m, 4H), 6.76 - 6.86 (m, 1H), 6.64 (dd, J = 5.6, 2.3 Hz, 1H), 4.93 (br. s., 1H), 4.22 - 4.38 (m, 1H), 3.69 - 3.87 (m, 1H), 3.43 - 3.59 (m, 2H), 3.35 - 3.42 (m, 1H), 2.27 (s, 3H), 1.90 (br. s., 2H)

LR MS (ES+): 538 ($M+Na^+$)

LR MS (ES-): 514 (M-H)

Example 133

1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(4-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}-1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea



Similar procedure as Example 132.


LR MS (ES+): 538 ($M+Na^+$)

18572 CIP PCT (AP)

LR MS (ES-): 514 (M-H)

Example 134

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid




To a stirred solution of methyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate (1.38g, 3.00mmol) in a mixture of solvents THF/MeOH (20ml/20ml) was added 2ml of 5M NaOH (10mmol) solution. The mixture was heated in a 72°C bath for 5 hours, cooled to room temperature and poured into 200ml of water. 2M HCl was added until pH = 3. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid as light brown solid. Yield: 1.28g, 96%.

^{1}H NMR (d_6-DMSO): 12.04 (br. s., 1H), 11.88 (br. s., 1H), 9.18 (s, 1H), 8.49 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.94 - 8.05 (m, 1H), 7.56 (d, J = 9.1 Hz, 2H), 7.31 - 7.42 (m, 2H), 7.01 - 7.21 (m, 4H), 6.81 (td, J = 5.2, 2.2 Hz, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 2.27 (s, 3H)

LR MS (ES-): 467 (M-H)

Example 135

methyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate



18572 CIP PCT (AP)


To a stirred solution of methyl 5-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylate (1.0g, 3.23mmol) in anhydrous THF (10ml) was added 2-fluoro-5-methyl-phenylisocyanate (488mg, 3.23mmol). The mixture was stirred at room temperature for one hour and poured into 200ml of 0.02M HCl solution with vigorous stirring. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give methyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate as white solid. Yield: 1.38g, 93%.

^{1}H NMR (d_6-DMSO): 12.14 (br. s., 1H), 9.17 (s, 1H), 8.49 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.99 (dd, J = 7.9, 1.8 Hz, 1H), 7.53 - 7.59 (m, 2H), 7.44 (dd, J = 3.2, 1.5 Hz, 1H), 7.36 (d, J = 2.3 Hz, 1H), 7.06 - 7.18 (m, 4H), 6.77 - 6.85 (m, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 3.72 (s, 3H), 2.28 (s, 3H)

LR MS (ES+): 483 ($M+Na^+$)

LR MS (ES-): 459 (M-H)

Preparation of1-tert-butyl 2-methyl 4-[4-(3-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1,2-dicarboxylate



Similar procedure as 1-tert-butyl 2-methyl 4-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1,2-dicarboxylate.


^{1}H NMR (d_6-DMSO): 8.38 (d, 1H), 8.01 (d, J = 1.5 Hz, 1H), 7.45 (d, J = 2.1 Hz, 1H), 7.37 (d, J = 1.5 Hz, 1H), 7.06 (t, J = 7.9 Hz, 1H), 6.67 (dd, J = 5.7, 2.2 Hz, 1H), 6.43 (d, J = 7.9 Hz, 1H), 6.20 - 6.33 (m, 2H), 5.32 (br. s., 2H), 3.72 - 3.85 (m, 3H), 1.53 (s, 9H)

LR MS (ES+): 432 ($M+Na^+$)

Example 136

methyl 4-{4-[3-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate

18572 CIP PCT (AP)



To a stirred solution of 1-tert-butyl 2-methyl 4-[4-(3-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1,2-dicarboxylate (150 mg, 0.37 mmol) in anhydrous THF (10ml) was added 2-fluoro-5-methyl-phenylisocyanate (67mg, 0.44mmol). The mixture was stirred at room temperature for 3 hours and poured into 100ml of water. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give the Boc-protected intermediate as brown solid. This intermediate was dissolved in 5ml of methylene chloride, and 3ml of trifluoroacetic acid was added. Stirring was continued for 20 minutes. The mixture was evaporated to dryness to give the crude product, which was purified by silica gel chromatography eluting with 5% MeOH/$CHCl_3$ to give methyl 4-{4-[3-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate as white solid. Yield: 67mg, 39%.


^{1}H NMR (d_6-DMSO): 12.18 (br. s., 1H), 9.23 (s, 1H), 8.47 (br. s., 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.63 (br. s., 1H), 7.25 - 7.47 (m, 4H), 7.16 (d, J = 7.9 Hz, 1H), 7.07 (dd, J = 11.4, 8.5 Hz, 1H), 6.72 - 6.85 (m, 2H), 6.65 (dd, J = 5.6, 2.1 Hz, 1H), 3.76 (s, 3H), 2.22 (s, 3H)

LR MS (ES+): 483 ($M+Na^+$)

LR MS (ES-): 459 (M-H)

Example 137

N-[dimethyl(oxido)-lambda~4~-sulfanylidene]-4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxamide



Similar procedure as Example 101.


LR MS (ES+): 544 ($M+Na^+$)

18572 CIP PCT (AP)

LR MS (ES-): 520 (M-H)

Example 138

4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N,N-dimethyl-1H-pyrrole-2-carboxamide




The title compound was isolated as a side product in the synthesis of Example 137.

LR MS (ES+): 474 (M+H)

LR MS (ES-): 472 (M-H

Example 139

4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-methyl-1H-pyrrole-2-carboxamide



A mixture of 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylic acid (50mg, 0.11mmol), HATU (50mg, 0.13mmol), 2M methylamine/ THF solution (0.1ml, 0.2mmol) and *N,N*-diisopropylethylamine (31mg, 0.24mmol) in anhydrous DMF (8ml) was stirred at room temperature for 10 minutes. The mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel chromatography with 3~5% $MeOH/CHCl_3$ to give 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-methyl-1H-pyrrole-2-carboxamide as white solid. Yield: 21mg, 41%.


18572 CIP PCT (AP)

^{1}H NMR (d_6-DMSO): 11.69 (br. s., 1H), 9.17 (s, 1H), 8.48 (d, J = 2.3 Hz, 1H), 8.32 (d, J = 5.6 Hz, 1H), 8.01 - 8.12 (m, 1H), 7.96 (dd, J = 7.8, 1.9 Hz, 1H), 7.48 - 7.61 (m, 2H), 7.43 (dd, J = 2.9, 1.5 Hz, 1H), 7.03 - 7.23 (m, 5H), 6.79 (dt, J = 8.1, 2.3 Hz, 1H), 6.61 (dd, J = 5.6, 2.3 Hz, 1H), 2.71 (d, J = 4.7 Hz, 3H), 2.26 (s, 3H)

LR MS (ES+): 482 ($M+Na^+$)

LR MS (ES-): 458 (M-H)


Preparation of 4-(4-aminophenoxy)-6-chloropyridin-2-amine



A stirred solution of 4-aminophenol (335mg, 3.1mmol) in anhydrous DMSO (8ml) was flushed with nitrogen and treated with 1M KOBu^t / THF solution (3.1ml, 3.1mmol). The mixture was stirred at room temperature under nitrogen for 10 minutes. 4,6-dichloropyridin-2-ylamine (500mg, 3.1mmol) was added and the mixture was heated at 88ºC for 16 hours, cooled to room temperature and poured into 100ml of water. The resulting precipitates were filtered, washed with water and dried to give the crude product, which was purified by silica gel chromatography with 2~5% MeOH/$CHCl_3$ to give 4-(4-aminophenoxy)-6-chloropyridin-2-amine as light brown solid. Yield: 350mg, 49%.

Example 140

1-tert-butyl 2-methyl 4-{6-amino-4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-1,2-dicarboxylate




Similar procedure as Example 148.

LR MS (ES+): 598 ($M+Na^+$)

18572 CIP PCT (AP)

Example 141

1-(4-{[2-amino-6-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)-3-(2-fluoro-5-methylphenyl)urea



Similar procedure as Example 148.


^{1}H NMR (d_6-DMSO): 11.02 (br. s., 1H), 9.11 (s, 1H), 8.44 (br. s., 1H), 7.97 (d, 1H), 7.50 (d, J = 8.8 Hz, 2H), 6.98 - 7.17 (m, 3H), 6.78 (br. s., 2H), 6.53 (br. s., 2H), 6.05 (br. s., 1H), 5.74 (br. s., 2H), 5.61 (s, 1H), 2.25 (s, 3H)

LR MS (ES+): 418 (M+H)

LR MS (ES-): 416 (M-H)

Example 142

4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylic acid




To a stirred solution of methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate (220mg, 0.48mmol) in THF/MeOH (3ml/10ml) was added 1M NaOH (4.0ml, 4.0mmol). The mixture was heated at 70°C for 2 hours, cooled to room temperature and poured into 100ml of water. 1M HCl was added until pH = 4 and the resulting precipitates were filtered, washed with water and dried *in vacuo* to give 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylic acid. Yield: 200mg, 94%.

^{1}H NMR (d_6-DMSO): 12.38 (br. s., 1H), 12.04 (br. s., 1H), 9.14 - 9.23 (m, 1H), 8.48 (d, J = 2.3 Hz, 1H), 8.34 (d, J = 5.6 Hz, 1H), 7.97 (dd, J = 7.9, 2.1 Hz, 1H), 7.60 (br. s., 1H), 7.50 - 7.58 (m,

18572 CIP PCT (AP)

2H), 7.30 (d, J = 2.1 Hz, 1H), 7.22 (s, 1H), 7.03 - 7.18 (m, 3H), 6.73 - 6.84 (m, 1H), 6.60 (dd, J = 5.6, 2.3 Hz, 1H), 2.25 (s, 3H)
LR MS (ES-): 445 (M-H)


Preparation of 1-tert-butyl 2-methyl 4-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1,2-dicarboxylate



A 100ml flask was charged with 4-((2-chloropyridin-4-yl)oxy)aniline (150mg, 0.68mmol), 1-tert-butyl 2-methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-1,2-dicarboxylate (260mg, 0.81mmol), 2M Na_2CO_3 solution (0.5ml, 1.0mmol), $PdCl_2(PPh_3)_2$ (5mg, 0.007mmol), 10ml of 1,4-dioxane and 3ml of water. The mixture was flushed with nitrogen and heated at 70°C for 30 minutes. The mixture was cooled to room temperature and poured into 100ml of water. The precipitates were filtered and dried to give the crude, which was further purified by silica gel chromatography eluting with 2-3% MeOH/$CHCl_3$ to give 1-tert-butyl 2-methyl 4-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1,2-dicarboxylate as light brown oil. Yield: 240mg, 86%.

Example 143

Methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate



To a stirred solution of 1-tert-butyl 2-methyl 4-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1,2-dicarboxylate (240 mg, 0.59 mmol) in anhydrous THF (10ml) was added 2-fluoro-5-methyl-phenylisocyanate (107mg, 0.71mmol). The mixture was stirred at room temperature for 30 minutes and poured into 100ml of water. The resulting precipitates were filtered, washed with


water and dried to give a brown oil. Purification by silica gel chromatography eluting with 2-3% MeOH/$CHCl_3$ gave the Boc-protected intermediate as light green oil, which was dissolved in 5ml of methylene chloride, followed by addition of 3ml of trifluoroacetic acid. The mixture was stirred at room temperature for 10 minutes, evaporated to dryness, and purified by silica gel chromatography eluting with 2-5% MeOH/$CHCl_3$ to give methyl 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxylate as white solid. Yield: 135mg, 50%.

^{1}H NMR (d_6-DMSO): 12.17 (br. s., 1H), 9.14 (s, 1H), 8.46 (d, J = 2.3 Hz, 1H), 8.33 (d, J = 5.9 Hz, 1H), 7.91 - 8.04 (m, 1H), 7.61 (dd, J = 3.1, 1.6 Hz, 1H), 7.53 (d, J = 9.1 Hz, 2H), 7.22 - 7.31 (m, 2H), 7.02 - 7.17 (m, 3H), 6.73 - 6.85 (m, 1H), 6.58 (dd, J = 5.7, 2.5 Hz, 1H), 3.76 (s, 3H), 2.26 (s, 3H)

LR MS (ES+): 483 ($M+Na^+$)

LR MS (ES-): 459 (M-H)

Preparation of tert-butyl 2-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1-carboxylate




To a stirred mixture of *N*-Boc-pyrrole-2-boronic acid (114mg, 0.54mmol) and 4-((2-chloropyridin-4-yl)oxy)aniline (100mg, 0.45mmol) in 8ml of 1,4-dioxane, was added $PdCl_2(PPh_3)_2$ (10mg, 0.014mmol) and 1M Na_2CO_3 aqueous solution (0.5ml, 1.0mmol). The mixture was heated at 72°C under N_2 for one hour, cooled to room temperature and poured into 100ml of water. The resulting mixture was extracted with EtOAc (2x50ml). The organic layers were combined, washed with brine (50ml), dried over Na_2SO_4, and evaporated to give a brown oil, which was purified by silica gel chromatography with a gradient of 20~50% EtOAc/hexanes to give tert-butyl 2-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1-carboxylate as colorless oil. Yield: 110mg, 70%.

Example 144

1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea

18572 CIP PCT (AP)




To a stirred solution of tert-butyl 2-[4-(4-aminophenoxy)pyridin-2-yl]-1H-pyrrole-1-carboxylate (100 mg, 0.28 mmol) in anhydrous THF (10ml) was added 2-fluoro-5-methyl-phenylisocyanate (51mg, 0.34mmol). The mixture was stirred at room temperature for one hour and poured into 100ml of water. The resulting mixture was extracted with EtOAc (2x50ml). The organic layers were combined, washed with brine (50ml), dried over Na_2SO_4, and evaporated to give a brown oil, which was purified by silica gel chromatography with 2-5% MeOH/$CHCl_3$ to give the Boc-protected intermediate as light green oil. The oil was dissolved in 5ml of methylene chloride, and 3ml of trifluoroacetic acid was added. Stirring was continued for 10 hours, and the mixture was evaporated to dryness. The brown residue was dissolved in methanol (5ml). This methanol solution was then added dropwise into 100ml of 1M $NaHCO_3$ solution with stirring. The resulting precipitates were filtered, washed with water, and dried *in vacuo* to give 1-(2-fluoro-5-methylphenyl)-3-(4-{[2-(1H-pyrrol-2-yl)pyridin-4-yl]oxy}phenyl)urea as light grey solid.

^{1}H NMR (d_6-DMSO): 11.43 (br. s., 1H), 9.14 (s, 1H), 8.46 (d, J = 2.6 Hz, 1H), 8.32 (d, J = 5.6 Hz, 1H), 7.96 (dd, J = 7.9, 1.8 Hz, 1H), 7.48 - 7.58 (m, 2H), 7.20 (d, J = 2.1 Hz, 1H), 7.04 - 7.16 (m, 3H), 6.75 - 6.86 (m, 2H), 6.67 (dt, J = 3.8, 1.9 Hz, 1H), 6.57 (dd, J = 5.9, 2.3 Hz, 1H), 6.05 - 6.13 (m, 1H), 2.25 (s, 3H)

Example 145

1-phenyl-3-{4-[6-(1H-pyrrol-2-yl)pyridin-3-yl]phenyl}urea




Similar procedure as Example 148.

^{1}H NMR (DMSO-d_6): 11.46 (br. s., 1H), 8.79 (s, 1H), 8.75 (d, J = 1.8 Hz, 1H), 8.67 (s, 1H), 7.98 (dd, J = 8.4, 2.5 Hz, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 7.6 Hz, 2H), 7.27 (t, J = 7.9 Hz, 2H), 6.96 (t, J = 7.3 Hz, 1H), 6.84 - 6.88 (m, 1H), 6.77 (t, J = 3.8 Hz, 1H), 6.11 - 6.16 (m, 1H)

18572 CIP PCT (AP)

Example 146

1-(2-fluoro-5-methylphenyl)-3-{3-[2-(1H-pyrrol-2-yl)pyridin-4-yl]phenyl}urea




Similar procedure as Example 148

LR MS (ES+): 387 ($M+H^+$)

Example 147

1-(2-fluoro-5-methylphenyl)-3-{4-[2-(1H-pyrrol-3-yl)pyridin-4-yl]phenyl}urea




Similar procedure as Example 148.

^{1}H NMR (d_6-DMSO): 11.72 (br. s., 1H), 9.49 (br. s., 1H), 8.63 (s, 1H), 8.53 (d, J = 6.4 Hz, 1H), 8.38 (br. s., 1H), 8.07 (d, J = 8.5 Hz, 2H), 8.00 - 8.04 (m, 1H), 7.97 (dd, J = 7.9, 1.8 Hz, 1H), 7.81 - 7.90 (m, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.13 (dd, J = 11.3, 8.4 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 6.98 (br. s., 1H), 6.84 (ddd, J = 7.8, 5.3, 2.1 Hz, 1H), 2.21 - 2.36 (m, 3H)

LR MS (ES+): 387 (M+H)


tert-butyl (4-(2-chloropyridin-4-yl)phenyl)carbamate



18572 CIP PCT (AP)

To a mixture of (4-boc-aminophenyl)boronic acid (200mg, 0.84mmol) and 2-chloro-4-bromopyridine (162mg, 0.84mmol) in 10ml of 1,4-dioxane, was added $PdCl_2(PPh_3)_2$ (10mg, 0.014mmol) and 1M Na_2CO_3 aqueous solution (0.5ml, 1.0mmol). The mixture was heated at 70°C under N_2 for 2 hours, cooled to room temperature and poured into 100ml of water. The brown precipitates were filtered, washed with water and dried to give tert-butyl (4-(2-chloropyridin-4-yl)phenyl)carbamate as the crude product.


4-(2-(1H-pyrrol-2-yl)pyridin-4-yl)aniline



To a mixture of N-Boc-pyrrole-2-boronic acid (210mg, 1.0mmol) and tert-butyl (4-(2-chloropyridin-4-yl)phenyl)carbamate (250mg, 0.82mmol) in 10ml of 1,4-dioxane, was added $PdCl_2(PPh_3)_2$ (10mg, 0.014mmol) and 1M Na_2CO_3 aqueous solution (0.75ml, 1.5mmol). The mixture was heated at 60°C under N_2 for 3 hours, cooled to room temperature and poured into 100ml of water. The precipitates were filtered, dried and purified by silica gel chromatography with 1-5% $MeOH/CHCl_3$ to give the intermediate as light yellow oil. This intermediate was dissolved in 10ml of methylene chloride and 3ml of trifluoroacetic acid was added. The mixture was stirred at room temperature for 16 hours and evaporated to dryness to give 4-(2-(1H-pyrrol-2-yl)pyridin-4-yl)aniline TFA salt as light brown solid. Yield: 290mg, 100%.

Example 148

1-(2-fluoro-5-methylphenyl)-3-{4-[2-(1H-pyrrol-2-yl)pyridin-4-yl]phenyl}urea



To a stirred suspension of 4-(2-(1H-pyrrol-2-yl)pyridin-4-yl)aniline TFA salt (60 mg, 0.17 mmol) in anhydrous THF (10ml) was added 2-fluoro-5-methyl-phenylisocyanate (48mg,

18572 CIP PCT (AP)

0.32mmol) and *N,N*-diisopropylethylamine (40 mg, 0.31 mmol). After 1 hour, the reaction mixture was evaporated and purified by silica gel chromatography with 2-3% MeOH/$CHCl_3$ to give 1-(2-fluoro-5-methylphenyl)-3-{4-[2-(1H-pyrrol-2-yl)pyridin-4-yl]phenyl}urea as off-white solid. Yield: 28mg.


^{1}H NMR (d_6-DMSO): 11.49 (br. s., 1H), 9.29 (br. s., 1H), 8.52 - 8.60 (m, 1H), 8.48 (d, J = 5.3 Hz, 1H), 7.94 - 8.04 (m, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 7.42 (dd, J = 5.3, 1.5 Hz, 1H), 7.12 (dd, J = 11.4, 8.2 Hz, 1H), 6.89 (s, 2H), 6.82 (dt, J = 5.4, 2.6 Hz, 1H), 6.16 (t, J = 2.9 Hz, 1H), 2.29 (s, 3H)

LR MS (ES+): 409 ($M+Na^+$)

LR MS (ES-): 385 (M-H)

Synthesis and characteriziation of additional compounds are listed below.

Example 149



5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(2H-tetrazol-5-yl)propyl]-1H-pyrrole-3-carboxamide

To a stirred solution of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (100mg, 0.22mmol) in 10ml of anhydrous DMF were added HATU (91mg, 0.24mmol) and N,N-diisopropylethylamine (85mg, 0.66mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of 3-(1H-tetrazol-5-yl)propan-1-amine hydrochloride (54mg, 0.33mmol). The mixture was stirred at room temperature for another 60 minutes and poured into 100ml of water with vigorous stirring. 1M HCl was added dropwise until pH = 5. The precipitates were filtered, washed with water and dried in vacuo to give 5-{4-[4-({[(2-fluoro-5-


methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(2H-tetrazol-5-yl)propyl]-1H-pyrrole-3-carboxamide as light brown solid. Yield: 105mg, 85%.

^{1}H NMR (DMSO-d_6): 11.83 (t, J = 2.9 Hz, 1H), 9.17 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 7.98 - 8.00 (m, 2H), 7.55 - 7.58 (m, 2H), 7.37 (dd, J = 3.2, 1.8 Hz, 1H), 7.14 - 7.17 (m, 3H), 7.11 (dd, J = 11.4, 8.2 Hz, 1H), 7.06 - 7.07 (m, 1H), 6.80 - 6.82 (m, 1H), 6.71 (dd, J = 5.6, 2.3 Hz, 1H), 3.24 - 3.27 (m, 2H), 2.90 (t, J = 7.8 Hz, 2H), 2.28 (s, 3H), 1.91 (quin, J = 7.3 Hz, 2H)

LR MS (ES-): 554 (M-H)

The following Example 150 was prepared using the experiment procedure described in Example 149, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 150



5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[2-(2H-tetrazol-5-yl)ethyl]-1H-pyrrole-3-carboxamide


^{1}H NMR (DMSO-d_6): 11.92 (br. s., 1H), 9.22 (s, 1H), 8.51 (d, J = 2.6 Hz, 1H), 8.40 (d, J = 5.9 Hz, 1H), 8.10 (t, J = 5.7 Hz, 1H), 7.98 (dd, J = 8.4, 1.9 Hz, 1H), 7.56 - 7.59 (m, 2H), 7.40 (br. s., 1H), 7.20 (br. s., 1H), 7.16 - 7.19 (m, 2H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.09 (br. s., 1H), 6.80 - 6.83 (m, 1H), 6.77 (br. s., 1H), 3.54 - 3.57 (m, 2H), 3.10 (t, J = 7.0 Hz, 2H), 2.28 (s, 3H)

LR MS (ES+): 542 (MH+)

LR MS (ES-): 540 (M-H)

18572 CIP PCT (AP)

Example 151



N-(3,3-diethoxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide


To a stirred solution of 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (Example 115) (700mg, 1.64mmol) in 10ml of anhydrous DMF were added HATU (684mg, 1.84mmol) and N,N-diisopropylethylamine (426mg, 3.3mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of 1-amino-3,3-diethoxypropane (294mg, 2.0mmol). The mixture was stirred at room temperature for another 10 minutes and poured into 150ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried in vacuo to give N-(3,3-diethoxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as white solid. Yield: 910mg, 100%.

^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 8.77 (s, 1H), 8.60 (s, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.53 - 7.60 (m, 2H), 7.35 (dd, J = 3.1, 1.6 Hz, 1H), 7.30 (s, 1H), 7.12 - 7.26 (m, 5H), 7.03 (t, J = 2.2 Hz, 1H), 6.80 (d, J = 7.3 Hz, 1H), 6.70 (dd, J = 5.9, 2.3 Hz, 1H), 4.53 (t, J = 5.4 Hz, 1H), 3.51 - 3.63 (m, 2H), 3.43 (dq, J = 9.7, 7.0 Hz, 2H), 3.16 - 3.24 (m, 2H), 2.28 (s, 3H), 1.68 - 1.78 (m, 2H), 1.11 (t, J = 7.0 Hz, 6H)

LR MS (ES-): 556 (M-H)

Example 152

18572 CIP PCT (AP)




N-(2-aminoethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

To a stirred suspension of tert-butyl (2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate (355mg, 0.60mmol) in 10ml of methylene chloride was added 5ml of trifluoroacetic acid. The mixture was stirred at room temperature for 30 minutes and evaporated to dryness under reduced pressure. The residue was re-dissolved in MeOH (5ml) and poured into 100ml of water with vigorous stirring. Saturated NaHCO3 solution was added until pH = 8~9. The precipitates were filtered, washed with water and dried in vacuo to give N-(2-aminoethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as brown solid. Yield: 260mg, 88%.

LR MS (ES+): 489 (MH+)

Example 153



tert-butyl (2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate


A mixture of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (300mg, 0.67mmol), HATU (280mg, 0.74mmol) and N,N-

diisopropylethylamine (190mg, 1.47mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of tert-butyl (2-aminoethyl)carbamate (128mg, 0.80mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give tert-butyl (2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate as white solid. Yield: 355mg, 90%.

^{1}H NMR (DMSO-d_6): 11.84 (br. s., 1H), 9.18 (s, 1H), 8.49 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.8, 2.2 Hz, 1H), 7.89 (t, J = 5.4 Hz, 1H), 7.54 - 7.60 (m, 2H), 7.35 - 7.38 (m, 1H), 7.08 - 7.19 (m, 4H), 7.05 (s, 1H), 6.78 - 6.87 (m, 2H), 6.73 (dd, J = 5.9, 2.3 Hz, 1H), 3.17 - 3.24 (m, 2H), 3.00 - 3.08 (m, 2H), 2.27 (s, 3H), 1.36 (s, 9H)

LR MS (ES+): 611 ($M+Na^+$)
LR MS (ES-): 587 (M-H)

Example 154



methyl [(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)amino]acetate

To a stirred solution of N-(3-aminopropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (260mg, 0.52mmol) and N,N-diisopropylethylamine (134mg, 1.04mmol) in 10ml of anhydrous DMF was added methyl bromoacetate (80mg, 0.52mmol). The mixture was stirred at room temperature for 40 minutes and poured into 100ml of water with vigorous stirring. The precipitates were filtered and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with a gradient of 3~10% MeOH/CHCl3 to afford methyl [(3-{[(5-{4-


18572 CIP PCT (AP)

[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)amino]acetate as white solid. Yield: 100mg, 34%.

^{1}H NMR (DMSO-d_6): 11.80 (br. s., 1H), 9.19 (s, 1H), 8.50 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.9, 2.1 Hz, 1H), 7.88 (t, J = 5.7 Hz, 1H), 7.55 - 7.58 (m, 2H), 7.35 (dd, J = 3.2, 1.8 Hz, 1H), 7.14 - 7.18 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.05 (dd, J = 2.5, 1.9 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.70 (dd, J = 5.6, 2.3 Hz, 1H), 3.61 (s, 3H), 3.32 (br. s., 2H), 3.19 - 3.23 (m, 2H), 2.53 (t, J = 6.9 Hz, 2H), 2.27 (s, 3H), 1.59 (quin, J = 6.9 Hz, 2H)

LR MS (ES+): 575 (MH+)
LR MS (ES-): 573 (M-H)

Example 155



methyl [(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)amino]acetate


To a stirred solution of N-(2-aminoethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (200mg, 0.41mmol) in 10ml of anhydrous DMF, were added N,N-diisopropylethylamine (137mg, 1.06mmol) and methyl bromoacetate (82mg, 0.54mmol). The mixture was stirred at room temperature for 1 hour and poured into 100ml of water. The precipitates were filtered, washed with water, and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with a gradient of 3~8% of methanol in chloroform to give methyl [(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)amino]acetate as white solid. Yield: 100mg, 43%.

18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 11.82 (br. s., 1H), 9.20 (s, 1H), 8.50 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 7.99 (dd, J = 7.9, 2.3 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.56 - 7.59 (m, 2H), 7.37 (dd, J = 3.1, 1.6 Hz, 1H), 7.15 - 7.17 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.05 - 7.06 (m, 1H), 6.79 - 6.82 (m, 1H), 6.71 (dd, J = 5.6, 2.3 Hz, 1H), 3.61 (s, 3H), 3.36 (s, 2H), 3.25 (q, J = 6.3 Hz, 2H), 2.64 (t, J = 6.5 Hz, 2H), 2.27 (s, 3H)

LR MS (ES+): 561 (MH+)
LR MS (ES-): 559 (M-H)

Example 156



dimethyl 2,2'-[(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)imino]diacetate


Example 156 was isolated from the preparation of Example 155.

^{1}H NMR (DMSO-d_6): 11.82 (t, J = 2.9 Hz, 1H), 9.18 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 8.4, 1.9 Hz, 1H), 7.77 (t, J = 5.4 Hz, 1H), 7.55 - 7.58 (m, 2H), 7.34 (dd, J = 2.9, 1.8 Hz, 1H), 7.14 - 7.18 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.04 (dd, J = 2.3, 1.8 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.71 (dd, J = 5.6, 2.3 Hz, 1H), 3.59 (s, 6H), 3.56 (s, 4H), 3.22 - 3.27 (m, 2H), 2.78 (t, J = 6.7 Hz, 2H), 2.27 (s, 3H)

LR MS (ES+): 633 (MH+)
LR MS (ES-): 631 (M-H)

18572 CIP PCT (AP)

Example 157



ethyl [4-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazin-1-yl]acetate

To a stirred solution of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide (200mg, 0.41mmol) and ethyl piperazinoacetate (141mg, 0.82mmol) in anhydrous DMF (10ml) was added acetic acid (10mg, 0.17mmol). The mixture was stirred under nitrogen for 30 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (0.8ml, 0.8mmol). The reaction mixture was stirred for another hour, and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water, and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with a gradient of 8~12% methanol/chloroform solution to give ethyl [4-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazin-1-yl]acetate as white solid. Yield: 90mg, 34%.


^{1}H NMR (DMSO-d_6): 11.81 (t, J = 2.9 Hz, 1H), 9.20 (s, 1H), 8.50 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 7.99 (dd, J = 7.3, 2.1 Hz, 1H), 7.81 (t, J = 5.7 Hz, 1H), 7.56 - 7.58 (m, 2H), 7.35 (dd, J = 3.2, 1.8 Hz, 1H), 7.14 - 7.17 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.05 (dd, J = 2.5, 1.9 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.70 - 6.71 (m, 1H), 4.07 (q, J = 7.2 Hz, 2H), 3.26 - 3.30 (m, 2H), 3.17 (s, 2H), 2.38 - 2.53 (m, 10H), 2.27 (s, 3H), 1.18 (t, J = 7.0 Hz, 3H)

LR MS (ES+): 644 (MH+)
LR MS (ES-): 642 (M-H)

18572 CIP PCT (AP)

The following Example 158 through 159 were prepared using the experiment procedure described in Example 160, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 158




ethyl [4-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)piperazin-1-yl]acetate

^{1}H NMR (DMSO-d_6): 11.81 (t, J = 3.1 Hz, 1H), 9.19 (s, 1H), 8.50 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.9, 2.6 Hz, 1H), 7.88 (t, J = 5.6 Hz, 1H), 7.55 - 7.58 (m, 2H), 7.35 (dd, J = 3.2, 1.8 Hz, 1H), 7.14 - 7.17 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.05 (dd, J = 2.5, 1.9 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.71 (dd, J = 5.6, 2.3 Hz, 1H), 4.07 (q, J = 7.1 Hz, 2H), 3.18 - 3.21 (m, 2H), 3.17 (s, 2H), 2.30 - 2.54 (m, 10H), 2.27 (s, 3H), 1.62 (quin, J = 7.0 Hz, 2H), 1.17 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 658 (MH+)

LR MS (ES-): 656 (M-H)

Example 159




18572 CIP PCT (AP)

5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[2-(hydroxymethyl)morpholin-4-yl]propyl}-1H-pyrrole-3-carboxamide

LR MS (ES+): 603 (MH+)

Example 160



5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[3-(hydroxymethyl)piperidin-1-yl]propyl}-1H-pyrrole-3-carboxamide

To a stirred solution of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide (120mg, 0.24mmol) and 3-piperidinemethanol (56mg, 0.49mmol) in anhydrous DMF (10ml) was added acetic acid (10mg, 0.17mmol). The mixture was stirred under nitrogen for 30 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (0.5ml, 0.5mmol). The reaction mixture was stirred for another hour, and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water, and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with a gradient of 10~20% methanol/chloroform solution to give 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[3-(hydroxymethyl)piperidin-1-yl]propyl}-1H-pyrrole-3-carboxamide as white solid. Yield: 58mg, 40%.


LR MS (ES+): 601 (MH+)

LR MS (ES-): 599 (M-H)

18572 CIP PCT (AP)

The following Example 161 was prepared using the experiment procedure described in Example 157, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 161




methyl rel-(2R,4S)-1-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)-4-hydroxypyrrolidine-2-carboxylate

^{1}H NMR (DMSO-d_6): 11.81 (t, J = 2.9 Hz, 1H), 9.17 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 8.4, 1.9 Hz, 1H), 7.77 (t, J = 5.6 Hz, 1H), 7.55 - 7.58 (m, 2H), 7.34 (dd, J = 3.2, 1.8 Hz, 1H), 7.14 - 7.18 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.04 (dd, J = 2.5, 1.9 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.70 - 6.72 (m, 1H), 4.88 (d, J = 4.4 Hz, 1H), 4.19 - 4.24 (m, 1H), 3.59 (s, 3H), 3.46 (t, J = 7.6 Hz, 1H), 3.26 - 3.31 (m, 2H), 3.15 - 3.21 (m, 1H), 2.75 (dt, J = 11.8, 7.4 Hz, 1H), 2.53 - 2.57 (m, 1H), 2.34 (dd, J = 9.7, 4.1 Hz, 1H), 2.28 (s, 3H), 1.95 (dt, J = 12.8, 7.3 Hz, 1H), 1.84 - 1.89 (m, 1H)

LR MS (ES+): 617 (MH+)
LR MS (ES-): 615 (M-H)

Example 162

18572 CIP PCT (AP)




5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide

To a stirred solution of N-(2,2-diethoxyethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (580mg, 1.03mmol) in 10ml of THF was added 1ml of 2M HCl. The mixture was heated under nitrogen at 60C for 2 hours, cooled to room temperature, and poured into 100ml of water. Saturated NaHCO3 solution was added until pH = 8. The precipitates were filtered, washed with water, and dried in vacuo to give 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide as light brown solid. Yield: 450mg, 90%.

LR MS (ES+): 488 (MH+)

LR MS (ES-): 486 (M-H)

Example 163



N-(2,2-diethoxyethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

A mixture of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (500mg, 1.12mmol), HATU (467mg, 1.23mmol) and N,N-

diisopropylethylamine (322mg, 2.5mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of aminoacetaldehyde diethyl acetal (194mg, 1.46mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give N-(2,2-diethoxyethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as white solid. Yield: 580mg, 92%.


^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 9.18 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.9, 2.3 Hz, 1H), 7.94 (t, J = 6.0 Hz, 1H), 7.54 - 7.60 (m, 2H), 7.40 (dd, J = 3.1, 1.6 Hz, 1H), 7.10 - 7.19 (m, 4H), 7.08 (t, J = 2.2 Hz, 1H), 6.78 - 6.84 (m, 1H), 6.71 (dd, J = 5.6, 2.3 Hz, 1H), 4.56 (t, J = 5.6 Hz, 1H), 3.62 (dq, J = 9.7, 7.0 Hz, 2H), 3.47 (dq, J = 9.7, 7.0 Hz, 2H), 3.24 (t, J = 5.7 Hz, 2H), 2.28 (s, 3H), 1.11 (t, J = 7.0 Hz, 6H)

LR MS (ES+): 562 (MH+)

LR MS (ES-): 560 (M-H)

The following Example 164 was prepared using the experiment procedure described in Example 160, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 164




methyl rel-(2R,4S)-1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)-4-hydroxypyrrolidine-2-carboxylate

^{1}H NMR (DMSO-d_6): 11.80 (t, J = 3.1 Hz, 1H), 9.17 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 7.99 (dd, J = 7.9, 2.3 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.55 - 7.58 (m, 2H), 7.34 (dd, J = 3.2, 1.8 Hz, 1H), 7.14 - 7.17 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.04 (dd, J = 2.5, 1.9 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.71 (dd, J = 5.7, 2.5 Hz, 1H), 4.87 (d, J = 4.4 Hz, 1H), 4.18 - 4.23 (m, 1H), 3.59 (s, 3H), 3.36 (t, J = 7.8 Hz, 1H), 3.17 - 3.25 (m, 3H), 2.64 (dt, J = 12.1, 7.9 Hz, 1H), 2.39 - 2.44 (m, 1H), 2.28 (s, 3H), 2.23 (dd, J = 9.5, 4.5 Hz, 1H), 1.96 (dt, J = 12.8, 7.2 Hz, 1H), 1.83 - 1.89 (m, 1H), 1.54 - 1.60 (m, 2H)

LR MS (ES+): 653 ($M+Na^+$)

LR MS (ES-): 629 (M-H)

Example 165



4-methoxy-4-oxobutyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate


To a stirred solution of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (150mg, 0.34mmol) in 10ml of anhydrous DMF were added methyl 4-bromobutanoate (123mg, 0.68mmol) and potassium carbonate (94mg, 0.68mmol). The mixture was heated at 60C for 2 hours, cooled to room temperature, and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 2~3% of methanol in chloroform to give 4-methoxy-4-oxobutyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate as off-white solid. Yield: 130mg, 71%.

18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 12.13 (br. s., 1H), 9.17 (s, 1H), 8.48 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.99 (dd, J = 7.9, 2.3 Hz, 1H), 7.54 - 7.57 (m, 2H), 7.43 (dd, J = 3.2, 1.8 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.13 - 7.16 (m, 2H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.08 (dd, J = 2.5, 1.9 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.68 (dd, J = 5.7, 2.5 Hz, 1H), 4.15 (t, J = 6.5 Hz, 2H), 3.58 (s, 3H), 2.45 (t, J = 7.3 Hz, 2H), 2.27 (s, 3H), 1.92 (quin, J = 6.8 Hz, 2H)

LR MS (ES+): 547 (MH+)
LR MS (ES-): 545 (M-H)

Example 166



5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoic acid

To a stirred solution of ethyl 5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoate (150mg, 0.26mmol) in 10ml of THF was added 2ml of 1M NaOH solution. The mixture was heated at 55C for 3 hours, cooled to room temperature and poured into 100mlof water. 2M HCl was added dropwise with vigorous stirring until pH = 4. The precipitates were filtered, washed with water, and dried in vacuo to give 5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoic acid as white solid. Yield: 130mg, 91%.

^{1}H NMR (DMSO-d_6): 11.96 (br. s., 1H), 11.82 (br. s., 1H), 9.18 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.9, 2.3 Hz, 1H), 7.85 (t, J = 5.7 Hz, 1H), 7.56 - 7.58 (m, 2H), 7.37 (br. s., 1H), 7.15 - 7.18 (m, 3H), 7.11 (dd, J = 11.4, 8.2 Hz, 1H), 7.07 (br. s., 1H), 6.79


18572 CIP PCT (AP)

- 6.83 (m, 1H), 6.72 (dd, J = 5.6, 2.3 Hz, 1H), 3.17 (q, J = 6.5 Hz, 2H), 2.28 (s, 3H), 2.23 (t, J = 7.2 Hz, 2H), 1.44 - 1.55 (m, 4H)

LR MS (ES+): 546 (MH+)

LR MS (ES-): 544 (M-H)

Example 167



ethyl 5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoate

A mixture of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (300mg, 0.67mmol), HATU (281mg, 0.74mmol) and N,N-diisopropylethylamine (258mg, 2.0mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of ethyl 5-aminovalerate hydrochloride (145mg, 0.80mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. 2M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 3~5% of methanol in chloroform to give ethyl 5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoate as white solid. Yield: 288mg, 75%.

^{1}H NMR (DMSO-d_6): 11.79 (t, J = 3.1 Hz, 1H), 9.17 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.98 (dd, J = 8.1, 2.2 Hz, 1H), 7.84 (t, J = 5.9 Hz, 1H), 7.55 - 7.58 (m, 2H), 7.35 (dd, J = 3.2, 1.8 Hz, 1H), 7.14 - 7.17 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.05 (dd, J = 2.6, 1.8 Hz, 1H), 6.79 - 6.82 (m, 1H), 6.70 - 6.72 (m, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.15 - 3.18 (m,


18572 CIP PCT (AP)

2H), 2.30 (t, J = 7.3 Hz, 2H), 2.27 (s, 3H), 1.51 - 1.56 (m, 2H), 1.44 - 1.50 (m, 2H), 1.16 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 574 (MH+)

LR MS (ES-): 572 (M-H)

Example 168



ethyl 4-(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazine-1-carboxylate

To a stirred solution of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide (200mg, 0.40mmol) and 1-ethoxycarbonylpiperazine (158mg, 1.0mmol) in anhydrous DMF (10ml) was added acetic acid (10mg, 0.17mmol). The mixture was stirred under nitrogen for 60 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (1.0ml, 1.0mmol). The reaction mixture was stirred for another hour, and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water, and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 5% methanol/chloroform solution to give ethyl 4-(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazine-1-carboxylate as white solid. Yield: 77mg, 30%.

^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 9.08 (d, J = 2.6 Hz, 1H), 8.97 (d, J = 2.6 Hz, 1H), 8.40 (d, J = 5.6 Hz, 1H), 8.26 (t, J = 9.1 Hz, 1H), 8.01 (dd, J = 7.9, 2.6 Hz, 1H), 7.82 (t, J = 5.9 Hz, 1H), 7.37 (dd, J = 3.2, 1.8 Hz, 1H), 7.29 (dd, J = 11.9, 2.8 Hz, 1H), 7.20 (d, J = 2.3 Hz, 1H), 7.12 (dd, J = 10.7, 7.8 Hz, 1H), 7.08 - 7.10 (m, 1H), 7.02 - 7.07 (m, 1H), 6.79 - 6.85 (m, 1H), 6.76


18572 CIP PCT (AP)

(dd, J = 5.7, 2.5 Hz, 1H), 4.02 (q, J = 7.0 Hz, 2H), 3.26 - 3.39 (m, 6H), 2.44 (t, J = 6.9 Hz, 2H), 2.33 - 2.41 (m, 4H), 2.28 (s, 3H), 1.17 (t, J = 7.0 Hz, 3H)

LR MS (ES+): 648 (MH+)

LR MS (ES-): 646 (M-H)

Example 169



5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide


To a stirred solution of N-(2,2-diethoxyethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (550mg, 0.95mmol) in 10ml of THF was added 2 ml of 2M HCl. The mixture was stirred at room temperature under nitrogen for overnight, and poured into 100ml of water with vigorous stirring. Saturated NaHCO3 solution was added until pH = 8. The precipitates were filtered, washed with water, and dried to give 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide as off-white solid. Yield: 475mg, 99%.

LR MS (ES+): 506 (MH+)

LR MS (ES-): 504 (M-H)

Example 170

18572 CIP PCT (AP)



N-(2,2-diethoxyethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

A mixture of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (500mg, 1.08mmol), HATU (456mg, 1.20mmol) and N,N-diisopropylethylamine (278mg, 2.16mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of aminoacetaldehyde diethyl acetal (173mg, 1.30mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give N-(2,2-diethoxyethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as white solid. Yield: 550mg, 88%.

^{1}H NMR (DMSO-d_6): 11.85 (br. s., 1H), 9.08 (d, J = 2.3 Hz, 1H), 8.97 (d, J = 2.6 Hz, 1H), 8.41 (d, J = 5.6 Hz, 1H), 8.26 (t, J = 9.1 Hz, 1H), 8.01 (dd, J = 7.9, 2.3 Hz, 1H), 7.94 (t, J = 6.0 Hz, 1H), 7.41 (dd, J = 3.1, 1.6 Hz, 1H), 7.29 (dd, J = 11.7, 2.6 Hz, 1H), 7.21 (d, J = 2.3 Hz, 1H), 7.08 - 7.16 (m, 2H), 7.05 (ddd, J = 9.1, 2.8, 1.3 Hz, 1H), 6.79 - 6.85 (m, 1H), 6.77 (dd, J = 5.7, 2.5 Hz, 1H), 4.54 - 4.59 (m, 1H), 3.57 - 3.68 (m, 2H), 3.47 (dq, J = 9.7, 7.0 Hz, 2H), 3.24 (t, J = 5.7 Hz, 2H), 2.28 (s, 3H), 1.11 (t, J = 7.0 Hz, 6H)


LR MS (ES+): 580 (MH+)
LR MS (ES-): 578 (M-H)

The following Example 171 was prepared using the experiment procedure described in Example 184, but with the appropriate reagent, reaction conditions and reactant substitutions that will be

18572 CIP PCT (AP)

readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 171



ethyl 4-{3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}piperazine-1-carboxylate


^{1}H NMR (DMSO-d_6): 11.84 (br. s., 1H), 10.15 (s, 1H), 8.44 (d, J = 5.9 Hz, 1H), 7.98 - 8.04 (m, 2H), 7.86 (t, J = 5.6 Hz, 1H), 7.66 (t, J = 9.7 Hz, 1H), 7.35 - 7.40 (m, 2H), 7.28 (d, J = 2.3 Hz, 1H), 7.13 - 7.20 (m, 2H), 7.04 - 7.10 (m, 1H), 6.83 (dd, J = 5.9, 2.3 Hz, 1H), 4.02 (q, J = 7.0 Hz, 2H), 3.31 - 3.38 (m, 4H), 3.16 - 3.24 (m, 2H), 2.29 (s, 3H), 2.28 - 2.35 (m, 6H), 1.63 (quin, J = 7.2 Hz, 2H), 1.17 (t, J = 7.0 Hz, 3H)

LR MS (ES+): 647 (MH+)
LR MS (ES-): 645 (M-H)

The following Example 172 was prepared using the experiment procedure described in Example 212, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 172

18572 CIP PCT (AP)




ethyl 4-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)piperazine-1-carboxylate

^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 9.08 (d, J = 2.6 Hz, 1H), 8.97 (d, J = 2.3 Hz, 1H), 8.40 (d, J = 5.9 Hz, 1H), 8.25 (t, J = 9.2 Hz, 1H), 7.99 - 8.03 (m, 1H), 7.86 (t, J = 5.6 Hz, 1H), 7.36 (dd, J = 2.9, 1.8 Hz, 1H), 7.29 (dd, J = 11.7, 2.6 Hz, 1H), 7.20 (d, J = 2.3 Hz, 1H), 7.08 - 7.15 (m, 2H), 7.04 (ddd, J = 9.1, 2.8, 1.3 Hz, 1H), 6.79 - 6.85 (m, 1H), 6.76 (dd, J = 5.6, 2.3 Hz, 1H), 4.02 (q, J = 7.0 Hz, 2H), 3.34 (dd, J = 5.6, 4.4 Hz, 4H), 3.16 - 3.24 (m, 2H), 2.29 - 2.34 (m, 6H), 2.28 (s, 3H), 1.63 (quin, J = 7.1 Hz, 2H), 1.16 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 662 (MH+)

LR MS (ES-): 660 (M-H)


Example 173



ethyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate

18572 CIP PCT (AP)

Example 174



methyl 3-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate

A mixture of 5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (Example 75) (1.50g, 3.36mmol), HATU (1.41g, 3.70mmol) and N,N-diisopropylethylamine (1.29g, 10mmol) in anhydrous DMF (15ml) was stirred at room temperature for 10 minutes, followed by addition of β-alanine methyl ester hydrochloride (558mg, 4.0mmol). The mixture was stirred for another 10 minutes and poured into 200ml of water with vigorous stirring. 2M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 3% of methanol in chloroform to give methyl 3-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate as off-white solid. Yield: 1.18g, 66%.


^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 8.99 (s, 1H), 8.59 (d, J = 2.1 Hz, 1H), 8.40 (d, J = 5.9 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.96 (t, J = 5.7 Hz, 1H), 7.37 (dd, J = 3.2, 1.8 Hz, 1H), 7.30 (s, 1H), 7.28 (dd, J = 11.7, 2.6 Hz, 1H), 7.23 - 7.25 (m, 1H), 7.20 (d, J = 2.6 Hz, 1H), 7.16 - 7.19 (m, 1H), 7.09 (t, J = 2.3 Hz, 1H), 7.04 (dd, J = 9.0, 3.1 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 6.76 (dd, J = 5.7, 2.5 Hz, 1H), 3.60 (s, 3H), 3.39 - 3.42 (m, 2H), 2.54 (t, J = 7.0 Hz, 2H), 2.29 (s, 3H)

LR MS (ES+): 532 (MH+)

LR MS (ES-): 530 (M-H)

Example 175

18572 CIP PCT (AP)



methyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate


A mixture of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid(Example 96) (200mg, 0.43mmol), HATU (179mg, 0.47mmol) and N,N-diisopropylethylamine (166mg, 1.29mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of β-alanine methyl ester hydrochloride (91mg, 0.65mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water with vigorous stirring. 2M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give methyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate as brown solid. Yield: 180mg, 76%.

^{1}H NMR (DMSO-d_6): 11.89 (br. s., 1H), 9.09 (d, J = 1.8 Hz, 1H), 8.97 (d, J = 2.6 Hz, 1H), 8.41 (d, J = 5.9 Hz, 1H), 8.26 (t, J = 9.1 Hz, 1H), 8.01 (dd, J = 7.5, 2.2 Hz, 1H), 7.98 (t, J = 5.7 Hz, 1H), 7.40 (br. s., 1H), 7.30 (dd, J = 11.9, 2.8 Hz, 1H), 7.23 (br. s., 1H), 7.10 - 7.14 (m, 2H), 7.04 - 7.07 (m, 1H), 6.79 - 6.83 (m, 2H), 3.59 (s, 3H), 3.39 - 3.42 (m, 2H), 2.54 (t, J = 7.0 Hz, 2H), 2.27 (s, 3H)

LR MS (ES+): 550 (MH+)
LR MS (ES-): 548 (M-H)

Example 176

18572 CIP PCT (AP)



methyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate


To a stirred solution of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid(Example 115) (200mg, 0.45mmol) in 10ml of anhydrous DMF were added HATU (190mg, 0.50mmol) and *N,N*-diisopropylethylamine (174mg, 1.35mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of methyl 4-aminobutyrate hydrochloride (104mg, 0.68mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water with vigorous stirring. 1M HCl was added slowly until pH=4. The precipitates were filtered, washed with water and dried in vacuo to give methyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate as white solid. Yield: 220mg, 90%.

^{1}H NMR (DMSO-d_6): 11.84 (br. s., 1H), 9.18 (s, 1H), 8.49 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.6, 2.3 Hz, 1H), 7.89 (t, J = 5.6 Hz, 1H), 7.56 - 7.59 (m, 2H), 7.38 (br. s., 1H), 7.15 - 7.18 (m, 3H), 7.11 (dd, J = 11.3, 8.4 Hz, 1H), 7.08 (br. s., 1H), 6.80 - 6.83 (m, 1H), 6.72 - 6.74 (m, 1H), 3.58 (s, 3H), 3.17 - 3.21 (m, 2H), 2.34 (t, J = 7.3 Hz, 2H), 2.28 (s, 3H), 1.73 (quin, J = 7.2 Hz, 2H)

LR MS (ES+): 546 (MH+)
LR MS (ES-): 544 (M-H)

Example 177

18572 CIP PCT (AP)



5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(4-hydrazino-4-oxobutyl)-1H-pyrrole-3-carboxamide


A mixture of 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid (Example 78) (120mg, 0.23mmol), HATU (95mg, 0.25mmol) and N,N-diisopropylethylamine (59mg, 0.46mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of hydrazine monohydrate (0.125ml, 2.6mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 10~12% of methanol in chloroform to give 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(4-hydrazino-4-oxobutyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 60mg, 49%.

^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 9.17 (s, 1H), 8.95 (br. s., 1H), 8.49 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 7.99 (dd, J = 7.9, 2.3 Hz, 1H), 7.88 (t, J = 5.9 Hz, 1H), 7.55 - 7.58 (m, 2H), 7.36 - 7.37 (m, 1H), 7.14 - 7.17 (m, 3H), 7.11 (dd, J = 11.4, 8.2 Hz, 1H), 7.06 (t, J = 2.3 Hz, 1H), 6.79 - 6.83 (m, 1H), 6.71 (dd, J = 5.7, 2.5 Hz, 1H), 4.13 - 4.15 (m, 2H), 3.16 (q, J = 6.7 Hz, 2H), 2.28 (s, 3H), 2.04 (t, J = 7.5 Hz, 2H), 1.69 (quin, J = 7.3 Hz, 2H)

LR MS (ES+): 546 (MH+)
LR MS (ES-): 544 (M-H)

Example 178

18572 CIP PCT (AP)



dimethyl 2,2'-({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}imino)diacetate


To a stirred solution of N-(3-aminopropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide (85mg, 0.17mmol) and N,N-diisopropylethylamine (100mg, 0.78mmol) in 10ml of anhydrous DMF was added methyl bromoacetate (100mg, 0.65mmol). The mixture was heated at 55°C for 30 minutes and poured into 100ml of water with vigorous stirring. The precipitates were filtered and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 3~5% of MeOH in $CHCl_3$ to afford dimethyl 2,2'-({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}imino)diacetate as white solid. Yield: 70mg, 64%.

^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 10.13 (s, 1H), 8.41 (d, J = 5.9 Hz, 1H), 7.99 (d, J = 6.2 Hz, 1H), 7.96 - 7.99 (m, 1H), 7.80 (t, J = 5.7 Hz, 1H), 7.63 (t, J = 9.5 Hz, 1H), 7.33 - 7.37 (m, 2H), 7.26 (d, J = 2.6 Hz, 1H), 7.13 (dd, J = 10.4, 8.1 Hz, 1H), 7.10 - 7.12 (m, 1H), 7.02 - 7.06 (m, 1H), 6.79 (dd, J = 5.7, 2.5 Hz, 1H), 3.57 (s, 6H), 3.49 (s, 4H), 3.17 (q, J = 6.7 Hz, 2H), 2.63 (t, J = 6.9 Hz, 2H), 2.26 (s, 3H), 1.55 (quin, J = 6.9 Hz, 2H)

LR MS (ES+): 650 (MH+)
LR MS (ES-): 648 (M-H)

Example 179

18572 CIP PCT (AP)



dimethyl 2,2'-({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}imino)diacetate


To a stirred solution of N-(2-aminoethyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide (100mg, 0.20mmol) and N,N-diisopropylethylamine (129mg, 1.0mmol) in 10ml of anhydrous DMF was added methyl bromoacetate (77mg, 0.50mmol). The mixture was heated at 55°C for 30 minutes and poured into 100ml of water with vigorous stirring. The precipitates were filtered and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 2~3% of MeOH in $CHCl_3$ to afford dimethyl 2,2'-({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}imino)diacetate as off-white solid. Yield: 80mg, 62%.

^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 10.12 (s, 1H), 8.41 (d, J = 5.9 Hz, 1H), 7.95 - 8.01 (m, 2H), 7.73 (t, J = 5.6 Hz, 1H), 7.60 - 7.65 (m, 1H), 7.32 - 7.37 (m, 2H), 7.25 (d, J = 2.6 Hz, 1H), 7.14 (dd, J = 10.4, 8.4 Hz, 1H), 7.09 (t, J = 2.2 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 3.57 (s, 6H), 3.54 (s, 4H), 3.21 (q, J = 6.5 Hz, 2H), 2.75 (t, J = 6.7 Hz, 2H), 2.26 (s, 3H)

LR MS (ES+): 636 (MH+)
LR MS (ES-): 634 (M-H)

Example 180

18572 CIP PCT (AP)




methyl ({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}amino)acetate

To a stirred solution of N-(3-aminopropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide (100mg, 0.20mmol) and N,N-diisopropylethylamine (52mg, 0.40mmol) in 10ml of anhydrous DMF was added methyl bromoacetate (30mg, 0.20mmol). The mixture was stirred at room temperature for 50 minutes and poured into 100ml of water with vigorous stirring. The precipitates were filtered and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 2~3% of MeOH in $CHCl_3$ to afford methyl ({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}amino)acetate as white solid. Yield: 40mg, 35%.

LR MS (ES+): 578 (MH+)
LR MS (ES-): 576 (M-H)

Example 181



methyl ({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}amino)acetate


18572 CIP PCT (AP)

To a stirred solution of N-(2-aminoethyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide (80mg, 0.16mmol) in 10ml of anhydrous DMF, were added N,N-diisopropylethylamine (60mg, 0.47mmol) and methyl bromoacetate (30mg, 0.20mmol). The mixture was stirred at room temperature for 1 hour and poured into 100ml of water. The precipitates were filtered, washed with water, and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with a gradient of 3~5% of methanol in chloroform to give methyl ({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}amino)acetate as white solid. Yield: 38mg, 41%.

^{1}H NMR (DMSO-d_6): 11.82 (br. s., 1H), 10.13 (s, 1H), 8.41 (d, J = 5.9 Hz, 1H), 7.96 - 8.02 (m, 2H), 7.81 (t, J = 5.7 Hz, 1H), 7.63 (t, J = 9.7 Hz, 1H), 7.33 - 7.39 (m, 2H), 7.26 (d, J = 1.8 Hz, 1H), 7.10 - 7.16 (m, 2H), 7.01 - 7.06 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 3.58 (s, 3H), 3.34 (s, 2H), 3.22 (q, J = 6.5 Hz, 2H), 2.61 (t, J = 6.5 Hz, 2H), 2.26 (s, 3H)

LR MS (ES+): 564 (MH+)
LR MS (ES-): 562 (M-H)

Example 182



N-(2-aminoethyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide


To a stirred suspension of tert-butyl {2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}carbamate (360mg, 0.61mmol) in 5ml of methylene chloride was added 3ml of trifluoroacetic acid. The mixture was stirred at room temperature for 20 minutes and evaporated to dryness under reduced pressure. The residue was re-dissolved in MeOH (5ml)

18572 CIP PCT (AP)

and poured into 100ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added until pH = 8~9. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(2-aminoethyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide as beige solid. Yield: 280mg, 94%.

LR MS (ES+): 492 (MH+)
LR MS (ES-): 490 (M-H)

Example 183



tert-butyl {2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}carbamate

A mixture of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (Example 13) (300mg, 0.67mmol), HATU (281mg, 0.74mmol) and *N,N*-diisopropylethylamine (190mg, 1.47mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of *tert*-butyl (2-aminoethyl)carbamate (160mg, 1.0mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried *in vacuo* to give tert-butyl {2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}carbamate as white solid. Yield: 395mg, 100%.


^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 10.12 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.95 - 8.01 (m, 2H), 7.85 (t, J = 5.7 Hz, 1H), 7.60 - 7.66 (m, 1H), 7.36 (dd, J = 2.9, 1.8 Hz, 1H), 7.34 (dd, J = 7.3, 2.3 Hz, 1H), 7.25 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 10.6, 8.2 Hz, 1H), 7.10 (t, J = 2.2 Hz, 1H), 7.02 - 7.06 (m, 1H), 6.82 - 6.85 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 3.18 (q, J = 6.5 Hz, 2H), 3.02 (q, J = 6.4 Hz, 2H), 2.26 (s, 3H), 1.34 (s, 9H)

18572 CIP PCT (AP)

LR MS (ES+): 592 (MH+)

LR MS (ES-): 590 (M-H)

Example 184



5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide


To a stirred solution of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide (205mg, 0.41mmol) in 10ml of anhydrous DMF were added 4-hydroxypiperidine (83mg, 0.82mmol) and acetic acid (10mg, 0.17mmol). The mixture was stirred at room temperature for 30 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (0.80ml, 0.80mmol) and stirring was continued for one more hour. The mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel flash chromatography eluting with 20% of MeOH in $CHCl_3$ to give 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide as white solid. Yield: 85mg, 35%.

^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 10.12 (s, 1H), 8.41 (d, J = 5.9 Hz, 1H), 7.96 - 8.01 (m, 2H), 7.84 (br. s., 1H), 7.63 (t, J = 9.5 Hz, 1H), 7.32 - 7.37 (m, 2H), 7.25 (d, J = 2.1 Hz, 1H), 7.14 (dd, J = 10.3, 8.5 Hz, 1H), 7.10 (s, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.6, 2.1 Hz, 1H), 4.47 (br. s., 1H), 3.39 (br. s., 1H), 3.16 (br. s., 2H), 2.65 (br. s., 2H), 2.26 (s, 3H), 2.23 (br. s., 2H), 1.92 (br. s., 2H), 1.66 (br. s., 2H), 1.58 (br. s., 2H), 1.34 (br. s., 2H)

18572 CIP PCT (AP)

LR MS (ES+): 590 (MH+)

Example 185



1-[4-({2-[4-(azetidin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(2-fluoro-5-methylphenyl)urea

A mixture of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (100mg, 0.22mmol), HATU (99mg, 0.26mmol) and N,N-diisopropylethylamine (62mg, 0.48mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of azetidine (20mg, 0.35mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. 2M HCl was added dropwise until pH = 4~5. The precipitates were filtered, washed with water and dried in vacuo to give 1-[4-({2-[4-(azetidin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(2-fluoro-5-methylphenyl)urea as light brown solid. Yield: 95mg, 87%.

1H NMR (DMSO-d6): 12.18 (br. s., 1H), 9.28 (s, 1H), 8.53 (d, J = 2.1 Hz, 1H), 8.43 (d, J = 5.9 Hz, 1H), 7.96 - 8.01 (m, 1H), 7.58 (d, J = 8.8 Hz, 2H), 7.48 (br. s., 1H), 7.34 (br. s., 1H), 7.08 - 7.22 (m, 4H), 6.81 (td, J = 5.3, 2.6 Hz, 2H), 4.39 (br. s., 2H), 3.97 (br. s., 2H), 2.22 - 2.31 (m, 5H)


LR MS (ES+): 508 (M+Na+)

LR MS (ES-): 484 (M-H)

The following Example 186 was prepared using the experiment procedure described in Example 187, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

18572 CIP PCT (AP)

Example 186




5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide

^{1}H NMR (DMSO-d_6): 11.82 (br. s., 1H), 10.12 (s, 1H), 8.41 (d, J = 5.9 Hz, 1H), 7.94 - 8.03 (m, 2H), 7.84 (t, J = 5.4 Hz, 1H), 7.63 (t, J = 9.5 Hz, 1H), 7.32 - 7.39 (m, 2H), 7.25 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 10.3, 8.5 Hz, 1H), 7.08 - 7.11 (m, 1H), 7.04 (dt, J = 8.2, 2.3 Hz, 1H), 6.80 (dd, J = 5.6, 2.3 Hz, 1H), 3.17 (q, J = 6.7 Hz, 2H), 2.20 - 2.45 (br. s., 10H), 2.26 (s, 3H), 2.12 (s, 3H), 1.55 - 1.62 (m, 2H)

LR MS (ES+): 589 (MH+)
LR MS (ES-): 587 (M-H)

Example 187



5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide

To a stirred solution of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (150mg,


18572 CIP PCT (AP)

0.33mmol) in 10ml of anhydrous DMF were added HATU (152mg, 0.40mmol) and *N,N*-diisopropylethylamine (94mg, 0.73mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of *N*-(3-aminopropyl)pyrrolidine (85mg, 0.66mmol), and stirring was continued for another 10 minutes. The mixture was poured into 50ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried *in vacuo* to give 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 160mg, 86%.

^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 10.12 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.99 (d, J = 6.2 Hz, 1H), 7.97 (br. s., 1H), 7.89 (t, J = 5.6 Hz, 1H), 7.63 (t, J = 9.5 Hz, 1H), 7.32 - 7.38 (m, 2H), 7.24 (d, J = 2.1 Hz, 1H), 7.14 (dd, J = 10.3, 8.5 Hz, 1H), 7.08 (s, 1H), 7.01 - 7.07 (m, 1H), 6.80 (dd, J = 5.6, 2.3 Hz, 1H), 3.19 (q, J = 6.7 Hz, 2H), 2.40 (br. s., 6H), 2.26 (s, 3H), 1.64 (br. s., 4H), 1.58 - 1.63 (m, 2H)

LR MS (ES+): 560 (MH+)
LR MS (ES-): 558 (M-H)

Example 188



methyl 1-[3-({[5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)propyl]pyrrolidine-2-carboxylate


To a stirred solution of 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide (140mg, 0.29mmol) in 10ml of anhydrous DMF were added L-proline methyl ester hydrochloride (96mg, 0.58mmol) and triethylamine (58mg, 0.58mmol). The mixture was stirred at room temperature for 30 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (0.60ml, 0.60mmol) and stirring was

continued for another 30 minutes. The mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel flash chromatography eluting with 5% of MeOH in $CHCl_3$ to give methyl 1-[3-({[5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)propyl]pyrrolidine-2-carboxylate as light beige solid. Yield: 70mg, 40%.

LR MS (ES+): 590 (MH+)
LR MS (ES-): 588 (M-H)

The following Example 189 was prepared using the experiment procedure described in Example 188, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 189




5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide

LR MS (ES+): 562 (MH+)
LR MS (ES-): 560 (M-H)

Example 190

18572 CIP PCT (AP)




5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide

To a stirred solution of N-(3,3-diethoxypropyl)-5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide (380mg, 0.69mmol) in 15ml of tetrahydrofuran was added 1ml of 2M HCl (2.0mmol). The mixture was stirred at room temperature for 90 minutes and poured into 100ml of water. 1M NaOH solution was added slowly until pH = 7~8. The precipitates were filtered, washed with water and dried in vacuo to give 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 270mg, 82%.

^{1}H NMR (CHLOROFORM-d): 10.50 (br. s., 1H), 9.84 (s, 1H), 8.36 - 8.44 (m, 2H), 8.30 (d, J = 6.2 Hz, 1H), 7.43 (s, 1H), 7.40 (br. s., 1H), 7.22 (t, J = 9.5 Hz, 1H), 7.06 (br. s., 1H), 6.80 - 6.88 (m, 2H), 6.73 - 6.79 (m, 1H), 6.42 (s, 1H), 6.23 (t, J = 5.7 Hz, 1H), 3.69 (q, J = 5.8 Hz, 2H), 2.84 (t, J = 5.7 Hz, 2H), 2.42 (s, 3H)

LR MS (ES+): 477 (MH+)
LR MS (ES-): 475 (M-H)

Example 191




18572 CIP PCT (AP)

5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-piperidin-1-ylpropyl)-1H-pyrrole-3-carboxamide

^{1}H NMR (DMSO-d_6): 11.79 (br. s., 1H), 9.71 (s, 1H), 8.39 (d, 1H), 7.85 (br. s., 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.58 (dd, J = 6.5, 2.9 Hz, 1H), 7.39 (t, J = 9.5 Hz, 1H), 7.34 (br. s., 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.06 - 7.09 (m, 1H), 7.04 - 7.06 (m, 1H), 6.72 (dd, J = 5.6, 2.3 Hz, 1H), 6.57 (d, 1H), 3.16 (q, J = 6.1 Hz, 2H), 2.28 (s, 3H), 2.21 - 2.30 (m, 6H), 1.59 (br. s., 2H), 1.45 (br. s., 4H), 1.33 (br. s., 2H)

LR MS (ES+): 546 (MH+)
LR MS (ES-): 544 (M-H)

Example 192




5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide

^{1}H NMR (DMSO-d_6): 11.79 (br. s., 1H), 9.71 (s, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.89 (t, J = 5.4 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.58 (dd, J = 6.2, 2.9 Hz, 1H), 7.39 (t, J = 9.5 Hz, 1H), 7.33 (dd, J = 2.9, 1.8 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.07 (dt, J = 8.9, 3.5 Hz, 1H), 7.01 - 7.05 (m, 1H), 6.72 (dd, J = 5.6, 2.3 Hz, 1H), 6.57 (d, J = 1.2 Hz, 1H), 3.19 (q, J = 6.7 Hz, 2H), 2.42 (br. s., 6H), 2.28 (s, 3H), 1.58 - 1.69 (m, 6H)

LR MS (ES+): 532 (MH+)
LR MS (ES-): 530 (M-H)

Example 193

18572 CIP PCT (AP)




5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide

^{1}H NMR (DMSO-d_6): 11.80 (br. s., 1H), 9.71 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.85 (t, J = 5.6 Hz, 1H), 7.78 (d, J = 1.5 Hz, 1H), 7.57 (dd, J = 6.5, 2.9 Hz, 1H), 7.39 (t, J = 9.5 Hz, 1H), 7.34 (br. s., 1H), 7.20 (d, J = 2.3 Hz, 1H), 7.06 - 7.09 (m, 1H), 7.05 - 7.06 (m, 1H), 6.72 (dd, J = 5.7, 2.2 Hz, 1H), 6.57 (s, 1H), 3.16 (q, J = 6.5 Hz, 2H), 2.31 (br. s., 10H), 2.28 (s, 3H), 2.13 (s, 3H), 1.59 (quin, J = 7.0 Hz, 2H)

LR MS (ES+): 561 (MH+)
LR MS (ES-): 559 (M-H)

Example 194



5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide


To a stirred solution of 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid (Example 28) (150mg, 0.36mmol) in 10ml of anhydrous DMF were added HATU (163mg, 0.43mmol) and *N,N*-diisopropylethylamine (102mg, 0.79mmol). The

mixture was stirred at room temperature for 10 minutes, followed by addition of 3-morpholinopropylamine (104mg, 0.72mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 10% methanol in chloroform to give 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 110mg, 56%.

^{1}H NMR (DMSO-d_6): 11.79 (br. s., 1H), 9.71 (s, 1H), 8.39 (d, J = 5.9 Hz, 1H), 7.84 (t, J = 5.6 Hz, 1H), 7.78 (d, J = 1.5 Hz, 1H), 7.58 (dd, J = 6.5, 2.9 Hz, 1H), 7.39 (t, J = 9.5 Hz, 1H), 7.33 - 7.36 (m, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.07 - 7.09 (m, 1H), 7.05 - 7.07 (m, 1H), 6.72 (dd, J = 5.7, 2.2 Hz, 1H), 6.57 (d, J = 1.5 Hz, 1H), 3.53 (t, J = 4.5 Hz, 4H), 3.17 (q, J = 6.7 Hz, 2H), 2.30 (br. s., 4H), 2.28 (s, 3H), 2.26 (t, J = 7.3 Hz, 2H), 1.60 (quin, J = 7.0 Hz, 2H)
LR MS (ES+): 548 (MH+)
LR MS (ES-): 546 (M-H)

The following Examples 195 and 196 were prepared using the experiment procedure described in Example 212, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 195




N-{3-[(2,3-dihydroxypropyl)(methyl)amino]propyl}-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

LR MS (ES+): 609 (MH+)

18572 CIP PCT (AP)

LR MS (ES-): 607 (M-H)

Example 196




methyl [(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)amino]acetate

^{1}H NMR (DMSO-d_6): 11.80 (br. s., 1H), 9.12 (d, J = 2.3 Hz, 1H), 9.01 (d, J = 2.6 Hz, 1H), 8.37 (d, J = 5.9 Hz, 1H), 8.22 (t, J = 9.1 Hz, 1H), 7.97 (dd, J = 7.0, 1.8 Hz, 1H), 7.88 (t, J = 5.7 Hz, 1H), 7.34 (dd, J = 3.1, 1.9 Hz, 1H), 7.25 (dd, J = 11.7, 2.9 Hz, 1H), 7.17 - 7.20 (m, 1H), 7.05 - 7.11 (m, 2H), 7.01 (dt, J = 9.3, 1.5 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.73 (dd, J = 5.6, 2.3 Hz, 1H), 3.59 (s, 3H), 3.36 (s, 2H), 3.19 (q, J = 6.7 Hz, 2H), 2.54 (t, J = 7.0 Hz, 2H), 2.25 (s, 3H), 1.58 (quin, J = 7.0 Hz, 2H)

LR MS (ES+): 593 (MH+)
LR MS (ES-): 591 (M-H)

Example 197




18572 CIP PCT (AP)

3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoic acid

^{1}H NMR (DMSO-d_6): 9.14 (d, *J*=2.34 Hz, 1 H) 9.01 (d, *J*=2.34 Hz, 1 H) 8.72 (t, *J*=5.42 Hz, 1 H) 8.54 (d, *J*=6.15 Hz, 1 H) 8.47 (s, 1 H) 8.41 (d, *J*=1.17 Hz, 1 H) 8.27 (t, *J*=9.08 Hz, 1 H) 8.00 (dd, *J*=7.62, 1.76 Hz, 1 H) 7.54 (d, *J*=2.34 Hz, 1 H) 7.33 (dd, *J*=11.87, 2.78 Hz, 1 H) 7.05 - 7.16 (m, 2 H) 6.95 (dd, *J*=5.86, 2.34 Hz, 1 H) 6.79 - 6.85 (m, 1 H) 3.40 - 3.49 (m, 2 H) 2.50 - 2.55 (m, 2 H) 2.28 (s, 3 H)

LR MS (ES-): 551 (M-H)

Example 198



methyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate


^{1}H NMR (DMSO-d_6): 9.08 (d, *J*=2.05 Hz, 1 H) 8.97 (d, *J*=2.64 Hz, 1 H) 8.72 (t, *J*=5.57 Hz, 1 H) 8.49 (d, *J*=5.86 Hz, 1 H) 8.39 (br. s, 2 H) 8.25 (t, *J*=9.08 Hz, 1 H) 8.01 (dd, *J*=7.76, 1.90 Hz, 1 H) 7.46 (d, *J*=2.34 Hz, 1 H) 7.30 (dd, *J*=11.87, 2.78 Hz, 1 H) 7.12 (dd, *J*=11.43, 8.20 Hz, 1 H) 7.05 (ddd, *J*=9.01, 2.71, 1.17 Hz, 1 H) 6.85 (dd, *J*=5.86, 2.34 Hz, 1 H) 6.81 (m, 1 H) 3.61 (s, 3 H) 3.43 - 3.52 (m, 2 H) 2.60 (t, *J*=6.89 Hz, 2 H) 2.28 (s, 3 H)

LR MS (ES+): 589 ($M+Na^+$)

LR MS (ES-): 565 (M-H)

Example 199

18572 CIP PCT (AP)




3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-2-yl)carbonyl]amino}propanoic acid

^{1}H NMR (DMSO-d_6): 11.93 (br. s., 1 H) 9.13 (d, *J*=1.47 Hz, 1 H) 9.01 (d, *J*=1.76 Hz, 1 H) 8.42 (d, *J*=5.86 Hz, 1 H) 8.21 - 8.31 (m, 2 H) 8.01 (dd, *J*=7.76, 1.61 Hz, 1 H) 7.65 (br. s., 1 H) 7.29 - 7.35 (m, 2 H) 7.24 (d, *J*=1.76 Hz, 1 H) 7.05 - 7.17 (m, 2 H) 6.79 - 6.86 (m, 2 H) 3.38 - 3.47 (m, 2 H) 2.47 - 2.51 (m, 2 H) 2.29 (s, 3 H)

LR MS (ES-): 534 (M-H)

Example 200



methyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-2-yl)carbonyl]amino}propanoate


^{1}H NMR (DMSO-d_6): 11.74 (br. s., 1 H) 9.06 (d, *J*=2.05 Hz, 1 H) 8.96 (d, *J*=2.64 Hz, 1 H) 8.36 (d, *J*=5.86 Hz, 1 H) 8.18 - 8.27 (m, 2 H) 8.01 (dd, *J*=7.62, 2.05 Hz, 1 H) 7.50 (dd, *J*=3.08, 1.61 Hz, 1 H) 7.23 - 7.29 (m, 2 H) 7.08 - 7.16 (m, 2 H) 7.02 (ddd, *J*=9.01, 2.56, 1.32 Hz, 1 H) 6.82 (m, 1 H) 6.69 (dd, *J*=5.71, 2.49 Hz, 1 H) 3.60 (s, 3 H) 3.40 - 3.49 (m, 2 H) 2.57 (t, *J*=7.03 Hz, 2 H) 2.28 (s, 3 H)

LR MS (ES+): 572 ($M+Na^+$)

LR MS (ES-): 548 (M-H)

18572 CIP PCT (AP)

Example 201




N-(3,3-diethoxypropyl)-4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxamide

^{1}H NMR (DMSO-d_6): 9.08 (d, *J*=2.05 Hz, 1 H) 8.97 (d, *J*=2.34 Hz, 1 H) 8.59 (t, *J*=5.42 Hz, 1 H) 8.49 (d, *J*=5.57 Hz, 1 H) 8.37 - 8.39 (m, 2 H) 8.25 (t, *J*=9.08 Hz, 1 H) 8.01 (dd, *J*=7.91, 1.76 Hz, 1 H) 7.46 (d, *J*=2.34 Hz, 1 H) 7.30 (dd, *J*=11.72, 2.64 Hz, 1 H) 7.12 (dd, *J*=11.43, 8.50 Hz, 1 H) 7.05 (ddd, *J*=9.01, 2.71, 1.17 Hz, 1 H) 6.85 (dd, *J*=5.71, 2.49 Hz, 1 H) 6.79 - 6.83 (m, 1 H) 4.56 (t, *J*=5.57 Hz, 1 H) 3.52 - 3.64 (m, 2 H) 3.45 (dq, *J*=9.67, 7.13 Hz, 2 H) 3.24 - 3.31 (m, 2 H) 2.28 (s, 3 H) 1.74 - 1.83 (m, 2 H) 1.11 (t, *J*=7.03 Hz, 6 H)

LR MS (ES+): 633 ($M+Na^+$)

LR MS (ES-): 609 (M-H)

Example 202



N-(3,3-diethoxypropyl)-4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxamide


^{1}H NMR (DMSO-d_6): 11.75 (br. s., 1 H) 9.07 (d, *J*=1.76 Hz, 1 H) 8.96 (d, *J*=2.34 Hz, 1 H) 8.38 (d, *J*=5.86 Hz, 1 H) 8.24 (t, *J*=9.08 Hz, 1 H) 8.08 (t, *J*=5.57 Hz, 1 H) 8.01 (dd, *J*=7.76, 1.90 Hz, 1 H) 7.49 - 7.55 (m, 1 H) 7.27 (m, 2 H) 7.08 - 7.18 (m, 2 H) 7.03 (m, 1 H) 6.82 (m, 1 H) 6.69 - 6.73 (m, 1 H) 4.55 (t, *J*=5.57 Hz, 1 H) 3.58 (dq, *J*=9.38, 7.03 Hz, 2 H) 3.44 (dq, *J*=9.67, 7.03 Hz, 2 H) 3.19 - 3.29 (m, 2 H) 2.27 (s, 3 H) 1.75 (q, *J*=6.45 Hz, 2 H) 1.11 (t, *J*=7.03 Hz, 6 H)

18572 CIP PCT (AP)

LR MS (ES+): 616 ($M+Na^+$)

LR MS (ES-): 592 (M-H)

Example 203



N-(3,3-diethoxypropyl)-5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide

To a stirred solution of 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid (300mg, 0.71mmol) in 10ml of anhydrous DMF were added HATU (324mg, 0.85mmol) and *N,N*-diisopropylethylamine (200mg, 1.55mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of 1-amino-3,3-diethoxypropane (157mg, 1.06mmol), and stirring was continued for another 10 minutes. The mixture was poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(3,3-diethoxypropyl)-5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide as white solid. Yield: 380mg, 97%.


^{1}H NMR (DMSO-d_6): 11.79 (br. s., 1H), 9.71 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.79 (t, J = 5.6 Hz, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.57 (dd, J = 6.3, 3.1 Hz, 1H), 7.39 (t, J = 9.4 Hz, 1H), 7.34 (dd, J = 2.8, 1.6 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.06 - 7.09 (m, 1H), 7.04 - 7.06 (m, 1H), 6.72 (dd, J = 5.6, 2.3 Hz, 1H), 6.57 (d, J = 1.8 Hz, 1H), 4.51 (t, J = 5.6 Hz, 1H), 3.54 (dq, J = 9.5, 7.1 Hz, 2H), 3.41 (dq, J = 9.4, 7.1 Hz, 2H), 3.18 (q, J = 7.0 Hz, 2H), 2.28 (s, 3H), 1.71 (q, J = 6.5 Hz, 2H), 1.08 (t, J = 7.0 Hz, 6H)

LR MS (ES+): 551 (MH+)

LR MS (ES-): 549 (M-H)

18572 CIP PCT (AP)

Example 204



N-(3,3-diethoxypropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide

To a stirred solution of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (200mg, 0.45mmol) in 10ml of anhydrous DMF were added HATU (205mg, 0.54mmol) and *N,N*-diisopropylethylamine (128mg, 0.99mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of 1-amino-3,3-diethoxypropane (100mg, 0.68mmol), and stirring was continued for another 10 minutes. The mixture was poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(3,3-diethoxypropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide as white solid. Yield: 250mg, 97%.


^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 10.12 (s, 1H), 8.41 (d, J = 5.9 Hz, 1H), 7.99 (d, J = 6.2 Hz, 1H), 7.96 - 7.98 (m, 1H), 7.79 (t, J = 5.6 Hz, 1H), 7.63 (t, J = 9.5 Hz, 1H), 7.36 (dd, J = 2.8, 1.9 Hz, 1H), 7.33 - 7.35 (m, 1H), 7.25 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 10.3, 8.5 Hz, 1H), 7.10 (s, 1H), 7.01 - 7.07 (m, 1H), 6.80 (dd, J = 5.9, 2.3 Hz, 1H), 4.51 (t, J = 5.4 Hz, 1H), 3.54 (dq, J = 9.4, 7.0 Hz, 2H), 3.41 (dq, J = 9.4, 7.1 Hz, 2H), 3.15 - 3.21 (m, 2H), 2.26 (s, 3H), 1.65 - 1.76 (m, 2H), 1.08 (t, J = 7.0 Hz, 6H)

LR MS (ES-): 577 (M-H)

The following Examples 205 and 206 were prepared using the experiment procedure described in Example 207, but with the appropriate reagent, reaction conditions and reactant substitutions

that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 205




5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[3-(hydroxymethyl)piperidin-1-yl]propyl}-1H-pyrrole-3-carboxamide

LR MS (ES+): 619 (MH+)

LR MS (ES-): 617 (M-H)

Example 206




5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[2-(hydroxymethyl)morpholin-4-yl]propyl}-1H-pyrrole-3-carboxamide

LR MS (ES+): 621 (MH+)

18572 CIP PCT (AP)

LR MS (ES-): 619 (M-H)

Example 207



5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide


To a stirred solution of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide (150mg, 0.29mmol) in 10ml of anhydrous DMF were added 4-hydroxypiperidine (59mg, 0.58mmol) and acetic acid (10mg, 0.17mmol). The mixture was stirred at room temperature for 30 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (0.60ml, 0.60mmol) and stirring was continued for another 60 minutes. The mixture was poured into 50ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel flash chromatography eluting with 20% of MeOH in $CHCl_3$ to give 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide as white solid. Yield: 110mg, 63%.

LR MS (ES+): 605 (MH+)
LR MS (ES-): 603 (M-H)

The following Example 208 was prepared using the experiment procedure described in Example 163, but with the appropriate reagent, reaction conditions and reactant substitutions that will be

readily realized by those of ordinary skill in this art without the exercise of undue experimentation.


Example 208



N-(3,3-diethoxypropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

The following Example 209 was prepared using the experiment procedure described in Example 170, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.


Example 209



N-(3,3-diethoxypropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

Example 210

18572 CIP PCT (AP)



{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid

To a stirred solution of methyl {[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate (100mg, 0.19mmol) in 10ml of MeOH was added 1M NaOH solution (1ml, 1mmol). The mixture was stirred at room temperature for one hour and poured into 100ml of water. 1M HCl was added dropwise with vigorous stirring until pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give {[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid as white solid. Yield: 95mg, 98%.


^{1}H NMR (DMSO-d_6): 12.41 (br. s., 1H), 11.86 (br. s., 1H), 9.06 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 8.20 (t, J = 6.0 Hz, 1H), 7.98 (dd, J = 7.6, 2.1 Hz, 1H), 7.40 (dd, J = 3.1, 1.6 Hz, 1H), 7.27 (dd, J = 11.9, 2.8 Hz, 1H), 7.20 (d, J = 2.3 Hz, 1H), 7.11 (s, 1H), 7.07 - 7.12 (m, 1H), 7.03 (dd, J = 9.1, 1.8 Hz, 1H), 6.77 - 6.82 (m, 1H), 6.75 (dd, J = 5.6, 2.3 Hz, 1H), 3.81 (d, J = 5.9 Hz, 2H), 2.25 (s, 3H)

LR MS (ES-): 520 (M-H)

The following Examples 211 was prepared using the experiment procedure described in Example 175, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

18572 CIP PCT (AP)

Example 211




methyl {[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate

^{1}H NMR (DMSO-d_6): 11.87 (t, J = 2.9 Hz, 1H), 9.06 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.32 (t, J = 5.9 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.3 Hz, 1H), 7.39 (dd, J = 3.2, 1.8 Hz, 1H), 7.27 (dd, J = 11.9, 2.8 Hz, 1H), 7.19 (d, J = 2.3 Hz, 1H), 7.06 - 7.12 (m, 2H), 7.02 (ddd, J = 9.0, 2.9, 1.0 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.74 (dd, J = 5.6, 2.3 Hz, 1H), 3.90 (d, J = 5.9 Hz, 2H), 3.61 (s, 3H), 2.25 (s, 3H)

LR MS (ES+): 558 (M+Na+)

LR MS (ES-): 534 (M-H)

Example 212



18572 CIP PCT (AP)

tert-butyl (3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate


A mixture of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (400mg, 0.86mmol), HATU (380mg, 1.0mmol) and *N,N*-diisopropylethylamine (244mg, 1.9mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of N-Boc-1,3-propanediamine (174mg, 1.0mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water with vigorous stirring. 1M HCl was added dropwise until pH=5. The precipitates were filtered, washed with water and dried *in vacuo* to give tert-butyl (3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate as white solid. Yield: 500mg, 94%.

^{1}H NMR (DMSO-d_6): 11.86 (br. s., 1H), 9.07 (d, J = 2.1 Hz, 1H), 8.95 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 8.24 (t, J = 9.2 Hz, 1H), 7.98 (dd, J = 7.6, 2.3 Hz, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.37 (br. s., 1H), 7.28 (dd, J = 11.7, 2.6 Hz, 1H), 7.20 (br. s., 1H), 7.11 (br. s., 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.03 (dd, J = 9.1, 1.8 Hz, 1H), 6.77 - 6.81 (m, 2H), 6.75 (t, J = 5.6 Hz, 1H), 3.14 (q, J = 6.7 Hz, 2H), 2.91 (q, J = 6.9 Hz, 2H), 2.25 (s, 3H), 1.54 (quin, J = 7.0 Hz, 2H), 1.34 (s, 9H)

LR MS (ES+): 643 (M+Na+)
LR MS (ES-): 619 (M-H)

Example 213

18572 CIP PCT (AP)



dimethyl 2,2'-[(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate

To a stirred suspension of N-(3-aminopropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (240mg, 0.46mmol) in 10ml of anhydrous THF were added N,N-diisopropylethylamine (1ml, 5.6mmol) and methyl bromoacetate (300mg, 2.0mmol). The mixture was heated at 55°C for 3 hours and poured into 100ml of water with vigorous stirring. The precipitates were filtered and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 3~4% of MeOH in $CHCl_3$ to afford dimethyl 2,2'-[(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate as white solid. Yield: 160mg, 52%.


^{1}H NMR (DMSO-d_6): 11.79 (br. s., 1H), 9.05 (d, J = 2.6 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.23 (t, J = 9.2 Hz, 1H), 7.98 (dd, J = 7.9, 2.3 Hz, 1H), 7.79 (t, J = 5.7 Hz, 1H), 7.33 (dd, J = 3.2, 1.8 Hz, 1H), 7.26 (dd, J = 11.7, 2.6 Hz, 1H), 7.18 (d, J = 2.6 Hz, 1H), 7.08 - 7.12 (m, 1H), 7.07 (dd, J = 2.5, 1.9 Hz, 1H), 7.01 (ddd, J = 9.0, 2.9, 1.0 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.73 (dd, J = 5.9, 2.3 Hz, 1H), 3.56 (s, 6H), 3.49 (s, 4H), 3.12 - 3.21 (m, 2H), 2.63 (t, J = 7.0 Hz, 2H), 2.25 (s, 3H), 1.49 - 1.60 (m, 2H)

LR MS (ES+): 687 (M+Na+)

LR MS (ES-): 663 (M-H)

18572 CIP PCT (AP)

Example 214



2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetic acid


To a stirred solution of dimethyl 2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate (100mg, 0.15mmol) in a mixture of THF/MeOH (5ml/5ml) was added 1M NaOH solution (1ml, 1mmol). The mixture was stirred at room temperature for 4 hours and poured into 50ml of water. 1M HCl was added dropwise with vigorous stirring until pH = 5. The precipitates were filtered, washed with water and dried *in vacuo* to give 2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetic acid as white solid. Yield: 82mg, 78%.

^{1}H NMR (DMSO-d_6): 12.23 (br. s., 1H), 11.77 (br. s., 1H), 9.16 (s, 1H), 8.48 (d, J = 2.3 Hz, 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.96 (dd, J = 7.9, 2.6 Hz, 1H), 7.84 (t, J = 5.7 Hz, 1H), 7.54 (d, J = 9.1 Hz, 2H), 7.52 - 7.55 (m, 1H), 7.32 (dd, J = 2.9, 1.8 Hz, 1H), 7.13 (d, J = 8.8 Hz, 2H), 7.11 - 7.15 (m, 1H), 7.08 (dd, J = 11.4, 8.2 Hz, 1H), 7.02 (t, J = 2.2 Hz, 1H), 6.76 - 6.80 (m, 1H), 6.67 (dd, J = 5.6, 2.3 Hz, 1H), 3.38 (s, 4H), 3.14 - 3.20 (m, 2H), 2.65 (t, J = 7.3 Hz, 2H), 2.25 (s, 3H), 1.56 (quin, J = 7.0 Hz, 2H)

LR MS (ES-): 617 (M-H)

18572 CIP PCT (AP)

Example 215



dimethyl 2,2'-[(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)imino]diacetate

To a stirred suspension of N-(2-aminoethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (120mg, 0.24mmol) in 10ml of anhydrous THF were added N,N-diisopropylethylamine (1ml, 5.6mmol) and methyl bromoacetate (300mg, 2.0mmol). The mixture was heated at 55°C for 2 hours and poured into 100ml of water with vigorous stirring. The precipitates were filtered and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 3~4% of MeOH in $CHCl_3$ to afford dimethyl 2,2'-[(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)imino]diacetate as white solid. Yield: 110mg, 71%.


^{1}H NMR (DMSO-d_6): 11.80 (t, J = 2.9 Hz, 1H), 9.05 (s, 1H), 8.94 (d, J = 2.3 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.22 (t, J = 9.1 Hz, 1H), 7.97 - 8.00 (m, 1H), 7.73 (t, J = 5.4 Hz, 1H), 7.32 (dd, J = 3.1, 1.6 Hz, 1H), 7.26 (dd, J = 11.7, 2.9 Hz, 1H), 7.17 (d, J = 2.3 Hz, 1H), 7.09 (dd, J = 11.4, 8.2 Hz, 1H), 7.04 - 7.06 (m, 1H), 7.02 (dt, J = 9.1, 1.5 Hz, 1H), 6.77 - 6.82 (m, 1H), 6.74 (dd, J = 5.9, 2.3 Hz, 1H), 3.56 (s, 6H), 3.54 (s, 4H), 3.21 (q, J = 6.3 Hz, 2H), 2.75 (t, J = 6.7 Hz, 2H), 2.25 (s, 3H)

LR MS (ES+): 673 (M+Na+)

LR MS (ES-): 649 (M-H)

18572 CIP PCT (AP)

Example 216



tert-butyl (2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate

A mixture of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (300mg, 0.65mmol), HATU (296mg, 0.78mmol) and *N,N*-diisopropylethylamine (185mg, 1.43mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of *tert*-butyl (2-aminoethyl)carbamate (125mg, 0.78mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. 1M HCl was added dropwise until pH=5. The precipitates were filtered, washed with water and dried *in vacuo* to give tert-butyl (2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate as white solid. Yield: 350mg, 89%.

^{1}H NMR (DMSO-d_6): 11.88 (br. s., 1H), 9.07 (d, J = 1.5 Hz, 1H), 8.95 (d, J = 2.6 Hz, 1H), 8.40 (d, J = 5.9 Hz, 1H), 8.25 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.3 Hz, 1H), 7.84 - 7.90 (m, 1H), 7.38 (br. s., 1H), 7.26 - 7.30 (m, 1H), 7.20 (br. s., 1H), 7.11 (br. s., 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.03 (dd, J = 8.8, 1.8 Hz, 1H), 6.82 (t, J = 5.7 Hz, 1H), 6.77 - 6.81 (m, 2H), 3.16 - 3.20 (m, 2H), 3.02 (q, J = 6.4 Hz, 2H), 2.25 (s, 3H), 1.34 (s, 9H)

LR MS (ES+): 629 (M+Na+)


LR MS (ES-): 605 (M-H)

The following Example 217 was prepared using the experiment procedure described in Example 207, but with the appropriate reagent, reaction conditions and reactant substitutions that will be

18572 CIP PCT (AP)

readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 217




methyl rel-(2R,4S)-1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)-4-hydroxypyrrolidine-2-carboxylate

^{1}H NMR (DMSO-d_6): 11.78 (br. s., 1H), 9.05 (s, 1H), 8.94 (d, J = 2.1 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.22 (t, J = 9.1 Hz, 1H), 7.97 - 8.00 (m, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.30 - 7.34 (m, 1H), 7.26 (dd, J = 11.7, 2.9 Hz, 1H), 7.17 (d, J = 2.1 Hz, 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.05 - 7.07 (m, 1H), 7.01 (dt, J = 9.0, 1.5 Hz, 1H), 6.76 - 6.82 (m, 1H), 6.73 (dd, J = 5.7, 2.5 Hz, 1H), 4.84 (d, J = 4.4 Hz, 1H), 4.14 - 4.21 (m, 1H), 3.57 (s, 3H), 3.33 (t, J = 7.6 Hz, 1H), 3.12 - 3.23 (m, 3H), 2.57 - 2.65 (m, 1H), 2.36 - 2.42 (m, 1H), 2.25 (s, 3H), 2.20 (dd, J = 9.7, 4.4 Hz, 1H), 1.93 (dt, J = 12.8, 7.2 Hz, 1H), 1.79 - 1.88 (m, 1H), 1.49 - 1.59 (m, 2H)

LR MS (ES+): 649 (MH+)
LR MS (ES-): 647 (M-H)

Example 218

18572 CIP PCT (AP)



{4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetic acid


To a stirred solution of ethyl {4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetate (175mg, 0.28mmol) in MeOH (8ml) was added 1M NaOH solution (1ml, 1mmol). The mixture was stirred at room temperature for 16 hours and poured into 50ml of water. 1M HCl was added dropwise with vigorous stirring until pH = 7. The precipitates were filtered, washed with water and dried *in vacuo* to give {4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetic acid as white solid. Yield: 160mg, 96%.

^{1}H NMR (DMSO-d_6): 11.87 (br. s., 1H), 9.05 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 2.1 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.21 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.8, 1.6 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.24 (dd, J = 11.7, 2.6 Hz, 1H), 7.13 (dd, J = 2.9, 1.8 Hz, 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.00 (dd, J = 9.0, 1.6 Hz, 1H), 6.93 (dd, J = 2.5, 1.9 Hz, 1H), 6.76 - 6.82 (m, 1H), 6.68 (dd, J = 5.7, 2.5 Hz, 1H), 3.61 (br. s., 4H), 3.15 (s, 2H), 2.53 (t, J = 4.8 Hz, 4H), 2.25 (s, 3H)

LR MS (ES-): 589 (M-H)

18572 CIP PCT (AP)

Example 219



ethyl {4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetate

A mixture of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (300mg, 0.65mmol), HATU (296mg, 0.78mmol) and N,N-diisopropylethylamine (185mg, 1.43mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of ethyl piperazinoacetate (168mg, 0.98mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried to give to the crude, which was purified by silica gel chromatography eluting with 5~8% of methanol in chloroform to afford ethyl {4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetate as white solid. Yield: 250mg, 63%.


^{1}H NMR (DMSO-d_6): 11.86 (br. s., 1H), 9.04 (d, J = 2.3 Hz, 1H), 8.93 (d, J = 2.6 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.21 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.3 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.24 (dd, J = 11.7, 2.6 Hz, 1H), 7.12 (dd, J = 3.2, 1.8 Hz, 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.00 (ddd, J = 8.9, 2.8, 1.2 Hz, 1H), 6.92 (dd, J = 2.5, 1.9 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.60 (br. s., 4H), 3.23 (s, 2H), 2.48 - 2.52 (m, 4H), 2.25 (s, 3H), 1.16 (t, J = 7.0 Hz, 3H)

LR MS (ES+): 641 (M+Na+)

18572 CIP PCT (AP)

LR MS (ES-): 617 (M-H)

Example 220



1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid

To a stirred suspension of methyl 1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylate (100mg, 0.16mmol) in 1ml of MeOH was added 0.2N NaOH solution (2ml, 0.4mmol). The mixture was heated at 50°C for 16 hours and cooled to room temperature. 1M HCl was added dropwise with vigorous stirring until pH = 7. The precipitates were filtered, washed with water and dried *in vacuo* to give 1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid as white solid. Yield: 72mg, 73%.


^{1}H NMR (DMSO-d_6): 11.83 (t, J = 2.9 Hz, 1H), 9.14 (d, J = 1.8 Hz, 1H), 9.02 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.21 (t, J = 9.1 Hz, 1H), 7.93 - 8.00 (m, 2H), 7.35 (dd, J = 3.1, 1.6 Hz, 1H), 7.26 (dd, J = 11.7, 2.6 Hz, 1H), 7.16 (d, J = 2.6 Hz, 1H), 7.08 (dd, J = 11.2, 8.2 Hz, 1H), 7.05 - 7.07 (m, 1H), 7.01 (dd, J = 9.0, 1.9 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.74 (dd, J = 5.7, 2.5 Hz, 1H), 3.46 - 3.52 (m, 2H), 3.25 (td, J = 13.3, 6.6 Hz, 1H), 3.15 - 3.22 (m, 1H), 3.04 (ddd, J = 12.4, 9.0, 6.5 Hz, 1H), 2.89 (ddd, J = 12.5, 9.1, 6.6 Hz, 1H), 2.79 (td, J = 10.3, 7.0 Hz, 1H), 2.25 (s, 3H), 2.07 - 2.17 (m, 1H), 1.87 - 1.94 (m, 1H), 1.79 - 1.87 (m, 1H), 1.70 - 1.79 (m, 2H), 1.58 - 1.69 (m, 1H)

LR MS (ES+): 619 (MH+)

LR MS (ES-): 617 (M-H)

18572 CIP PCT (AP)

Example 221




1-(2-fluoro-5-methylphenyl)-3-[2-fluoro-4-({2-[4-(piperazin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]urea

To a stirred solution of tert-butyl 4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazine-1-carboxylate (200mg, 0.32mmol) in 10ml of methylene chloride was added 3ml of TFA. The mixture was stirred at room temperature for 30 minutes, and evaporated to dryness under reduced pressure. The residue was re-dissolved in 5ml of methanol and poured into 100ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added until pH=9. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 12% methanol in chloroform to give 1-(2-fluoro-5-methylphenyl)-3-[2-fluoro-4-({2-[4-(piperazin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]urea as white solid. Yield: 145mg, 86%

^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 9.05 (s, 1H), 8.94 (s, 1H), 8.37 (d, J = 5.9 Hz, 1H), 8.21 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.3 Hz, 1H), 7.36 (d, 1H), 7.23 (dd, J = 11.7, 2.9 Hz, 1H), 7.10 (s, 1H), 7.06 - 7.10 (m, 1H), 6.99 (dd, J = 8.7, 1.6 Hz, 1H), 6.90 (t, J = 2.2 Hz, 1H), 6.79 (dt, J = 5.5, 2.7 Hz, 1H), 6.68 (dd, J = 5.7, 2.5 Hz, 1H), 3.42 - 3.56 (m, 4H), 2.61 - 2.70 (m, 4H), 2.25 (s, 3H)

Example 222

18572 CIP PCT (AP)




N-(2-aminoethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

To a stirred suspension of tert-butyl (2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate (300mg, 0.49mmol) in 10ml of methylene chloride was added 3ml of trifluoroacetic acid. The mixture was stirred at room temperature for 30 minutes and evaporated to dryness under reduced pressure. The residue was re-dissolved in MeOH (5ml) and poured into 100ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added until pH = 8~9. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(2-aminoethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as beige solid. Yield: 200mg, 80%.

LR MS (ES+): 507 (M+Na+)

LR MS (ES-): 505 (M-H)

Example 223




N-(3-aminopropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)

To a stirred suspension of tert-butyl (3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate (450mg, 0.72mmol) in 10ml of methylene chloride was added 5ml of trifluoroacetic acid. The mixture was stirred at room temperature for 20 minutes and evaporated to dryness under reduced pressure. The residue was re-dissolved in MeOH (5ml) and poured into 100ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added until pH = 8~9. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(3-aminopropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as grey solid. Yield: 320mg, 85%.

LR MS (ES+): 521 (MH+)

Example 224



tert-butyl 4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazine-1-carboxylate

To a stirred solution of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (300mg, 0.65mmol) in 10ml of anhydrous DMF were added HATU (296mg, 0.78mmol) and *N,N*-diisopropylethylamine (185mg, 1.43mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of tert-butyl 1-piperazinecarboxylate (182mg, 0.98mmol).


18572 CIP PCT (AP)

The mixture was stirred for another 10 minutes and poured into 100ml of water. 1M HCl was added slowly until pH=5. The precipitates were filtered, washed with water and dried in vacuo to give tert-butyl 4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazine-1-carboxylate as white solid. Yield: 290mg, 84%.

^{1}H NMR (acetone): 11.10 (br. s., 1H), 8.52 (d, J = 3.2 Hz, 1H), 8.38 - 8.44 (m, 3H), 8.15 (dd, J = 7.9, 2.3 Hz, 1H), 7.37 (d, J = 2.3 Hz, 1H), 7.31 (dd, J = 3.2, 1.8 Hz, 1H), 7.12 (dd, J = 11.7, 2.9 Hz, 1H), 6.99 - 7.06 (m, 3H), 6.81 - 6.85 (m, 1H), 6.79 (dd, J = 5.9, 2.6 Hz, 1H), 3.64 - 3.71 (m, 4H), 3.41 - 3.47 (m, 4H), 2.31 (s, 3H), 1.44 (s, 9H)

LR MS (ES+): 655 (M+Na+)
LR MS (ES-): 631 (M-H)

Example 225



5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide


To a stirred solution of N-(3,3-diethoxypropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (240mg, 0.40mmol) in 10ml of THF, was added 2M HCl (1ml, 2mmol). The mixture was stirred at room temperature for 1 hour, and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried in vacuo to give 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide as brown solid. Yield: 186mg, 89%.

LR MS (ES+): 542 (M+Na+)

18572 CIP PCT (AP)

LR MS (ES-): 518 (M-H)

Example 226



5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide

To a stirred solution of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (200mg, 0.43mmol) in 10ml of anhydrous DMF were added HATU (198mg, 0.52mmol) and *N,N*-diisopropylethylamine (166mg, 1.3mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of N-(3-aminopropyl)pyrrolidine (110mg, 0.86mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give the crude which was purified by silica gel chromatography eluting with 10~20% of methanol in chloroform to give 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 160mg, 65%.

^{1}H NMR (DMSO-d_6): 11.78 (t, J = 2.9 Hz, 1H), 9.06 (dd, J = 2.1, 0.6 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.6, 2.1 Hz, 1H), 7.89 (t, J = 5.7 Hz, 1H), 7.32 (dd, J = 3.2, 1.8 Hz, 1H), 7.26 (dd, J = 11.9, 2.8 Hz, 1H), 7.16 (d, J = 2.6 Hz, 1H), 7.09 (dd, J = 11.4, 8.2 Hz, 1H), 7.03 - 7.05 (m, 1H), 7.02 (ddd, J = 9.0, 2.9, 1.0 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.74 (dd, J = 5.9, 2.3 Hz, 1H), 3.14 - 3.22 (m, 2H), 2.40 (br. s., 6H), 2.25 (s, 3H), 1.58 - 1.67 (m, 6H)


LR MS (ES+): 575 (MH+)

LR MS (ES-): 573 (M-H)

18572 CIP PCT (AP)

The following Example 232 was prepared using the experiment procedure described in Example 234, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 227



2-methoxyethyl 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate


^{1}H NMR (DMSO-d_6): 12.12 (t, J = 3.1 Hz, 1H), 9.05 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 2.3 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.22 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 8.2, 2.1 Hz, 1H), 7.41 (dd, J = 3.4, 1.6 Hz, 1H), 7.39 (d, J = 2.3 Hz, 1H), 7.25 (dd, J = 11.7, 2.6 Hz, 1H), 7.10 (d, J = 2.3 Hz, 1H), 7.09 (dd, J = 12.0, 9.1 Hz, 1H), 7.00 (ddd, J = 9.2, 2.7, 1.0 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.73 (dd, J = 5.7, 2.5 Hz, 1H), 4.23 - 4.26 (m, 2H), 3.55 - 3.59 (m, 2H), 3.27 (s, 3H), 2.25 (s, 3H)

LR MS (ES+): 545 (M+Na+)
LR MS (ES-): 521 (M-H)

The following Example 228 was prepared using the experiment procedure described in Example 207, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 228

18572 CIP PCT (AP)




methyl 1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylate

^{1}H NMR (DMSO-d_6): 11.78 (t, J = 3.1 Hz, 1H), 9.05 (d, J = 2.6 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.9 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.6 Hz, 1H), 7.84 (t, J = 5.7 Hz, 1H), 7.32 (dd, J = 2.9, 1.8 Hz, 1H), 7.26 (dd, J = 11.7, 2.9 Hz, 1H), 7.15 (d, J = 2.3 Hz, 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.04 - 7.05 (m, 1H), 7.01 (ddd, J = 9.0, 2.8, 1.2 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.74 (dd, J = 5.7, 2.5 Hz, 1H), 3.57 (s, 3H), 3.16 - 3.21 (m, 2H), 3.14 (dd, J = 9.0, 5.4 Hz, 1H), 2.94 - 3.02 (m, 1H), 2.62 (dt, J = 11.7, 7.6 Hz, 1H), 2.37 (dt, J = 12.3, 6.3 Hz, 1H), 2.26 - 2.32 (m, 1H), 2.25 (s, 3H), 1.94 - 2.05 (m, 1H), 1.67 - 1.78 (m, 3H), 1.57 (quin, J = 7.0 Hz, 2H)

LR MS (ES+): 633 (MH+)
LR MS (ES-): 631 (M-H)

Example 229



3-morpholin-4-ylpropyl 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate


18572 CIP PCT (AP)

To a stirred suspension of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (200mg, 0.43mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 124mg, 0.65mmol) in 10ml of anhydrous tetrahydrofuran were added N-(3-hydroxypropyl)morpholine (125mg, 0.86mmol) and 4-dimethylaminopyridine (10mg, 0.08mmol). The mixture was heated at 60°C for 16 hours, cooled to room temperature and evaporated to dryness. The residue was purified by silica gel chromatography eluting with 3~5% of methanol in chloroform to afford 3-morpholin-4-ylpropyl 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate as white solid. Yield: 90mg, 35%.

^{1}H NMR (DMSO-d_6): 12.10 (t, J = 3.1 Hz, 1H), 9.05 (d, J = 2.6 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.39 (d, J = 5.9 Hz, 1H), 8.22 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.3 Hz, 1H), 7.41 (dd, J = 3.2, 1.5 Hz, 1H), 7.39 (d, J = 2.3 Hz, 1H), 7.24 (dd, J = 11.7, 2.6 Hz, 1H), 7.07 - 7.11 (m, 2H), 7.00 (dd, J = 8.9, 2.8 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.72 (dd, J = 5.7, 2.5 Hz, 1H), 4.15 (t, J = 6.6 Hz, 2H), 3.53 (t, J = 4.7 Hz, 4H), 2.35 (t, J = 7.2 Hz, 2H), 2.32 (br. s., 4H), 2.25 (s, 3H), 1.78 (quin, J = 6.9 Hz, 2H)

LR MS (ES+): 592 (MH+)
LR MS (ES-): 590 (M-H)

Example 230



dimethyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate


18572 CIP PCT (AP)

To a stirred solution of 5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (150mg, 0.34mmol) in 10ml of anhydrous DMF were added HATU (156mg, 0.41mmol) and *N,N*-diisopropylethylamine (175mg, 1.36mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of L-glutamic acid dimethyl ester hydrochloride (108mg, 0.51mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 3~5% methanol in chloroform to give dimethyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate as white solid. Yield: 120mg, 59%.

^{1}H NMR (DMSO-d_6): 11.87 (t, J = 2.9 Hz, 1H), 8.96 (s, 1H), 8.56 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.20 (t, J = 9.1 Hz, 1H), 8.11 (d, J = 7.6 Hz, 1H), 7.43 (dd, J = 3.1, 1.9 Hz, 1H), 7.27 (s, 1H), 7.25 (dd, J = 11.7, 2.9 Hz, 1H), 7.19 - 7.23 (m, 2H), 7.12 - 7.17 (m, 2H), 7.01 (dd, J = 8.1, 2.5 Hz, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.73 (dd, J = 5.7, 2.5 Hz, 1H), 4.37 (ddd, J = 9.6, 7.6, 5.1 Hz, 1H), 3.59 (s, 3H), 3.55 (s, 3H), 2.40 (t, J = 7.5 Hz, 2H), 2.26 (s, 3H), 1.98 - 2.10 (m, 1H), 1.86 - 1.97 (m, 1H)

LR MS (ES+): 626 (M+Na+)
LR MS (ES-): 602 (M-H)

Example 231



ethyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate

18572 CIP PCT (AP)


To a stirred solution of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (200mg, 0.43mmol) in 10ml of anhydrous DMF were added HATU (179mg, 0.47mmol) and *N,N*-diisopropylethylamine (166mg, 1.29mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of β-alanine ethyl ester hydrochloride (100mg, 0.65mmol). The mixture was stirred for another 10 minutes and poured into 100ml of water with vigorous stirring. 1M HCl was added slowly until pH=5. The precipitates were filtered, washed with water and dried in vacuo to give ethyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate as white solid. Yield: 200mg, 82%.

^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 9.06 (d, J = 2.1 Hz, 1H), 8.94 (d, J = 2.6 Hz, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.98 (dd, J = 7.9, 2.3 Hz, 1H), 7.93 (t, J = 5.7 Hz, 1H), 7.35 (br. s., 1H), 7.26 (dd, J = 11.7, 2.9 Hz, 1H), 7.17 (d, J = 2.6 Hz, 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.06 - 7.08 (m, 1H), 7.02 (dd, J = 8.7, 2.8 Hz, 1H), 6.77 - 6.81 (m, 1H), 6.74 (dd, J = 5.7, 2.5 Hz, 1H), 4.03 (q, 2H), 3.35 - 3.39 (m, 2H), 2.49 (t, J = 7.04 Hz, 2H), 2.25 (s, 3H), 1.14 (t, J = 7.0 Hz, 3H)

LR MS (ES+): 564 (MH+)

LR MS (ES-): 562 (M-H)

Example 232



18572 CIP PCT (AP)


dimethyl 2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate

To a stirred suspension of N-(3-aminopropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (200mg, 0.40mmol) and N,N-diisopropylethylamine (0.5ml, 2.8mmol) in 10ml of anhydrous THF was added methyl bromoacetate (200mg, 1.30mmol). The mixture was heated at 60°C for 16 hours and poured into 100ml of water with vigorous stirring. The precipitates were filtered and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 5% of MeOH in $CHCl_3$ to afford dimethyl 2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate as white solid. Yield: 210mg, 82%.

^{1}H NMR (DMSO-d_6): 11.77 (t, J = 2.9 Hz, 1H), 9.14 (s, 1H), 8.46 (d, J = 2.9 Hz, 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.96 (dd, J = 7.9, 2.3 Hz, 1H), 7.79 (t, J = 5.7 Hz, 1H), 7.52 - 7.56 (m, 2H), 7.32 (dd, J = 3.1, 1.6 Hz, 1H), 7.11 - 7.15 (m, 3H), 7.08 (dd, J = 11.4, 8.2 Hz, 1H), 7.02 (dd, J = 2.3, 1.8 Hz, 1H), 6.76 - 6.80 (m, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 3.56 (s, 6H), 3.48 (s, 4H), 3.12 - 3.20 (m, 2H), 2.63 (t, J = 7.0 Hz, 2H), 2.25 (s, 3H), 1.54 (quin, J = 7.0 Hz, 2H)

LR MS (ES+): 669 (M+Na+)
LR MS (ES-): 645 (M-H)

Example 233



18572 CIP PCT (AP)

2-methoxyethyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate

To a stirred solution of 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoic acid (300mg, 0.56mmol) in 10ml of anhydrous DMF were added HATU (255mg, 0.67mmol) and *N,N*-diisopropylethylamine (217mg, 1.68mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of 2-methoxyethanol (0.50ml, 6.3mmol). The mixture was heated at 66°C for 1 hour, and poured into 100ml of water with vigorous stirring. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with ethyl acetate to give 2-methoxyethyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate as white solid. Yield: 215mg, 65%.


^{1}H NMR (DMSO-d_6): 11.78 (t, J = 3.1 Hz, 1H), 9.14 (s, 1H), 8.46 (d, J = 2.9 Hz, 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.96 (dd, J = 7.9, 2.3 Hz, 1H), 7.85 (t, J = 5.9 Hz, 1H), 7.52 - 7.56 (m, 2H), 7.33 (dd, J = 3.2, 1.8 Hz, 1H), 7.11 - 7.15 (m, 3H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 7.03 (dd, J = 2.5, 1.9 Hz, 1H), 6.76 - 6.80 (m, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 4.07 - 4.10 (m, 2H), 3.45 - 3.49 (m, 2H), 3.21 (s, 3H), 3.13 - 3.19 (m, 2H), 2.32 (t, J = 7.5 Hz, 2H), 2.25 (s, 3H), 1.70 (quin, J = 7.2 Hz, 2H)

LR MS (ES+): 612 (M+Na+)
LR MS (ES-): 588 (M-H)

The following Example 234 was prepared using the experiment procedure described in Example 233, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 234

18572 CIP PCT (AP)




3-hydroxy-2,2-bis(hydroxymethyl)propyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate

^{1}H NMR (DMSO-d_6): 11.79 (t, J = 2.9 Hz, 1H), 9.14 (s, 1H), 8.46 (d, J = 2.6 Hz, 1H), 8.35 (d, J = 5.9 Hz, 1H), 7.96 (dd, J = 7.6, 2.3 Hz, 1H), 7.88 (t, J = 5.7 Hz, 1H), 7.52 - 7.56 (m, 2H), 7.35 (dd, J = 3.2, 1.8 Hz, 1H), 7.12 - 7.15 (m, 3H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 7.04 (dd, J = 2.5, 1.9 Hz, 1H), 6.76 - 6.80 (m, 1H), 6.68 (dd, J = 5.6, 2.3 Hz, 1H), 4.33 (t, J = 5.4 Hz, 3H), 3.89 (s, 2H), 3.33 (d, J = 5.3 Hz, 6H), 3.17 (q, J = 6.7 Hz, 2H), 2.29 (t, J = 7.5 Hz, 2H), 2.25 (s, 3H), 1.70 (quin, J = 7.2 Hz, 2H)

LR MS (ES+): 672 (M+Na+)

LR MS (ES-): 648 (M-H)

Example 235




N-[3-(4-hydroxypiperidin-1-yl)propyl]-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

To a stirred solution of 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide (150mg, 0.31mmol) in 10ml of anhydrous DMF were added 4-hydroxypiperidine (59mg, 0.58mmol) and acetic acid (10mg, 0.17mmol). The mixture was stirred at room temperature for 60 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (0.60ml, 0.60mmol). Stirring was continued for another 60 minutes and the mixture was poured into 50ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel flash chromatography eluting with 20% of MeOH in $CHCl_3$ to give N-[3-(4-hydroxypiperidin-1-yl)propyl]-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as off-white solid. Yield: 102mg, 58%.

LR MS (ES+): 569 (MH+)
LR MS (ES-): 567 (M-H)

Example 236



5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide


To a stirred solution of N-(3-hydroxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (1.0g, 2.06mmol) in 20ml of anhydrous DMF was added Dess-Martin periodinane (1.22g, 2.88mmol). The mixture was stirred at room temperature under nitrogen for 80 minutes and poured into 100ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added until pH=9. The precipitates were filtered, washed with water and dried in vacuo to give the crude 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-

carboxamide as light brown solid, which was used in the next step without further purification. Yield: 1.0g, 100%.

LR MS (ES+): 484 (MH+)

LR MS (ES-): 482 (M-H)

Example 237



N-(3-hydroxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

To a stirred solution of 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (1.00g, 2.34mmol) in 20ml of anhydrous DMF were added HATU (1.07g, 2.80mmol) and *N,N*-diisopropylethylamine (604mg, 4.68mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of 3-amino-1-propanol (263mg, 3.51mmol). The mixture was stirred for another 5 minutes and poured into 200ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried in vacuo to give N-(3-hydroxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as white solid. Yield: 1.10g, 97%.


^{1}H NMR (DMSO-d_6): 12.02 (br. s., 1H), 8.82 (s, 1H), 8.62 (s, 1H), 8.41 (d, J = 6.2 Hz, 1H), 7.85 - 7.95 (m, 1H), 7.53 - 7.61 (m, 2H), 7.45 - 7.51 (m, 1H), 7.25 - 7.31 (m, 2H), 7.19 - 7.25 (m, 2H), 7.09 - 7.19 (m, 3H), 6.81 - 6.88 (m, 1H), 6.78 (d, J = 7.3 Hz, 1H), 3.42 (t, J = 6.3 Hz, 2H), 3.22 (q, J = 6.5 Hz, 2H), 2.26 (s, 3H), 1.61 (quin, J = 6.7 Hz, 2H)

LR MS (ES+): 486 (M+Na+)

LR MS (ES-): 484 (M-H)

18572 CIP PCT (AP)

Example 238



1-[4-({2-[4-(hydrazinocarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(3-methylphenyl)urea

To a stirred solution of 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (100mg, 0.23mmol) in 10ml of anhydrous DMF were added HATU (105mg, 0.28mmol) and *N,N*-diisopropylethylamine (89mg, 0.69mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of hydrazine monohydrate (0.25ml, 5.2mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give 1-[4-({2-[4-(hydrazinocarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(3-methylphenyl)urea as white solid. Yield: 98mg, 95%.


^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 9.22 - 9.36 (m, 1H), 8.74 (s, 1H), 8.57 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.51 - 7.56 (m, 2H), 7.36 (br. s., 1H), 7.27 (s, 1H), 7.19 - 7.23 (m, 1H), 7.09 - 7.15 (m, 4H), 7.02 - 7.06 (m, 1H), 6.77 (d, J = 7.9 Hz, 1H), 6.67 (dd, J = 5.9, 2.3 Hz, 1H), 2.25 (s, 3H)

LR MS (ES+): 465 (M+Na+)

LR MS (ES-): 441 (M-H)

Example 239

18572 CIP PCT (AP)



5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide


To a stirred solution of 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (100mg, 0.23mmol) in 10ml of anhydrous DMF were added HATU (106mg, 0.28mmol) and *N,N*-diisopropylethylamine (90mg, 0.70mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of N-(3-aminopropyl)morpholine (68mg, 0.47mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 110mg, 85%.

^{1}H NMR (DMSO-d_6): 11.77 (t, J = 2.9 Hz, 1H), 8.74 (s, 1H), 8.57 (s, 1H), 8.35 (d, J = 5.9 Hz, 1H), 7.83 (t, J = 5.7 Hz, 1H), 7.51 - 7.55 (m, 2H), 7.32 (dd, J = 3.1, 1.6 Hz, 1H), 7.27 (s, 1H), 7.21 (d, J = 8.5 Hz, 1H), 7.10 - 7.15 (m, 4H), 7.01 (dd, J = 2.5, 1.9 Hz, 1H), 6.77 (d, J = 7.3 Hz, 1H), 6.67 (dd, J = 5.6, 2.3 Hz, 1H), 3.53 (t, J = 4.7 Hz, 4H), 3.14 - 3.19 (m, 2H), 2.26 - 2.33 (m, 6H), 2.25 (s, 3H), 1.60 (quin, J = 7.1 Hz, 2H)

LR MS (ES+): 555 (MH+)
LR MS (ES-): 553 (M-H)

18572 CIP PCT (AP)

Example 240



3-hydroxy-2,2-bis(hydroxymethyl)propyl 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate

To a stirred suspension of 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (150mg, 0.35mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 102mg, 0.53mmol) in 10ml of anhydrous tetrahydrofuran were added pentaerythritol (143mg, 1.05mmol) and 4-dimethylaminopyridine (10mg, 0.08mmol). The mixture was heated at 60°C for 16 hours, cooled to room temperature and evaporated to dryness. The residue was purified by C-18 reverse phase chromatography eluting with a gradient of 10~50% of acetonitrile in water to afford 3-hydroxy-2,2-bis(hydroxymethyl)propyl 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate as white solid. Yield: 46mg, 24%.

^{1}H NMR (DMSO-d_6): 12.08 (t, J = 2.9 Hz, 1H), 8.73 (s, 1H), 8.57 (s, 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.50 - 7.56 (m, 2H), 7.40 (dd, J = 3.2, 1.8 Hz, 1H), 7.38 (d, J = 2.3 Hz, 1H), 7.27 (s, 1H), 7.21 (d, J = 8.5 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.11 (d, J = 9.1 Hz, 2H), 7.07 - 7.09 (m, 1H), 6.77 (d, J = 7.6 Hz, 1H), 6.62 (dd, J = 5.9, 2.3 Hz, 1H), 4.34 (t, J = 5.3 Hz, 3H), 4.03 (s, 2H), 3.42 (d, J = 5.3 Hz, 6H), 2.25 (s, 3H)


LR MS (ES+): 547 (MH+)

LR MS (ES-): 545 (M-H)

18572 CIP PCT (AP)

The following Example 241 was prepared using the experiment procedure described in Example 238, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 241




1-(2-fluoro-5-methylphenyl)-3-[4-({2-[4-(hydrazinocarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]urea

^{1}H NMR (DMSO-d_6): 11.79 (t, J = 3.1 Hz, 1H), 9.16 (s, 1H), 9.11 (t, J = 4.0 Hz, 1H), 8.47 (d, J = 2.6 Hz, 1H), 8.35 (d, J = 5.9 Hz, 1H), 7.96 (dd, J = 7.9, 2.3 Hz, 1H), 7.52 - 7.56 (m, 2H), 7.34 (dd, J = 2.9, 1.8 Hz, 1H), 7.11 - 7.15 (m, 3H), 7.08 (dd, J = 11.4, 8.2 Hz, 1H), 7.03 (dd, J = 2.5, 1.9 Hz, 1H), 6.75 - 6.81 (m, 1H), 6.67 (dd, J = 5.6, 2.3 Hz, 1H), 4.21 (d, J = 3.8 Hz, 2H), 2.25 (s, 3H)

LR MS (ES+): 483 (M+Na+)

LR MS (ES-): 459 (M-H)

Example 242



5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide

18572 CIP PCT (AP)


To a stirred solution of N-(3,3-diethoxypropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide (250mg, 0.43mmol) in 10ml of tetrahydrofuran was added 1ml of 1M HCl (1.0mmol). The mixture was stirred at room temperature for 60 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 205mg, 94%.

^{1}H NMR (DMSO-d_6): 11.83 (t, J = 3.1 Hz, 1H), 10.12 (s, 1H), 9.65 (t, J = 1.9 Hz, 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.97 - 8.01 (m, 2H), 7.95 (t, J = 5.7 Hz, 1H), 7.61 - 7.66 (m, 1H), 7.32 - 7.37 (m, 2H), 7.25 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 10.6, 8.2 Hz, 1H), 7.09 - 7.10 (m, 1H), 7.02 - 7.06 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 3.40 - 3.48 (m, 2H), 2.59 (td, J = 6.6, 2.1 Hz, 2H), 2.27 (s, 3H)

LR MS (ES-): 503 (M-H)

The following Example 248 was prepared using the experiment procedure described in Example 184, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 243



methyl (2S)-1-{3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}pyrrolidine-2-carboxylate


18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 11.82 (br. s., 1H), 10.13 (s, 1H), 8.42 (d, J = 5.9 Hz, 1H), 7.94 - 8.04 (m, 2H), 7.86 (t, J = 5.7 Hz, 1H), 7.58 - 7.69 (m, 1H), 7.32 - 7.38 (m, 2H), 7.25 (d, J = 2.3 Hz, 1H), 7.11 - 7.19 (m, 1H), 7.08 - 7.11 (m, 1H), 7.01 - 7.09 (m, 1H), 6.81 (dd, J = 5.7, 2.5 Hz, 1H), 3.58 (s, 3H), 3.11 - 3.24 (m, 3H), 2.93 - 3.05 (m, 1H), 2.56 - 2.70 (m, 1H), 2.37 - 2.45 (m, 1H), 2.30 - 2.37 (m, 1H), 2.27 (s, 3H), 1.93 - 2.09 (m, 1H), 1.65 - 1.81 (m, 3H), 1.52 - 1.65 (m, 2H)

LR MS (ES+): 618 (MH+)
LR MS (ES-): 616 (M-H)

The following Example 249 was prepared using the experiment procedure described in Example 264, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 244




5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-hydroxypropyl)-1H-pyrrole-3-carboxamide

^{1}H NMR (DMSO-d_6): 11.82 (br. s., 1H), 10.13 (s, 1H), 8.42 (d, J = 5.9 Hz, 1H), 7.95 - 8.04 (m, 2H), 7.83 (t, J = 5.7 Hz, 1H), 7.59 - 7.70 (m, 1H), 7.32 - 7.40 (m, 2H), 7.26 (d, J = 2.3 Hz, 1H), 7.12 - 7.13 (m, 1H), 7.11 - 7.19 (m, 1H), 7.01 - 7.09 (m, 1H), 6.81 (dd, J = 5.6, 2.3 Hz, 1H), 4.43 (t, J = 5.3 Hz, 1H), 3.41 (q, J = 6.2 Hz, 2H), 3.15 - 3.26 (m, 2H), 2.27 (s, 3H), 1.60 (quin, J = 6.7 Hz, 2H)

LR MS (ES+): 507 (MH+)
LR MS (ES-): 505 (M-H)


18572 CIP PCT (AP)

Example 245



ethyl 4-{N-[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]-S-methylsulfonimidoyl}butanoate

Example 246



N,N'-diethyl-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanediamide

To a stirred solution of 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioic acid (100mg, 0.17mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 83mg, 0.43mmol) in 10ml of anhydrous DMF was added 2M ethylamine solution in THF (0.43ml, 0.86mmol). The mixture was stirred at room temperature for overnight and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give the crude, which was purified by silica gel chromatography eluting with 5~8% of methanol in chloroform to afford N,N'-diethyl-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanediamide as white solid. Yield: 76mg, 69%.


18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 11.86 (t, J = 3.1 Hz, 1H), 10.12 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.96 - 8.01 (m, 2H), 7.79 - 7.83 (m, 2H), 7.75 (t, J = 5.6 Hz, 1H), 7.63 (dd, J = 10.4, 9.0 Hz, 1H), 7.46 (dd, J = 3.2, 1.8 Hz, 1H), 7.34 (dd, J = 7.2, 2.2 Hz, 1H), 7.28 (d, J = 2.3 Hz, 1H), 7.19 (dd, J = 2.5, 1.9 Hz, 1H), 7.14 (dd, J = 10.6, 8.5 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 4.20 - 4.32 (m, 1H), 3.02 - 3.08 (m, 2H), 2.97 - 3.03 (m, 2H), 2.26 (s, 3H), 2.00 - 2.15 (m, 2H), 1.86 - 1.97 (m, 1H), 1.73 - 1.85 (m, 1H), 0.98 (t, J = 7.2 Hz, 3H), 0.94 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 633 (MH+)

LR MS (ES-): 631 (M-H)

Example 247



1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid


To a stirred solution of methyl 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylate (Example 50) (68mg, 0.11mmol) in a mixture of THF/MeOH (5ml/5ml) was added 1M NaOH solution (1ml, 1mmol). The mixture was stirred at room temperature for 16 hours and poured into 30ml of water. 1M HCl was added dropwise with vigorous stirring until pH = 7. The precipitates were filtered, washed with water and dried *in vacuo* to give 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid as light reddish solid. Yield: 60mg, 91%.

18572 CIP PCT (AP)

LR MS (ES+): 601 (MH+)

LR MS (ES-): 599 (M-H)

Example 248



2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioic acid

To a stirred solution of dimethyl 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioate (320mg, 0.53mmol) in MeOH (20ml) was added 1M NaOH solution (2ml, 2mmol). The mixture was stirred at room temperature for 16 hours and poured into 100ml of water. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioic acid as white solid. Yield: 305mg, 100%.

^{1}H NMR (DMSO-d_6): 12.47 (br. s., 1H), 12.09 (br. s., 1H), 11.88 (t, J = 2.9 Hz, 1H), 10.12 (s, 1H), 8.42 (d, J = 5.9 Hz, 1H), 7.94 - 8.02 (m, 3H), 7.63 (dd, J = 10.4, 8.4 Hz, 1H), 7.46 (dd, J = 3.2, 1.8 Hz, 1H), 7.35 (dd, J = 7.3, 2.6 Hz, 1H), 7.29 (d, J = 2.6 Hz, 1H), 7.18 - 7.21 (m, 1H), 7.14 (dd, J = 10.6, 8.5 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 4.32 (ddd, J = 9.8, 7.7, 4.8 Hz, 1H), 2.30 (t, J = 7.6 Hz, 2H), 2.27 (s, 3H), 1.97 - 2.07 (m, 1H), 1.80 - 1.91 (m, 1H)


LR MS (ES+): 579 (MH+)

LR MS (ES-): 577 (M-H)

18572 CIP PCT (AP)

The following Example 249 was prepared using the experiment procedure described in Example 259, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 249




dimethyl 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioate

^{1}H NMR (DMSO-d_6): 11.94 (br. s., 1H), 10.13 (s, 1H), 8.44 (d, J = 5.9 Hz, 1H), 8.13 (d, J = 7.3 Hz, 1H), 7.95 - 8.05 (m, 2H), 7.60 - 7.69 (m, 1H), 7.49 (dd, J = 3.1, 1.6 Hz, 1H), 7.35 (dd, J = 7.5, 2.5 Hz, 1H), 7.31 (d, J = 2.3 Hz, 1H), 7.21 (t, J = 2.2 Hz, 1H), 7.10 - 7.19 (m, 1H), 7.01 - 7.09 (m, 1H), 6.84 (dd, J = 5.9, 2.3 Hz, 1H), 4.30 - 4.46 (m, 1H), 3.61 (s, 3H), 3.56 (s, 3H), 2.41 (t, J = 7.5 Hz, 2H), 2.27 (s, 3H), 1.99 - 2.13 (m, 1H), 1.84 - 1.99 (m, 1H)

LR MS (ES+): 607 (MH+)
LR MS (ES-): 605 (M-H)

Example 250



18572 CIP PCT (AP)


N-(3-aminopropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide

To a stirred suspension of tert-butyl (3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate (70mg, 0.12mmol) in 10ml of methylene chloride was added 1ml of trifluoroacetic acid. The mixture was stirred at room temperature for 2 hours and evaporated to dryness under reduced pressure. The residue was re-dissolved in MeOH (5ml) and poured into 100ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added until pH = 8~9. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(3-aminopropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide as yellow solid. Yield: 40mg, 63%.

LR MS (ES+): 503 (MH+)

LR MS (ES-): 501 (M-H)

Example 251



tert-butyl (3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate

To a stirred solution of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (100mg, 0.22mmol) in 10ml of anhydrous DMF were added HATU (100mg, 0.26mmol) and *N,N*-diisopropylethylamine (85mg, 0.66mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of N-Boc-1,3-propanediamine (57mg, 0.33mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water with vigorous stirring.


18572 CIP PCT (AP)

2M HCl was added dropwise until pH=5. The precipitates were filtered, washed with water and dried *in vacuo* to give tert-butyl (3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate as white solid. Yield: 120mg, 89%.

^{1}H NMR (DMSO-d_6): 11.79 (br. s., 1H), 9.16 (s, 1H), 8.47 (d, J = 2.6 Hz, 1H), 8.35 (d, J = 5.6 Hz, 1H), 7.96 (dd, J = 7.5, 2.2 Hz, 1H), 7.81 (t, J = 5.9 Hz, 1H), 7.51 - 7.56 (m, 2H), 7.32 (dd, J = 3.2, 1.8 Hz, 1H), 7.12 - 7.15 (m, 2H), 7.11 - 7.13 (m, 1H), 7.08 (dd, J = 11.4, 8.2 Hz, 1H), 7.01 - 7.02 (m, 1H), 6.76 - 6.80 (m, 1H), 6.75 (t, J = 6.3 Hz, 1H), 6.69 (dd, J = 5.9, 2.3 Hz, 1H), 3.14 (q, J = 6.7 Hz, 2H), 2.91 (q, J = 6.7 Hz, 2H), 2.25 (s, 3H), 1.53 (quin, J = 7.0 Hz, 2H), 1.33 (s, 9H)

LR MS (ES+): 625 (M+Na+)
LR MS (ES-): 601 (M-H)

Example 252



N-(3-aminopropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide


To a stirred suspension of tert-butyl {3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}carbamate (100mg, 0.165mmol) in 10ml of methylene chloride was added 1ml of trifluoroacetic acid. The mixture was stirred at room temperature for 60 minutes and evaporated to dryness under reduced pressure. The residue was re-dissolved in MeOH (5ml) and poured into 100ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added until pH = 8~9. The precipitates were filtered, washed with water and dried *in vacuo* to give N-(3-aminopropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-

methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide as grey solid. Yield: 70mg, 84%.

LR MS (ES+): 506 (MH+)
LR MS (ES-): 504 (M-H)

The following Example 253 was prepared using the experiment procedure described in Example 254, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

Example 253




tert-butyl {3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}carbamate

^{1}H NMR (DMSO-d_6): 11.82 (t, J = 2.9 Hz, 1H), 10.12 (s, 1H), 8.41 (d, J = 5.9 Hz, 1H), 7.96 - 8.01 (m, 2H), 7.81 (t, J = 5.9 Hz, 1H), 7.60 - 7.66 (m, 1H), 7.36 (dd, J = 3.2, 1.8 Hz, 1H), 7.34 (dd, J = 7.2, 2.2 Hz, 1H), 7.25 (d, J = 2.6 Hz, 1H), 7.14 (dd, J = 10.6, 8.5 Hz, 1H), 7.11 (dd, J = 2.6, 1.8 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 6.75 (t, J = 6.0 Hz, 1H), 3.12 - 3.18 (m, 2H), 2.87 - 2.96 (m, 2H), 2.26 (s, 3H), 1.54 (quin, J = 7.0 Hz, 2H), 1.34 (s, 9H)

LR MS (ES+): 606 (MH+)
LR MS (ES-): 604 (M-H)

Example 254

18572 CIP PCT (AP)



5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide

To a stirred solution of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (100mg, 0.22mmol) in 10ml of anhydrous DMF were added HATU (100mg, 0.26mmol) and *N,N*-diisopropylethylamine (85mg, 0.66mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of N-(3-aminopropyl)morpholine (48mg, 0.33mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. The precipitates were filtered, washed with water and dried in vacuo to give 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide as white solid. Yield: 122mg, 95%.


^{1}H NMR (DMSO-d_6): 11.81 (br. s., 1H), 10.12 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.96 - 8.01 (m, 2H), 7.84 (br. s., 1H), 7.61 - 7.65 (m, 1H), 7.36 (dd, 1H), 7.34 (dd, J = 7.3, 2.3 Hz, 1H), 7.25 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 10.4, 8.4 Hz, 1H), 7.11 (dd, J = 2.3, 1.8 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 3.54 (br. s., 4H), 3.18 (q, J = 6.6 Hz, 2H), 2.31 (br. s., 6H), 2.27 (s, 3H), 1.61 (br. s., 2H)

LR MS (ES+): 576 (MH+)

LR MS (ES-): 574 (M-H)

18572 CIP PCT (AP)

Example 255



5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid


To a stirred solution of tert-butyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate (75mg, 0.11mmol) in 5ml of methylene chloride was added 1ml of TFA. The mixture was stirred at room temperature for 90 minutes, and evaporated to dryness under reduced pressure. The residue was re-dissolved in 5ml of methanol and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried in vacuo to give 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid as white solid. Yield: 60mg, 87%.

^{1}H NMR (DMSO-d_6): 12.05 (br. s., 1H), 11.90 (br. s., 1H), 10.13 (s, 1H), 8.43 (d, J = 5.9 Hz, 1H), 7.97 - 8.02 (m, 2H), 7.83 (t, J = 5.6 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.64 (dd, J = 9.7, 8.8 Hz, 1H), 7.50 (br. s., 1H), 7.34 (dd, J = 7.5, 1.9 Hz, 1H), 7.31 (d, J = 2.1 Hz, 1H), 7.23 (br. s., 1H), 7.14 (dd, J = 10.3, 8.5 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.83 (d, J = 5.3 Hz, 1H), 4.32 (td, J = 8.7, 5.3 Hz, 1H), 3.00 - 3.09 (m, 2H), 2.27 (s, 3H), 2.18 - 2.25 (m, 2H), 1.88 - 1.99 (m, 1H), 1.74 - 1.86 (m, 1H), 0.97 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 606 (MH+)
LR MS (ES-): 604 (M-H)

18572 CIP PCT (AP)

Example 256



tert-butyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate

To a stirred suspension of 5-tert-butoxy-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid (150mg, 0.24mmol) in 10ml of anhydrous tetrahydrofuran were added HATU (109mg, 0.29mmol) and *N,N*-diisopropylethylamine (93mg, 0.72mmol). The mixture was heated at 60°C for 15 minutes and cooled to room temperature, followed by addition of 2M ethylamine solution in THF (0.18ml, 0.36mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water with vigorous stirring. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 3~5% methanol in chloroform to give tert-butyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate as white solid. Yield: 100mg, 64%.


^{1}H NMR (DMSO-d_6): 11.86 (br. s., 1H), 10.12 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.96 - 8.01 (m, 2H), 7.82 (t, J = 5.7 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.63 (dd, J = 10.1, 8.7 Hz, 1H), 7.48 (dd, J = 2.9, 1.8 Hz, 1H), 7.34 (dd, J = 7.3, 1.8 Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 7.19 - 7.22 (m, 1H), 7.14 (dd, J = 10.4, 8.4 Hz, 1H), 7.02 - 7.06 (m, 1H), 6.80 (dd, J = 5.6, 2.3 Hz, 1H), 4.31 (td, J = 8.7, 5.3 Hz, 1H), 2.99 - 3.10 (m, 2H), 2.26 (s, 3H), 2.17 - 2.24 (m, 2H), 1.86 - 1.96 (m, 1H), 1.72 - 1.83 (m, 1H), 1.35 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H)

18572 CIP PCT (AP)

LR MS (ES+): 662 (MH+)

LR MS (ES-): 660 (M-H)

Example 257



5-tert-butoxy-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid


To a stirred solution of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (150mg, 0.33mmol) in 10ml of anhydrous DMF were added HATU (150mg, 0.39mmol) and *N,N*-diisopropylethylamine (128mg, 0.99mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of L-Glutamic acid 5-tert-butyl ester (102mg, 0.50mmol). The mixture was heated at 60°C for 30 minutes, cooled to room temperature, and poured into 100ml of water. 2M HCl was added dropwise with vigorous stirring until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give 5-tert-butoxy-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid as white solid. Yield: 185mg, 87%.

^{1}H NMR (DMSO-d_6): 12.49 (br. s., 1H), 11.88 (br. s., 1H), 10.12 (s, 1H), 8.42 (d, J = 5.9 Hz, 1H), 7.96 - 8.02 (m, 2H), 7.95 (d, J = 7.9 Hz, 1H), 7.63 (dd, J = 10.1, 8.7 Hz, 1H), 7.46 (dd, J = 3.1, 1.6 Hz, 1H), 7.34 (dd, J = 7.3, 1.8 Hz, 1H), 7.29 (d, J = 2.6 Hz, 1H), 7.19 (dd, J = 2.6, 1.8 Hz, 1H), 7.14 (dd, J = 10.4, 8.4 Hz, 1H), 7.02 - 7.06 (m, 1H), 6.80 (dd, J = 5.6, 2.3 Hz, 1H), 4.32 (ddd, 1H), 2.28 (t, J = 7.9 Hz, 2H), 2.26 (s, 3H), 1.94 - 2.04 (m, 1H), 1.80 - 1.89 (m, 1H), 1.36 (s, 9H)

18572 CIP PCT (AP)

LR MS (ES-): 633 (M-H)

Example 258



3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid


To a stirred solution of methyl 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate (82mg, 0.15mmol) in a mixture of THF/MeOH (10ml/10ml) was added 1M NaOH solution (1ml, 1mmol). The mixture was stirred at room temperature for 2 hours and poured into 100ml of water. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid as white solid. Yield: 70mg, 88%.

^{1}H NMR (DMSO-d_6): 12.15 (br. s., 1H), 11.85 (br. s., 1H), 10.13 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 8.00 (d, J = 5.9 Hz, 1H), 7.97 - 7.99 (m, 1H), 7.91 (t, J = 5.6 Hz, 1H), 7.61 - 7.66 (m, 1H), 7.38 (br. s., 1H), 7.35 (dd, J = 7.6, 2.1 Hz, 1H), 7.26 (d, J = 2.3 Hz, 1H), 7.11 - 7.16 (m, 2H), 7.02 - 7.07 (m, 1H), 6.82 (dd, J = 5.6, 2.1 Hz, 1H), 3.32 - 3.38 (m, 2H), 2.43 (t, J = 7.0 Hz, 2H), 2.27 (s, 3H)

LR MS (ES-): 519 (M-H)

18572 CIP PCT (AP)

Example 259



methyl 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate

To a stirred solution of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (100mg, 0.22mmol) in 10ml of anhydrous DMF were added HATU (100mg, 0.26mmol) and *N,N*-diisopropylethylamine (85mg, 0.66mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of β-alanine methyl ester hydrochloride (46mg, 0.33mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. 2M HCl was added dropwise with vigorous stirring until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give methyl 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate as white solid. Yield: 110mg, 92%.


^{1}H NMR (DMSO-d_6): 11.83 (br. s., 1H), 10.12 (s, 1H), 8.41 (d, J = 5.6 Hz, 1H), 7.96 - 8.02 (m, 2H), 7.94 (t, J = 5.7 Hz, 1H), 7.63 (dd, J = 10.1, 9.0 Hz, 1H), 7.37 (dd, J = 2.9, 1.8 Hz, 1H), 7.34 (dd, J = 7.5, 1.9 Hz, 1H), 7.26 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 10.4, 8.4 Hz, 1H), 7.10 (dd, J = 2.3, 1.8 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.7, 2.5 Hz, 1H), 3.57 (s, 3H), 3.36 - 3.41 (m, 2H), 2.52 (t, J = 6.9 Hz, 2H), 2.27 (s, 3H)

LR MS (ES+): 557 (M+Na+)

LR MS (ES-): 533 (M-H)


18572 CIP PCT (AP)

Example 260



ethyl 4-{N-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]-S-methylsulfonimidoyl}butanoate

Example 261



methyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate


To a stirred suspension of 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-methoxy-5-oxopentanoic acid (260mg, 0.44mmol) in 20ml of anhydrous tetrahydrofuran were added HATU (200mg, 0.53mmol) and *N,N*-diisopropylethylamine (170mg, 1.32mmol). The mixture was heated at 60°C for 15 minutes and cooled to room temperature, followed by addition of 2M ethylamine solution in THF (0.44ml, 0.88mmol). The mixture was stirred for another 5 minutes, and poured into 100ml of water with vigorous stirring. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was purified by silica gel chromatography eluting with 2~5% methanol in

chloroform to give methyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate as white solid. Yield: 127mg, 47%.

^{1}H NMR (DMSO-d_6): 11.87 (br. s., 1H), 10.12 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 7.95 - 8.01 (m, 2H), 7.85 (t, J = 5.6 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.63 (dd, J = 10.1, 8.7 Hz, 1H), 7.48 (dd, J = 3.1, 1.6 Hz, 1H), 7.34 (dd, J = 7.5, 1.9 Hz, 1H), 7.29 (d, J = 2.6 Hz, 1H), 7.20 (dd, J = 2.5, 1.6 Hz, 1H), 7.14 (dd, J = 10.4, 8.4 Hz, 1H), 7.02 - 7.07 (m, 1H), 6.80 (dd, J = 5.9, 2.3 Hz, 1H), 4.32 (td, J = 8.7, 5.6 Hz, 1H), 3.54 (s, 3H), 2.97 - 3.10 (m, 2H), 2.29 - 2.33 (m, 2H), 2.26 (s, 3H), 1.91 - 2.01 (m, 1H), 1.78 - 1.89 (m, 1H), 0.97 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 642 (M+Na+)
LR MS (ES-): 618 (M-H)

Example 262



2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-methoxy-5-oxopentanoic acid


To a stirred solution of 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (60mg, 0.13mmol) in 10ml of anhydrous DMF were added HATU (61mg, 0.16mmol) and *N,N*-diisopropylethylamine (52mg, 0.40mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of 5-methyl L-glutamate (32mg, 0.20mmol). The mixture was heated at 60°C for 1 hour, cooled to room temperature and poured into 100ml of water with vigorous stirring. 2M HCl was added slowly until pH=4. The precipitates were filtered, washed with water and dried *in vacuo* to give 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-

methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-methoxy-5-oxopentanoic acid as white solid. Yield: 30mg, 38%.

^{1}H NMR (DMSO-d_6): 12.53 (br. s., 1H), 11.89 (br. s., 1H), 10.12 (s, 1H), 8.43 (d, J = 5.9 Hz, 1H), 7.96 - 8.01 (m, 3H), 7.63 (dd, J = 10.3, 8.5 Hz, 1H), 7.47 (dd, J = 3.1, 1.6 Hz, 1H), 7.34 (dd, J = 7.3, 2.1 Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 7.18 - 7.20 (m, 1H), 7.14 (dd, J = 10.4, 8.4 Hz, 1H), 7.01 - 7.07 (m, 1H), 6.81 (dd, J = 5.6, 2.3 Hz, 1H), 4.32 (ddd, J = 9.5, 8.0, 5.1 Hz, 1H), 3.55 (s, 3H), 2.37 - 2.41 (m, 2H), 2.26 (s, 3H), 1.99 - 2.10 (m, 1H), 1.83 - 1.95 (m, 1H)

LR MS (ES-): 591 (M-H)

Example 263



N,N'-diethyl-2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanediamide


To a stirred solution of 2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid(Example 63) (100mg, 0.17mmol) in 10ml of anhydrous DMF was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 84mg, 0.44mmol). The mixture was stirred at room temperature for 30 minutes, followed by addition of 2M ethylamine solution in THF (0.45ml, 0.90mmol). The mixture was stirred for another 16 hours, and poured into 100ml of water with vigorous stirring. 2M HCl was added dropwise until

pH=4. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel chromatography eluting with 3~5% of methanol in chloroform to afford N,N'-diethyl-2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanediamide as white solid. Yield: 60mg, 55%.

^{1}H NMR (DMSO-d_6): 11.82 (br. s., 1H), 9.14 (s, 1H), 8.46 (d, J = 2.6 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 7.96 (dd, J = 7.9, 2.1 Hz, 1H), 7.82 (d, J = 8.2 Hz, 1H), 7.80 (t, J = 5.6 Hz, 1H), 7.75 (t, J = 5.3 Hz, 1H), 7.51 - 7.56 (m, 2H), 7.42 (dd, J = 3.1, 1.6 Hz, 1H), 7.15 (d, J = 2.3 Hz, 1H), 7.12 - 7.15 (m, 2H), 7.11 (dd, J = 2.6, 1.8 Hz, 1H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.75 - 6.80 (m, 1H), 6.68 (dd, J = 5.9, 2.3 Hz, 1H), 4.25 (td, J = 8.6, 5.1 Hz, 1H), 3.02 - 3.07 (m, 2H), 2.97 - 3.02 (m, 2H), 2.25 (s, 3H), 2.00 - 2.14 (m, 2H), 1.86 - 1.95 (m, 1H), 1.74 - 1.83 (m, 1H), 0.97 (t, J = 7.2 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H)

LR MS (ES+): 652 (M+Na+)
LR MS (ES-): 628 (M-H)

Example 264



5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid


To a stirred solution of tert-butyl 5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoate (34mg, 0.055mmol) in 5ml of methylene chloride was added 2ml of TFA. The mixture was stirred at room temperature for 1 hour, and evaporated to dryness under reduced pressure. The residue

was re-dissolved in 5ml of methanol and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water and dried in vacuo to give 5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid as white solid. Yield: 26mg, 84%.

^{1}H NMR (DMSO-d_6): 12.04 (br. s., 1H), 11.85 (br. s., 1H), 10.19 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.82 (t, J = 5.7 Hz, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 1.5 Hz, 1H), 7.68 - 7.70 (m, 1H), 7.68 (d, J = 1.8 Hz, 1H), 7.45 (dd, J = 3.1, 1.6 Hz, 1H), 7.38 - 7.43 (m, 1H), 7.25 (d, J = 2.3 Hz, 1H), 7.16 (dd, J = 2.3, 1.8 Hz, 1H), 6.88 - 6.91 (m, 1H), 6.74 (dd, J = 5.6, 2.3 Hz, 1H), 6.56 (d, J = 1.5 Hz, 1H), 4.31 (td, J = 8.7, 5.3 Hz, 1H), 2.98 - 3.10 (m, 2H), 2.29 (s, 3H), 2.17 - 2.26 (m, 2H), 1.89 - 1.98 (m, 1H), 1.75 - 1.84 (m, 1H), 0.97 (t, J = 7.2 Hz, 3H)

LR MS (ES-): 558 (M-H)

Example 265



tert-butyl 5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoate


To a stirred suspension of 5-tert-butoxy-2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid (100mg, 0.17mmol) in 10ml of anhydrous tetrahydrofuran were added HATU (76mg, 0.20mmol) and *N,N*-diisopropylethylamine (66mg, 0.51mmol). The mixture was heated at 60°C for 15 minutes and cooled to room temperature, followed by addition of 2M ethylamine solution in THF (0.25ml, 0.50mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water with vigorous stirring. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give the crude, which was

purified by silica gel chromatography eluting with 3~5% methanol in chloroform to give tert-butyl 5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoate as white solid. Yield: 82mg, 78%.

^{1}H NMR (DMSO-d_6): 11.84 (br. s., 1H), 10.19 (s, 1H), 8.39 (d, J = 5.6 Hz, 1H), 7.80 (t, J = 5.6 Hz, 1H), 7.75 - 7.79 (m, 2H), 7.68 - 7.70 (m, 1H), 7.68 (d, J = 1.5 Hz, 1H), 7.45 (dd, J = 3.1, 1.6 Hz, 1H), 7.38 - 7.43 (m, 1H), 7.24 (d, J = 2.3 Hz, 1H), 7.16 (dd, J = 2.6, 1.8 Hz, 1H), 6.88 - 6.91 (m, 1H), 6.74 (dd, J = 5.9, 2.3 Hz, 1H), 6.56 (d, J = 1.8 Hz, 1H), 4.30 (td, J = 8.7, 5.4 Hz, 1H), 2.99 - 3.09 (m, 2H), 2.29 (s, 3H), 2.13 - 2.25 (m, 2H), 1.86 - 1.96 (m, 1H), 1.75 - 1.81 (m, 1H), 1.34 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H)

LR MS (ES+): 638 (M+Na+)
LR MS (ES-): 614 (M-H)

Example 266




5-tert-butoxy-2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid

To a stirred solution of 5-tert-butyl 1-methyl 2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)pentanedioate (170mg, 0.28mmol) in a mixture of THF/MeOH (10ml/10ml) was added 1M NaOH solution (2ml, 2mmol). The mixture was stirred at room temperature for 2 hours and poured into 100ml of water. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give 5-tert-butoxy-2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid as white solid. Yield: 145mg, 87%.

^{1}H NMR (DMSO-d_6): 12.48 (br. s., 1H), 11.88 (br. s., 1H), 10.20 (s, 1H), 8.40 (d, J = 5.9 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.76 (d, J = 1.8 Hz, 1H), 7.67 - 7.71 (m, 2H), 7.45 (br. s., 1H), 7.41 (t, J = 8.2 Hz, 1H), 7.26 (d, J = 1.5 Hz, 1H), 7.16 (br. s., 1H), 6.90 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H), 6.76 (d, J = 3.8 Hz, 1H), 6.56 (dd, J = 1.8, 0.6 Hz, 1H), 4.31 (ddd, J = 9.8, 7.9, 4.8 Hz, 1H), 2.29 (s, 3H), 2.25 - 2.29 (m, 2H), 1.94 - 2.05 (m, 1H), 1.79 - 1.89 (m, 1H), 1.35 (s, 9H)

LR MS (ES-): 587 (M-H)

Example 267



5-tert-butyl 1-methyl 2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)pentanedioate

To a stirred solution of 5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxylic acid (Example 32)(140mg, 0.35mmol) in 10ml of anhydrous DMF were added HATU (160mg, 0.42mmol) and *N,N*-diisopropylethylamine (135mg, 1.05mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of L-Glutamic acid 5-tert-butyl 1-methyl ester hydrochloride (135mg, 0.53mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. 2M HCl was added dropwise with vigorous stirring until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give 5-tert-butyl 1-methyl 2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)pentanedioate as white solid. Yield: 170mg, 81%.


^{1}H NMR (DMSO-d_6): 11.96 (br. s., 1H), 10.21 (s, 1H), 8.42 (d, J = 5.9 Hz, 1H), 8.10 (d, J = 7.6 Hz, 1H), 7.77 (d, J = 1.5 Hz, 1H), 7.68 - 7.72 (m, 2H), 7.48 (br. s., 1H), 7.42 (t, J = 8.4 Hz, 1H),

18572 CIP PCT (AP)

7.29 (br. s., 1H), 7.19 (br. s., 1H), 6.91 (dd, J = 7.6, 1.8 Hz, 1H), 6.80 (br. s., 1H), 6.56 (d, J = 1.2 Hz, 1H), 4.37 (ddd, J = 9.5, 7.5, 5.3 Hz, 1H), 3.60 (s, 3H), 2.29 (s, 3H), 2.28 (t, J = 7.6 Hz, 2H), 1.94 - 2.02 (m, 1H), 1.82 - 1.91 (m, 1H), 1.35 (s, 9H)

LR MS (ES+): 625 (M+Na+)
LR MS (ES-): 601 (M-H)

Example 268




1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylic acid

To a stirred solution of tert-butyl 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylate (22mg, 0.033mmol) in 2ml of methylene chloride was added 1ml of TFA. The mixture was stirred at room temperature for 16 hours, and evaporated to dryness under reduced pressure. The residue was re-dissolved in 2ml of methanol and poured into 10ml of water with vigorous stirring. Saturated $NaHCO_3$ solution was added dropwise until pH=7. The precipitates were filtered, washed with water and dried in vacuo to give 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylic acid as light reddish solid. Yield: 18mg, 90%.

The following Example 269 was prepared using the experiment procedure described in Example 271, but with the appropriate reagent, reaction conditions and reactant substitutions that will be readily realized by those of ordinary skill in this art without the exercise of undue experimentation.

18572 CIP PCT (AP)


Example 269



tert-butyl 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylate

LR MS (ES+): 657 (MH+)
LR MS (ES-): 655 (M-H)

Example 270




dimethyl 2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate

A mixture of 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (120mg, 0.26mmol), HATU (110mg, 0.29mmol) and N,N-diisopropylethylamine (100mg, 0.78mmol) in anhydrous DMF (10ml) was stirred at room temperature for 10 minutes, followed by addition of L-glutamic acid dimethyl ester hydrochloride (66mg, 0.31mmol). The mixture

was heated at 50°C for 15 minutes, cooled to room temperature and poured into 100ml of water with vigorous stirring. 2M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give dimethyl 2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate as white solid. Yield: 130mg, 81%.

^{1}H NMR (DMSO-d_6): 11.91 (br. s., 1H), 9.08 (d, J = 2.3 Hz, 1H), 8.97 (d, J = 2.6 Hz, 1H), 8.42 (d, J = 5.6 Hz, 1H), 8.25 (t, J = 9.1 Hz, 1H), 8.14 (d, J = 7.6 Hz, 1H), 8.01 (dd, J = 7.9, 2.3 Hz, 1H), 7.47 (dd, J = 3.1, 1.6 Hz, 1H), 7.30 (dd, J = 11.7, 2.6 Hz, 1H), 7.24 (d, J = 2.6 Hz, 1H), 7.17 - 7.18 (m, 1H), 7.12 (dd, J = 11.4, 8.2 Hz, 1H), 7.05 (ddd, J = 9.0, 2.8, 1.2 Hz, 1H), 6.81 - 6.83 (m, 1H), 6.77 (dd, J = 5.7, 2.5 Hz, 1H), 4.38 - 4.42 (m, 1H), 3.62 (s, 3H), 3.58 (s, 3H), 2.42 (t, J = 7.5 Hz, 2H), 2.28 (s, 3H), 2.07 (dtd, J = 13.6, 7.9, 5.4 Hz, 1H), 1.91 - 1.98 (m, 1H)
LR MS (ES+): 644 ($M+Na^+$)
LR MS (ES-): 620 (M-H)

Example 271



2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid

To a stirred solution of dimethyl 2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate (75mg, 0.12mmol) in 10ml of MeOH was added 2ml of 1M NaOH. The mixture was heated at 60°C for one hour, cooled to room temperature and poured into 100ml of water with vigorous stirring. 2M HCl was added dropwise until pH=4. The precipitates were filtered, washed with water and dried in vacuo to give 2-{[(5-{4-[3-fluoro-4-


18572 CIP PCT (AP)

({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid as off-white solid. Yield: 72mg, 100%.

^{1}H NMR (DMSO-d_6) : 12.48 (br. s., 1H), 12.10 (br. s., 1H), 11.88 (br. s., 1H), 9.06 (d, J = 1.5 Hz, 1H), 8.94 (d, J = 2.1 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.23 (t, J = 9.1 Hz, 1H), 7.93 - 8.02 (m, 2H), 7.45 (br. s., 1H), 7.27 (dd, J = 11.7, 2.6 Hz, 1H), 7.23 (s, 1H), 7.17 (br. s., 1H), 7.09 (dd, J = 11.3, 8.4 Hz, 1H), 7.02 (dd, J = 9.1, 1.5 Hz, 1H), 6.79 (td, J = 5.2, 2.5 Hz, 1H), 6.75 (d, J = 3.5 Hz, 1H), 4.32 (ddd, J = 9.5, 7.8, 5.0 Hz, 1H), 2.30 (t, J = 7.6 Hz, 2H), 2.25 (s, 3H), 1.95 - 2.08 (m, 1H), 1.79 - 1.92 (m, 1H)

LR MS (ES-): 592 (M-H)

Example 272




5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide

To a stirred solution of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide (100mg, 0.20mmol) in 10ml of anhydrous DMF were added 4-hydroxypiperidine (30mg, 0.30mmol) and acetic acid (10mg, 0.17mmol). The mixture was stirred at room temperature for 30 minutes, followed by addition of 1M sodium cyanoborohydride solution in THF (0.30ml, 0.30mmol) and stirring was continued for one more hour. The mixture was poured into 100ml of water. The precipitates were filtered, washed with water and dried to give the crude, which was purified by silica gel flash chromatography eluting with 20% of MeOH in $CHCl_3$ to give 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide as white solid. Yield: 55mg, 47%.

18572 CIP PCT (AP)

LR MS (ES+): 587 (MH+)
LR MS (ES-): 585 (M-H)

Example 273




5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide

To a stirred solution of N-(3,3-diethoxypropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide (800mg, 1.39mmol) in 10ml of THF was added 2M HCl (1ml, 1mmol). The mixture was stirred at room temperature under nitrogen for 1.5 hours, and poured into 100ml of water with vigorous stirring. The precipitates were filtered, washed with water, and dried in vacuo to give 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide as off-white solid. Yield: 680mg, 98%.

LR MS (ES+): 524 (M+Na+)
LR MS (ES-): 500 (M-H)

Example 274




18572 CIP PCT (AP)

3-morpholin-4-ylpropyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate

To a stirred suspension of 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylic acid (100mg, 0.22mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 63mg, 0.33mmol) in 10ml of anhydrous tetrahydrofuran were added N-(3-hydroxypropyl)morpholine (64mg, 0.44mmol) and 4-dimethylaminopyridine (10mg, 0.08mmol). The mixture was heated at 60°C for 3 hours, cooled to room temperature and evaporated to dryness. The residue was purified by silica gel chromatography eluting with 3~5% of methanol in chloroform to afford 3-morpholin-4-ylpropyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate as white solid. Yield: 72mg, 56%.

LR MS (ES+): 574 (MH+)
LR MS (ES-): 572 (M-H)

Example 275



3-[({5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid

To a stirred solution of methyl 3-[({5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate (80mg, 0.16mmol) in a mixture of THF/MeOH (5ml/5ml) was added 1M NaOH solution (1ml, 1mmol). The mixture was stirred at room temperature for 3 hours and poured into 50ml of water. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give 3-[({5-[4-(2-fluoro-5-


18572 CIP PCT (AP)

{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid as white solid. Yield: 70mg, 90%.

^{1}H NMR (DMSO-d_6): 12.15 (br. s., 1H), 11.85 (br. s., 1H), 10.18 (s, 1H), 8.42 (d, J = 5.6 Hz, 1H), 8.02 (dd, J = 7.6, 2.3 Hz, 1H), 7.97 - 8.00 (m, 1H), 7.91 (t, J = 5.6 Hz, 1H), 7.63 (dd, J = 10.3, 8.8 Hz, 1H), 7.55 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.38 (br. s., 1H), 7.26 (d, J = 2.3 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 7.12 (br. s., 1H), 6.91 (d, J = 7.6 Hz, 1H), 6.81 (dd, J = 5.7, 2.5 Hz, 1H), 3.32 - 3.37 (m, 2H), 2.43 (t, J = 7.0 Hz, 2H), 2.27 (s, 3H)


LR MS (ES-): 501 (M-H)

Example 276



5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid

Example 277



methyl 3-[({5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate

To a stirred solution of 5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid (Example 275) (100mg, 0.23mmol) in 10ml of anhydrous


18572 CIP PCT (AP)

DMF were added HATU (100mg, 0.26mmol) and *N,N*-diisopropylethylamine (85mg, 0.66mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of β-alanine methyl ester hydrochloride (46mg, 0.33mmol). The mixture was stirred for another 5 minutes and poured into 100ml of water. 2M HCl was added dropwise with vigorous stirring until pH = 4. The precipitates were filtered, washed with water and dried in vacuo to give methyl 3-[({5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate as white solid. Yield: 110mg, 92%.

^{1}H NMR (DMSO-d_6): 11.95 (br. s., 1H), 10.19 (s, 1H), 8.44 (d, J = 5.9 Hz, 1H), 8.03 (dd, J = 7.6, 2.3 Hz, 1H), 8.00 (ddd, J = 8.7, 4.5, 2.3 Hz, 1H), 7.97 (t, J = 5.7 Hz, 1H), 7.64 (dd, J = 10.3, 8.5 Hz, 1H), 7.55 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.43 (br. s., 1H), 7.31 (br. s., 1H), 7.20 (t, J = 7.8 Hz, 1H), 7.18 (br. s., 1H), 6.91 (d, J = 7.9 Hz, 1H), 6.88 (br. s., 1H), 3.57 (s, 3H), 3.35 - 3.42 (m, 2H), 2.52 (t, J = 6.9 Hz, 2H), 2.27 (s, 3H)

LR MS (ES+): 539 (M+Na+)
LR MS (ES-): 515 (M-H)

Example 278



3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoic acid

To a stirred solution of methyl 3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate (85mg, 0.16mmol) in a mixture of THF/MeOH (5ml/5ml) was added 1M NaOH solution (2ml, 2mmol). The mixture was heated at 50°C for one hour and poured into 100ml of water. 1M HCl was added dropwise with vigorous stirring until pH = 4.


18572 CIP PCT (AP)

The precipitates were filtered, washed with water and dried *in vacuo* to give 3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoic acid as white solid. Yield: 80mg, 96%.

^{1}H NMR (DMSO-d_6): 12.17 (br. s., 1H), 9.15 (s, 1H), 8.68 (t, J = 5.6 Hz, 1H), 8.46 (d, J = 2.6 Hz, 1H), 8.44 (d, J = 5.6 Hz, 1H), 8.36 (d, J = 1.2 Hz, 1H), 8.33 (d, J = 1.2 Hz, 1H), 7.95 (dd, J = 7.9, 2.3 Hz, 1H), 7.51 - 7.56 (m, 2H), 7.41 (d, J = 2.3 Hz, 1H), 7.12 - 7.17 (m, 2H), 7.08 (dd, J = 11.4, 8.2 Hz, 1H), 6.77 - 6.80 (m, 1H), 6.76 (dd, J = 5.9, 2.3 Hz, 1H), 3.38 - 3.44 (m, 2H), 2.49 (t, J = 7.0 Hz, 2H), 2.25 (s, 3H)

LR MS (ES-): 533 (M-H)

Example 279



methyl 3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate

To a stirred solution of 4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxylic acid(Example 123) (100mg, 0.22mmol) in 10ml of anhydrous DMF were added HATU (100mg, 0.26mmol) and *N,N*-diisopropylethylamine (85mg, 0.66mmol). The mixture was stirred at room temperature for 10 minutes, followed by addition of β-alanine methyl ester hydrochloride (46mg, 0.33mmol). The mixture was stirred for another 10 minutes, and poured into 100ml of water with vigorous stirring. 1M HCl was added dropwise until pH = 4. The precipitates were filtered, washed with water and dried *in vacuo* to give methyl 3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate as off-white solid. Yield: 115mg, 97%.

18572 CIP PCT (AP)

^{1}H NMR (DMSO-d_6): 9.21 (s, 1H), 8.70 (t, J = 5.6 Hz, 1H), 8.45 - 8.50 (m, 2H), 8.36 (d, J = 18.2 Hz, 2H), 7.93 - 7.97 (m, 1H), 7.55 (d, J = 8.8 Hz, 2H), 7.45 (br. s., 1H), 7.16 (d, J = 9.1 Hz, 2H), 7.08 (dd, J = 11.3, 8.4 Hz, 1H), 6.72 - 6.88 (m, 2H), 3.58 (s, 3H), 3.39 - 3.50 (m, 2H), 2.57 (t, J = 6.9 Hz, 2H), 2.25 (s, 3H)

LR MS (ES+): 571 (M+Na+)
LR MS (ES-): 547 (M-H)

3.2 Biological Testing

Biological data for the compounds of the present invention was generated by the use of one or more of the following assays.

VEGF Stimulated Ca.sup.++ Signal in Vitro

Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37.degree. C./5% CO.sub.2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37.degree. C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 .mu.M) or at concentrations ranging from 0.01 to 10.0 .mu.M followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples. IC.sub.50 values for test compounds were calculated from % inhibition of VEGF stimulated responses in the absence of inhibitor.

VEGFR2 Kinase Assay

18572 CIP PCT (AP)

The cytoplasmic domain of the human VEGF receptor (VEGFR-2) was expressed as a Histidine-tagged fusion protein following infection of insect cells using an His engineered baculovirus. His-VEGFR-2 was purified to homogeneity, as determined by SDS-PAGE, using nickel resin chromatography. Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 .mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 .mu.L reaction volumes containing 3.6 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 .mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 .mu.l of O-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 .mu.l of 2.5N H.sub.2 SO.sub.4 to each well and read using a microplate ELISA reader set at 492 nm. IC.sub.50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values. Compounds of the current invention have the IC50 value in the range of 0.01 to 500 nM.

VEGF-induced Dermal Extravasation in Guinea Pig (Miles Assay)

Male Hartley guinea pigs (300-600 g) were anesthetized with isofluorane, sheared, and given a single dose of drug or the respective vehicle. The guinea pigs were dosed orally unless indicated otherwise in Table 3. Ten minutes prior to the end of drug treatment, guinea pigs were anesthetized with isofluorane, and 0.5% Evans blue dye (EBD) in PBS (13-15 mg/kg dose of EBD) was injected intravenously. After 5 minutes, triplicate intradermal injections of 100 ng rhVEGF.sub.165 in 100 .mu.l PBS and of 100 .mu.l PBS alone were administered on the flank. After 20 minutes, each animal was cuthanized with Pentosol, and the skin containing the intradermal injection sites was removed for image analysis.

18572 CIP PCT (AP)

Using an analog video camera coupled to a PC, an image of each trans-illuminated skin sample was captured, and the integrated optical density of each injection site was measured using ImagePro 4. For each skin sample, the difference between the mean optical density of the VEGF sites and mean optical density of the PBS sites is the measure of VEGF-induced EBD extravasation in that animal. These measured values were averaged per study group to determine the mean VEGF-induced EBD extravasation for each experimental condition, and the group means were then compared to assess inhibition of VEGF-induced EBD extravasation in the drug-treated groups relative to the vehicle-treated controls.

To determine the dose required for 50% inhibition (ID.sub.50), the percent inhibition data was plotted as a function of oral dose, using the `best-fit` analysis within MicroSoft Excel software. The ID.sub.50 value was verified visually by using the plotted data (horizontal line from 50% y value, at intersection with best-fit line drop vertical line to x axis (dose).

Laser-induced Choroidal Neovascularization (CNV) in Rat (CNV Assay).

CNV was induced and quantified in this model as previously described (Edelman and Castro. Exp. Eye Res. 2000; 71:523-533). On day 0, male Brown Norway rats (200-300 g) were anesthetized with 100 mg/kg Ketamine and 10 mg/kg Xylazine, and pupils were dilated with 1% Tropicamide. Using the blue-green setting of a Coherent Novus Argon Laser, 3 laser bums (90 mW for 0.1 s; 100 .mu.m diameter) were given to each eye between the retinal vessels around the optic nerve head. Rats were dosed with test compounds in their indicated vehicles orally once daily.

On day 10, rats were sacrificed with 100% CO.sub.2, and blood vessels were labeled by vascular perfusion with 10 mg/ml FITC-dextran (MW 2.times.10.sup.6). Using an epifluorescence microscope (20.times.) coupled to a spot digital camera and a PC, images were obtained from the flat mounts of the RPE-choroid-sclera from each eye, and the area occupied by hyperfluorescent neovessels within each laser lesion was measured using ImagePro 4 software.

To determine the dose required for 50% inhibition (ID.sub.50), the percent inhibition data was plotted as a function of oral dose, using the `best-fit` analysis within MicroSoft Excel software. The ID.sub.50 value was verified visually by using the plotted data (horizontal line from 50% y value, at intersection with best-fit line drop vertical line to x axis (dose).

18572 CIP PCT (AP)

The foregoing description can be employed to practice the present invention, and represents the best mode contemplated. It should not be construed as limiting the overall scope hereof.

Rabbit Eye VEGF Permeability Model

Assay used was detailed by Jeffrey Edelman, etc in Exp. Eye. Res. 80(2005), Pg 249-258.

PDGF Stimulated Ca^{2+} Signal in Vitro

Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of PDGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. NHDF-Ad (Normal human dermal fibroblasts) (Lonza) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C/5% CO_2 . Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 4 times (ELx405-CW, Bio-Tek) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.001nM to 10 μM followed by PDGF stimulation (10 ng/mL). Changes in fluorescence at 515nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples. IC_{50} values for test compounds were calculated from % inhibition of PDGF stimulated responses in the absence of inhibitor.

Table II and III present the biodata of some of the compounds of the present invention.

18572 CIP PCT (AP)

Table II: Biodata of Compounds of the Present Invention with Amide Linker

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
1		28		
2	8	28		
3		28		
4	6	29		
5		2956		
6		506		
7	12	34		
8	8	28		
9	30	47		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
10	46	41		
11	28	23	34	
12				
13	16	27		
14	15	33	15	
15	51	26		73
16	17	21		
17	22	20		61
18	10	31		
19	30	37		135
20	83	28		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
21	12	24		39
22	18	29	13	105
23	13	35		
24	55	24		
25	30	25		
26	39	120		
27	45	66		
28	38	52		
29	18	55		
30	29	37		94

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
31	14	29	20	
32	22	46		
33	18	56		
34	7	70		
35	27	29		
36		10028		
37	1005	2610		

18572 CIP PCT (AP)

Table III: Biodata of Compounds of the Present Invention with Urea Linker

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
38		10		
39		23		
40		11		
41		11		
42		60		
43		16		
44		24		
45		17		
46	2	28		
47	107	17		
48	16	12		
49	145	27		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
50	5	32		
51		16		
52		25		
53	43	28		44
54	130	29		191
55	32	23		26
56	81	20		
57	102	45		
58	211	36		
59	34	29		
60	27	23		
61	91	39		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
62	122	43		
63	111	30		
64	16	39		
65		15	4	
66		17	3	
67	31	31		
68		16		
69		24	5	
70	2	20		
71		20		
72	7	15		
73		11		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
74	7	12		
76	2	14	3	
76	3	14		
77	8	10		
78	25	15	4	
79	13	38		
80	176	69		
81		19		
82	17	19		
83		22	5	
84		13		
85	6	30		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
86		27		
87	5	25		
88	374	477		
89	5	23		
90	8	17	6	21
91	17	14		38
92	37	9		39
93	6	5	5	14
94	10	6		10
95	30	32		
96	3	17		69
97	8	18		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
98	62	51		
99	49	46		
100	12	13		
101	4	8		82
102	10	35		8
103	24	20		
104	23	27		
105	87	15		
106	16	21		
107	13	21		
108	17	14	13	43
109	16	23		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
110	8	38	10	32
111	13	71		
112	13	18		
113	23	25		
114	13	22		
115	2	15	2	44
116	12	17		
117	6	18		
118	22	85		
119	12	54		
120	43	98		
121	37	14	20	102

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
122	142	130		
123	13	24		85
124	23	36		
125	22	31		
126	16	116		
127	20	21		91
128	10	53		
129	12	102		
130	5	43	16	32
131	8	31		
132	22	15		
133	66	15		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
134	4	31	4	
135	11	47		
136	29	22		
137	14	33		
138		30		
139	14	30		
140		10000		
141		2704		
142	111	28		
143	16	12		
144	28	26		
145	10000	10000		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)
146	10000	7007		
147	10000	3505		
148	10000	1382		

18572 CIP PCT (AP)

Table IV - Biodata of Compounds of the Present Invention with Amide or Urea Linker

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
149		4	6		13
150		5	7		16
154	14	7	8		15
155	4	8	7		20
156	9	11	8		31
157	3	10	8		39
158	11	11	6		29
159	26	11	9		33
160		9	7		19
161	10	9	9		20
164	5	9	10		17
165	12	10	17		35
166		5	6		11

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
167	11	9	21		27
168	11	10	17		12
171	21	23	91		33
172	13	10	11		19
174		8			42
175				32	34
176				78	38
177		15			
178		24	60		
179		21	50		
180		14	32		53
181		22	65		132
182		33	86		

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
183		24	100		
184		19	51		49
185	8	16	40		63
186					
187		15	27		98
188	5	27	32		
189	15	34	37		
191		25	42		
192		26	34		
193	11	31	35		
194		23	25		
195		7	9		19

5

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
196		8	10		19
205		8	9		15
206		9	12		17
207		7	10		17
210		12	8		13
211	3	9	8		12
212	6	13	20		45
213	3	9	13		38
214		22	8		23
215	4	5	13		34
216		17	16	214	59
217	10	5	10		21
218		5	9		16

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
219	8	9	8		29
220		13	11		23
221	15	11	7		19
222		9	15		29
223		13	12		16
224		10	21		
226		6	9		
227		9	11		
228		11	8		9
229	13	11	11		9
230	2	6	9	31	12
231				32	43
232	5	9	16		20

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
233	5	9			22
234		8	11		17
235			14		15
237	3	8	8		19
238	4	19			28
239	2	7			16
240		7			
241	4	10	19		27
243	5	16	39		80
244		12	31		94
246		42	62		54
247		15	25		21

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
248		56	28		157
249		33	46		55
250		24	8		54
251		46	18		79
252		24	25		99
253		64	36		200
254		24	35		35
255		28	44		185
256		55	24		167
257		53	18		180
258		36	21		41
259		35	23		47
261		12		108	100

18572 CIP PCT (AP)

Example#	VEGFR2 Cellular IC_{50} (nM)	VEGFR2 Enzyme IC_{50} (nM)	VEGFR1 Enzyme IC_{50} (nM)	PDGFβ Cellular IC_{50} (nM)	PDGFβ Enzyme IC_{50} (nM)
262		67			66
263		14			46
265		18			
266		31			
268		15			
270	8	7	8		18
272		19			
274	10	11	16		27
275		19			
277		13			
278		14	15		16
279	1	21			23

5

18572 CIP PCT (AP)

What is claimed is:

1. A compound selected from the group consisting of :

(1') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(2H-tetrazol-5-yl)propyl]-1H-pyrrole-3-carboxamide;

(2') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[2-(2H-tetrazol-5-yl)ethyl]-1H-pyrrole-3-carboxamide;

(3') N-(3,3-diethoxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(4') N-(2-aminoethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(5') tert-butyl (2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate;

(6') methyl [(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)amino]acetate;

(7') methyl [(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)amino]acetate;

(8') dimethyl 2,2'-[(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)imino]diacetate;

(9') ethyl [4-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazin-1-yl]acetate;

(10') ethyl [4-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)piperazin-1-yl]acetate

(11') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[2-(hydroxymethyl)morpholin-4-yl]propyl}-1H-pyrrole-3-carboxamide;

(12') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[3-(hydroxymethyl)piperidin-1-yl]propyl}-1H-pyrrole-3-carboxamide

(13') methyl rel-(2R,4S)-1-(2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino] carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)-4-hydroxypyrrolidine-2-carboxylate;

(14') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide;

(15') N-(2,2-diethoxyethyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(16') methyl rel-(2R,4S)-1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)-4-hydroxypyrrolidine-2-carboxylate;

(17') 4-methoxy-4-oxobutyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate;

(18') 5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy] pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoic acid;

(19') ethyl 5-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanoate;

(20') ethyl 4-(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)piperazine-1-carboxylate;

(21') 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(2-oxoethyl)-1H-pyrrole-3-carboxamide;

(22') N-(2,2-diethoxyethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(23') ethyl 4-{3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}piperazine-1-carboxylate;

(24') ethyl 4-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)piperazine-1-carboxylate;

(25') ethyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate;

(26') methyl 3-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate;

(27') methyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate;

(28') methyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate;

(29') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(4-hydrazino-4-oxobutyl)-1H-pyrrole-3-carboxamide;

(30') dimethyl 2,2'-({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl) amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl) amino]propyl}imino)diacetate

(31') dimethyl 2,2'-({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino] carbonyl}phenoxy) pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}imino) diacetate

(32') methyl ({3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}amino)acetate;

(33') methyl ({2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}amino)acetate;

(34') N-(2-aminoethyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino] carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide

(35') tert-butyl {2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]ethyl}carbamate;

(36') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide;

(37') 1-[4-({2-[4-(azetidin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(2-fluoro-5-methylphenyl)urea;

(38') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide;

(39') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide;

(40') methyl 1-[3-({[5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)propyl]pyrrolidine-2-carboxylate;

(41') 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide;

(42') 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide;

(43') 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-piperidin-1-ylpropyl)-1H-pyrrole-3-carboxamide;

(44') 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide;

(45') 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxamide;

(46') 5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide;

(47') N-{3-[(2,3-dihydroxypropyl)(methyl)amino]propyl}-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(48') methyl [(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)amino]acetate;

(49') 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoic acid;

(50') methyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate;

(51') 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-2-yl)carbonyl]amino}propanoic acid;

(52') methyl 3-{[(4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-2-yl)carbonyl]amino}propanoate;

(53') N-(3,3-diethoxypropyl)-4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}thiophene-2-carboxamide;

(54') N-(3,3-diethoxypropyl)-4-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-2-carboxamide;

(55') N-(3,3-diethoxypropyl)-5-(4-{4-fluoro-3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrole-3-carboxamide;

(56') N-(3,3-diethoxypropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide;

(57') 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[3-(hydroxymethyl)piperidin-1-yl]propyl}-1H-pyrrole-3-carboxamide;

(58') 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-{3-[2-(hydroxymethyl)morpholin-4-yl]propyl}-1H-pyrrole-3-carboxamide;

(59') 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide;

(60') N-(3,3-diethoxypropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(61') N-(3,3-diethoxypropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(62') {[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetic acid;

(63') methyl {[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}acetate;

(64') tert-butyl (3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate;

(65') dimethyl 2,2'-[(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate;

(66') 2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridine-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetic acid;

(67') dimethyl 2,2'-[(2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)imino]diacetate;

(68') tert-butyl (2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}ethyl)carbamate;

(69') methyl rel-(2R,4S)-1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl) amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino} propyl)-4-hydroxypyrrolidine-2-carboxylate;

(71') {4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetic acid;

(72') ethyl {4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazin-1-yl}acetate;

(73') 1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid;

(74') 1-(2-fluoro-5-methylphenyl)-3-[2-fluoro-4-({2-[4-(piperazin-1-ylcarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]urea;

(75') N-(2-aminoethyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino] carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(76') N-(3-aminopropyl)-5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino] carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(77') tert-butyl 4-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]piperazine-1-carboxylate;

(78') 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy] pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide;

(79') 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy] pyridin-2-yl}-N-(3-pyrrolidin-1-ylpropyl)-1H-pyrrole-3-carboxamide;

(80') 2-methoxyethyl 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate;

(81') methyl 1-(3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylate;

(82') 3-morpholin-4-ylpropyl 5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate;

(83') dimethyl 2-{[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate;

(84') ethyl 3-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propanoate;

(85') dimethyl 2,2'-[(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)imino]diacetate;

(86') 2-methoxyethyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate;

(87') 3-hydroxy-2,2-bis(hydroxymethyl)propyl 4-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}butanoate;

(88') N-[3-(4-hydroxypiperidin-1-yl)propyl]-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(89') 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide;

(90') N-(3-hydroxypropyl)-5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(91') 1-[4-({2-[4-(hydrazinocarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]-3-(3-methylphenyl)urea;

(92') 5-{4-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide;

(93') 3-hydroxy-2,2-bis(hydroxymethyl)propyl 5-{4-[4-({[(3-methylphenyl)amino] carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate;

(94') 1-(2-fluoro-5-methylphenyl)-3-[4-({2-[4-(hydrazinocarbonyl)-1H-pyrrol-2-yl]pyridin-4-yl}oxy)phenyl]urea;

(95') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide;

(96') methyl (2S)-1-{3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino] carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl} pyrrolidine-2-carboxylate;

(97') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-hydroxypropyl)-1H-pyrrole-3-carboxamide;

(98') ethyl 4-{N-[(5-{4-[3-fluoro-4-({[(3-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]-S-methylsulfonimidoyl} butanoate;

(99') N,N'-diethyl-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanediamide;

(101') 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy] pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-2-carboxylic acid;

(102') 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy) pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioic acid;

(103') dimethyl 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]pentanedioate;

(104') N-(3-aminopropyl)-5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxamide;

(105') tert-butyl (3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)carbamate;

(106') N-(3-aminopropyl)-5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino] carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxamide;

(107') tert-butyl {3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl} phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propyl}carbamate;

(108') 5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-N-(3-morpholin-4-ylpropyl)-1H-pyrrole-3-carboxamide;

(109') 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino] carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid;

(110') tert-butyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl) amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate;

(111') 5-tert-butoxy-2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoic acid;

(112') 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid;

(113') methyl 3-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate;

(114') ethyl 4-{N-[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]-S-methylsulfonimidoyl}butanoate;

(115') methyl 5-(ethylamino)-4-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-oxopentanoate;

(116') 2-[({5-[4-(2-fluoro-5-{[(2-fluoro-5-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]-5-methoxy-5-oxopentanoic acid;

(117') N,N'-diethyl-2-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanediamide;

(118') 5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid;

(119') tert-butyl 5-(ethylamino)-4-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoate;

(120') 5-tert-butoxy-2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy}pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)-5-oxopentanoic acid;

(121') 5-tert-butyl 1-methyl 2-({[5-(4-{3-[(3-methyl-2-furoyl)amino]phenoxy} pyridin-2-yl)-1H-pyrrol-3-yl]carbonyl}amino)pentanedioate;

(122') 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy] pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylic acid;

(123') tert-butyl 1-(3-{[(5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}propyl)pyrrolidine-3-carboxylate;

(124') dimethyl 2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioate;

(125') 2-{[(5-{4-[3-fluoro-4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-1H-pyrrol-3-yl)carbonyl]amino}pentanedioic acid;

(126') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-pyrrole-3-carboxamide;

(127') 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy]pyridin-2-yl}-N-(3-oxopropyl)-1H-pyrrole-3-carboxamide;

(128') 3-morpholin-4-ylpropyl 5-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl} amino)phenoxy]pyridin-2-yl}-1H-pyrrole-3-carboxylate;

(129') 3-[({5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoic acid;

(130') 5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy)pyridin-2-yl]-1H-pyrrole-3-carboxylic acid;

(131') methyl 3-[({5-[4-(2-fluoro-5-{[(3-methylphenyl)amino]carbonyl}phenoxy) pyridin-2-yl]-1H-pyrrol-3-yl}carbonyl)amino]propanoate;

(132') 3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenoxy] pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoic acid; and

(133') methyl 3-{[(4-{4-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino) phenoxy]pyridin-2-yl}-2-thienyl)carbonyl]amino}propanoate,

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a therapeutic effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, wherein the composition comprises tablets, capsules, intravenous injections, intramuscular injections, local injections, topical creams, gels and ointments, eye drops, eye ointments, eye sprays, ophthalmic suspensions, ophthalmic emulsions, intravitreal injections, subtenon injections, ophthalmic biodrodible implant, and non-bioeordible ophthalmic inserts and depots.

4. A method for the treatment of a disease or condition selected from the group consisting of colorectal cancer, lung cancer, hematological cancer, renal cancer, liver cancer, breast cancer, diabetic retinopathy, macular degeneration, age-related macular degeneration, retinopathy of prematurity, ocular angiogenesis, retinal edema, retinal ischemia, diabetic macular edema, cystoid macular edema, retinal vein occlusion, branch vein occlusion, preretinal neovascularization, laser-induced choroidal neovascularization, neovascularization associated with keratoplasty, glaucoma and ocular tumors, arthritis, restenosis, hepatic cirrhosis, atherosclerosis, psoriasis, diabetes mellitus, wound healing, inflammation, neurodegenerative diseases and immune disorders in the human being, comprising administering to a mammal in need of such treatment at least one compound of claim 1 or a pharmaceutically acceptable salt thereof.

5. The method of claim 4, where said disease or condition is selected from the group consisting of: diabetic retinopathy, macular degeneration, age-related macular degeneration, retinopathy of prematurity, ocular angiogenesis, retinal edema, retinal ischemia, diabetic macular edema, cystoid macular edema, retinal vein occlusion, branch vein occlusion, preretinal neovascularization, laser-induced choroidal neovascularization, and neovascularization associated with keratoplasty.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/069337

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D401/04 C07D401/14 C07D405/14 C07D409/04 C07D409/14
A61K31/443 A61K31/4436 A61K31/4439 A61P35/00 A61P27/02
A61P29/00 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2011/028995 A1 (ALLERGAN INC [US]; GUO XIALING [US]; ZHU ZHEN [US]) 10 March 2011 (2011-03-10)	1-5
L	claims 1-19; examples 1-148; table II and III	1-5

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 February 2014	17/02/2014

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Sáez Díaz, R

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2013/069337

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2011028995 A1	10-03-2011	AU 2010289353 A1	29-03-2012
		AU 2010289359 A1	29-03-2012
		CA 2772625 A1	10-03-2011
		CA 2772718 A1	10-03-2011
		CN 102498114 A	13-06-2012
		CN 102686577 A	19-09-2012
		EP 2473501 A1	11-07-2012
		EP 2473513 A1	11-07-2012
		JP 2013503901 A	04-02-2013
		JP 2013503903 A	04-02-2013
		KR 20120047313 A	11-05-2012
		KR 20120082890 A	24-07-2012
		RU 2012109233 A	10-10-2013
		RU 2012112151 A	10-10-2013
		SG 178963 A1	27-04-2012
		SG 178965 A1	27-04-2012
		US 2011053905 A1	03-03-2011
		US 2011053973 A1	03-03-2011
		WO 2011028995 A1	10-03-2011
		WO 2011029001 A1	10-03-2011